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ABSTRACT 
Alyssa Joy Cozzo: The Influence of Overweight- and Obesity-associated Mammary Adipose 
Inflammation on Progression of Triple-Negative Breast Cancer 
(Under the direction of Liza Makowski Hayes) 
 
Triple-negative breast cancers (TNBCs) are a collection of highly proliferative and 
invasive breast cancers primarily comprised of the basal-like (BBC) and claudin-low (CLBCs) 
molecular subtypes. We previously reported that weight gain and weight loss regulated pre-
neoplastic lesion formation, tumor latency, and tumor progression in C3(1)-TAg mice, a 
transgenic model of spontaneous BBC. These findings coincided with elevated concentration of 
hepatocyte growth factor (HGF), ligand for the proto-oncogene cMET, in the mammary 
microenvironment of high-fat diet (HFD)-fed mice. Thus, herein we conducted a two-phase 
study investigating whether crizotinib, an inhibitor of cMET, would delay onset of BBC in low-fat 
(LFD) and HFD-fed C3(1)-TAg mice. When administered prophylactically – before tumor onset – 
crizotinib did not significantly affect tumor progression or tumor burden. However, with 
therapeutic treatment following tumor development, crizotinib significantly reduced tumor 
multiplicity and vascularity in LFD- and HFD-fed C3(1)-TAg mice. These findings emphasize the 
importance of clarifying “windows of susceptibility” during which HGF/cMET signaling may play 
disproportionately greater roles in BBC onset and progression. 
We next hypothesized that adult weight gain and an inflammatory overweight mammary 
microenvironment would augment CLBC progression, while weight loss before tumor 
development would normalize overweight-associated tumor promotion. Therefore, a C3(1)-TAg-
derived CLBC cell line was orthotopically transplanted into lean, overweight, and formerly 
overweight female FVB/NJ mice. Indeed, overweight accelerated tumor progression and 
iv 
 
induced pro-inflammatory changes in the mammary gland, including increased growth factor 
expression and crown-like structure formation. Weight loss abrogated overweight-induced tumor 
growth and reduced expression of mitogenic and metastasis-associated signaling pathways in 
tumors, significantly attenuating inflammation-induced CLBC progression. Interestingly, 
overweight also resulted in enhanced expression of a mast cell transcriptional signature in 
whole mammary tissue. Increased mast cell scores were also observed in cancer-adjacent 
breast tissue of overweight and obese relative to normal weight breast cancer patients. 
Conversely, lower intratumoral mast cell score was significantly associated with both triple-
negative subtype and elevated risk-of-recurrence score in human breast cancers. Taken 
together, our results support that excess adiposity facilitates TNBC aggression. Further 
elucidation of adiposity-driven mechanisms of tumor progression and the efficacy of preventive 
measures such as weight loss could have tremendous potential for public health.
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CHAPTER 1: CONTRIBUTION OF ADIPOSE TISSUE TO DEVELOPMENT OF CANCER1 
Didactic Synopsis 
Major teaching points:  
1. Solid tumor growth requires the interaction of tumor cells with the surrounding tissue, 
leading to a view of tumors as communities rather than exclusively tumor cells. 
2. Adipose tissue, or fat, plays important roles in cancer risk and outcome because many 
tumors grow close to or in direct contact with adipose.  
3. The adipose community – or microenvironment - includes adipocytes and adipose-
associated stromal and vascular components, such as fibroblasts and other connective 
tissue cells, stem cells, endothelial cells, innate and adaptive immune cells, and 
extracellular signaling and matrix components.  
4. Herein, we review the cellular and non-cellular parts of the adipose “organ” and the 
mechanisms by which varied microenvironmental components contribute to tumor 
development, with emphasis on obesity.  
5. Obesity dramatically modifies the adipose tissue microenvironment in numerous ways, 
which intriguingly resemble shifts observed within the tumor microenvironment.  
6. Understanding neighboring adipose is critical in tumorigenesis. 
                                                          
1This chapter was published as an Overview Article within the journal Comprehensive Physiology. The original 
citation is as follows: Cozzo, A.J., Fuller, A.M. and Makowski, L., Contribution of Adipose Tissue to Development of 
Cancer. Comprehensive Physiology. Published Online: 12 DEC 2017. DOI: 10.1002/cphy.c170008 
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Introduction 
Cancer is characterized by fundamental aberrations in cellular behavior, including the 
ability to multiply indefinitely in the absence of growth-promoting factors and a resistance to 
signals that normally result in programmed cell death (apoptosis) [1]. In the case of solid tumors, 
carcinogenic transformation and cell proliferation are followed by establishment of a vascular 
supply, called tumor angiogenesis, 
which facilitates the delivery of 
oxygen and nutrients to the growing 
tumor [1]. Subsequent invasion into 
and migration through surrounding 
tissues allows for the establishment 
of nearby satellite tumors or entry 
into the lymphatic or vascular 
systems for dissemination and 
secondary tumor formation 
(metastases) [1]. Solid tumor growth 
and tissue invasion require the 
interaction of tumor cells with the 
surrounding tissue, and it is well 
established that communication between cancer cells and the tissue-level context in which they 
reside, collectively referred to as the tumor “microenvironment”, is pivotal in determining 
whether a given tumor will exist in dormancy or progress to malignancy [2]. The tumor 
microenvironment includes, but is not limited to, the tumor cells themselves, blood vessels 
(endothelial cells and pericytes), lymphatic vessels (lymphendothelial cells), adipocytes, 
fibroblasts, and various stem and progenitor cells [3] (Figure 1). Also present is a wide variety 
of innate and adaptive immune cells, which can act as critical anti-tumor defenses or, 
Figure 1. Tumors as communities. Tumor cells co-exist 
with a variety of stromal and immune cells and reside in a 
complex mixture of signaling molecules and extracellular 
matrix components. Adjacent adipose tissue may provide 
a hospitable environment to developing tumors.  
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alternatively, play central roles in tumor promotion. The tumor “stroma” is the connective, 
functionally supportive framework of the tumor, and by definition refers to a complex mixture of 
signaling molecules and extracellular matrix (ECM) components, as well as the stromal cells 
(e.g., fibroblasts and pericytes) that produce and are embedded within them [4]. However, the 
term “stroma” may also be used to collectively refer to all of the aforementioned cell types and 
secreted factors, as all are present within the cancer cell-adjacent tissue. Thus, considerable 
heterogeneity, both within the cancer cells themselves and among the interacting stromal cells, 
leads to a view of tumors as communities, and the process of tumorigenesis as a tissue-level 
phenomenon occurring in conjunction with intrinsic genetic deviations within individual cancer 
cells [5].  
Due to the ubiquitous nature of adipose tissue, many types of solid tumors grow in 
proximate or direct contact with adipocytes and other adipose-associated cell populations. 
Although the specific nature of the reciprocal communication occurring between a developing 
tumor and adjacent adipose tissue is an area of active study, a growing body of literature 
indicates that these interactions with the local adipose milieu are important drivers of 
malignancy. Many of these studies have focused on dysregulated adipose and associated 
systemic metabolic dysfunction in the context of obesity, as there is now adequate evidence 
establishing a link between obesity/adiposity and elevated risk for, or accelerated progression 
of, several cancers. Following an overview of the adipose organ, we will briefly address 
epidemiologic links between obesity and cancer. Subsequently, we have chosen to emphasize 
the local physical and paracrine roles of adipose tissue in solid tumor development and 
malignancy by focusing on individual components of the adipose tissue microenvironment. 
Although adipose dysfunction in obesity will be addressed frequently throughout this review, we 
aim to provide the reader with an understanding of the recently described mechanistic links 
between cancer development or progression and adipose tissue per se, as opposed to obesity-
associated systemic alterations such as metabolic dysfunction. 
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The Adipose Organ 
Adipose tissue is a type of loose connective tissue that was long considered to be 
largely physiologically inert, primarily storing energy in the form of lipids while cushioning and 
insulating the body. However, adipose tissue is also a substantial contributor to whole body 
endocrine signaling, modulating feeding behavior and total body energy expenditure, as well as 
hematopoiesis and lymphopoiesis, overall immune function, and reproduction [6, 7]. 
Additionally, adipose tissue is now understood to contribute to the pathogenesis of a variety of 
regional and systemic diseases. The adipose tissue “organ” is in fact comprised of several 
distinct adipose depots (Figure 2), each of which differentially exerts systemic and regional 
control on overall energy metabolism and signaling based on location and adipose tissue 
subtype. Broadly, adipose depots can be divided according to anatomic location into 
subcutaneous and visceral subtypes. Whole adipose depots, or specific regions within depots, 
may be further subclassified as white, brown, or beige depending on, among other factors, 
adipocyte mitochondrial content, with a higher relative number of mitochondria corresponding to 
a darker adipocyte hue. In humans, subcutaneous adipose tissue comprises ~80% of total body 
fat, and is contained primarily in the abdominal, gluteal, and femoral depots [8] (Figure 2A). The 
breast fat pad is also a nontrivial contributor to total subcutaneous fat content in women. On the 
other hand, visceral depots represent approximately 5-20% of total body fat in normal weight 
(i.e., not overweight or obese) individuals [8]. Visceral adipose tissue surrounds vital organs, 
and includes omental, mesenteric, and epiploic adipose, as well as the gonadal, epicardial, and 
retroperitoneal fat pads. Finally, numerous smaller depots, such as intramuscular, intraorbital, 
and bone marrow adipose, nourish and protect tissues throughout the body. While the majority 
of these depots are comprised of white adipose tissue – discussed further in the Adipocytes 
section below – smaller brown and beige adipose tissue caches are also found in adults [9, 10]. 
Importantly, due to similarities in the location and composition of adipose depots and endocrine 
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function relative to humans, the laboratory mouse (Mus musculus) is a commonly used model 
for investigation of adipose tissue anatomy and physiology (Figure 2B). 
 
 
Figure 2. The adipose organ is comprised of several distinct adipose depots. Adipose depot locations 
and subtypes in A) humans and B) mice (panel B adapted from [11] with permission). 
 
Although adipocytes constitute approximately 90% of adipose tissue volume, the 
adipose tissue microenvironment is a rich ecosystem of additional stromal and vascular 
components (often referred to collectively as stromal-vascular cells). The stromal-vascular 
compartment of human white adipose tissue includes endothelial cells (10-20% of cells), 
pericytes (3-5%), fibroblasts and other connective tissue cells (15-30%), and stem and 
progenitor cells (0.1%), which reside within a complex milieu of signaling molecules and ECM 
components [12] (Figure 3). Adipose tissue also contains a rich and varied collection of innate 
and adaptive immune cells (macrophages, dendritic cells, mast cells, eosinophils, neutrophils, 
and lymphocytes; 25-45%) [12]. However, the exact cellular proportions, degree of vascularity, 
ECM composition, metabolic characteristics, and secretory products of adipose tissue vary 
according to numerous factors, including depot location, sex, age, health status, and extent of 
adipose accumulation [8]. 
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Figure 3. Approximate composition of human white adipose tissue stromal-vascular fraction 
(percent cellularity). 
 
Obesity and Cancer 
Adipose tissue exhibits an almost unlimited capacity to expand, a unique property that 
has received increased attention in recent years as obesity has moved to the forefront of global 
public health concerns. Overweight and obesity, defined by the World Health Organization 
(WHO) as abnormal or excessive adiposity that presents a risk to health, are frequently 
measured at the population level using the body mass index (BMI), an individual’s weight in 
kilograms divided by the square of his or her height in meters. However, it must be 
acknowledged that, at an individual level, the BMI formula can vary considerably by sex and 
race and says little about body composition, often underestimating adiposity [13, 14]. For this 
reason, additional measures specifically of adiposity, such as waist circumference or the Body 
Adiposity Index (BAI; [hip circumference (cm)/height (m)1.5-18]) developed by Bergman et al. 
[15], are sometimes used to correlate adiposity with disease risk.  
 
Current status of the obesity epidemic, globally and in the United States 
Since the recognition of obesity as a global epidemic in 1997 [16], increasing resources 
have been allocated to more completely understanding the prevalence, risk factors, and long-
term consequences of this health hazard. For example, a recent quantitative meta-analysis 
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published in The Lancet analyzed 1,698 population-based data sources, encompassing 186 
countries and more than 19.2 million adult participants (9.9 million men and 9.3 million women), 
to evaluate trends in mean BMI over the last four decades [17]. The authors reported a global 
increase in overall age-adjusted prevalence of obesity in men from 3.2% to 10.8%, and in 
women from 6.4% to 14.9%, between 1975 and 2014 [17] (Figure 4A). An additional cross-
sectional analysis of the United States National Health and Nutrition Examination Survey 
(NHANES) for the years 2013-2014 reports that the overall age-adjusted prevalence of obesity 
(again by BMI) among men and women in the US has now reached a staggering 35% and 
40.4%, respectively [18]. Furthermore, extreme obesity (or class 3 obesity, defined as BMI >40) 
in the US is currently 9.9% for women and 5.5% for men [18], considerably higher than the 
global prevalence of 1.6% and 0.64%, respectively [17] (Figure 4B). Importantly, a 
disproportionate burden of obesity and overweight is observed among women who self-identify 
as Hispanic or non-Hispanic black minorities; NHANES data indicate that the overall age-
adjusted prevalence of obesity in non-Hispanic black and Hispanic women measures 57.2% 
and 46.9% respectively, compared to 38.2% in non-Hispanic white women [18] (Figure 4C). 
Finally, it should be noted that rising obesity rates are not restricted to adults. The prevalence of 
obesity in US children and adolescents ages 2 to 19 years old rose from approximately 10% 
during the 1988-1994 NHANES period to 17.0% in the 2011-2014 period, with extreme obesity 
more than doubling from approximately 2.5% to 5.8% [19]. 
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Figure 4. Rising global and US obesity rates. A) Global age-adjusted prevalence of obesity in men and 
women, 1975 and 2014; B) Class III obesity (BMI >40), globally and US; C) US obesity prevalence by race, 
ethnicity [17]. 
 
The obesity-cancer link 
Cancer is currently the second leading cause of death in the United States and is 
expected to surpass heart disease as the leading cause of death within the next few years [20]. 
Approximately 40-60% of cancer patients are classified as overweight or obese [21, 22], and in 
2004 it was estimated that overweight and obesity accounted for one in seven cancer deaths in 
men and one in five in women [23]. Importantly, obesity is differentially associated with 
increased risk of cancer development and increased risk of poorer cancer prognosis. Indeed, 
there is adequate evidence to support an association between obesity and increased risk of 
developing colorectal, post-menopausal breast, endometrial, kidney, esophageal, liver, 
gallbladder, pancreatic, and thyroid cancers, as well as non-Hodgkin’s lymphoma and myeloma 
[24-28]. There is also strong support for an influence on outcome for several cancer types for 
which an association between obesity and increased risk of onset remains ambiguous. The 
American Society of Clinical Oncology (ASCO) has acknowledged that obesity contributes to 
poorer cancer prognosis following diagnosis in a number of ways, including by impairing the 
delivery of systemic cancer therapies and by elevating risk of both tumor recurrence and 
development of additional primary malignancies [29].  
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Interestingly, there is also a body of literature that supports a protective effect of obesity 
in overall survival for some cancer types, a finding known as the “obesity paradox”. Potential 
explanations for the obesity paradox emphasize methodological issues, such as unmeasured 
confounders and/or a reliance on BMI as a metric for obesity [30, 31]. As mentioned previously, 
BMI is a rather crude mathematical estimate that does not capture important considerations 
such as percent adiposity, regional distribution of adiposity (e.g., android vs gynoid obesity), or 
differences in lean mass. Gonzalez et al. reported that the use of body composition indices 
resulted in a disappearance of the obesity paradox in 175 cancer patients in which BMI was 
previously associated with a protective effect, emphasizing the importance of considering body 
composition in epidemiologic analyses of cancer outcomes [32]. In fact, when body composition 
was included, loss of lean mass (sarcopenia) was a more important prognostic indicator than 
BMI for patients exhibiting cancer-associated cachexia, a systemic wasting syndrome frequently 
observed in end-stage cancer patients that is characterized by a rapid loss of both skeletal 
muscle and adipose tissue [32, 33]. Thus, additional evidence is needed to determine whether 
isolated reports of the obesity paradox are simply artefactual or in fact clinically relevant. 
Nevertheless, leading hypotheses seeking to explain observed connections between 
obesity and increased cancer morbidity and mortality emphasize factors such as metabolic 
disruption-induced growth factor dysregulation; higher levels of circulating adipokines and 
cytokines secreted by inflamed obese adipose tissue; and elevated production of estrogens by 
adipose tissue [34, 35]. These hypotheses emphasize the role of adipose as an endocrine 
organ and obesity as a potential state of adipose endocrine dysfunction. However, the 
mechanisms whereby adipose accumulation increases risk of tumor onset and/or mediates 
tumor progression in adipose-adjacent cancers are multifactorial, complex, and likely 
tissue/organ-specific, in part due to unique paracrine and physical interactions occurring 
between cancer cells and adjacent adipose tissue. Moreover, growth and invasion of some solid 
tumors into adjacent adipose may promote tumor aggression even in the absence of obesity. 
For example, irrespective of BMI, adipose tissue invasion at the tumor margin is associated with 
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an increase in lymph node metastasis in patients with invasive breast carcinoma [36]. Thus, 
whether select adipose-mediated mechanisms of tumor promotion are merely exacerbated by 
obesity or are unique to a dysregulated obese adipose microenvironment in many cases 
remains to be determined. In this review, we have especially highlighted the role of adipose 
tissue in the development and progression of breast and prostate cancers due to the prevalence 
of these cancer types in the US population and their significant contributions to cancer-related 
mortality (see below). 
Breast and prostate cancers are the most frequently diagnosed cancers and the second 
leading causes of cancer-related death among US men and women, respectively [20]. Due to 
their now recognized genetic and molecular heterogeneity, these cancer types have been 
shown to exhibit complex associations with obesity. For example, although the association 
between obesity and risk of postmenopausal breast cancer is now well established, the 
relationship between obesity and premenopausal breast cancer risk remains controversial and 
appears to be dependent upon breast cancer subtype. Specifically, recent work has clarified an 
association between obesity and premenopausal onset of triple-negative breast cancers 
(TNBCs), with differential risk according to race [37-41]. Studies from our lab and others have 
also demonstrated that diet‑induced obesity is associated with accelerated TNBC latency (time 
to development of a palpable tumor) in ovary-intact preclinical mouse models [42-45]. In 
patients with confirmed breast cancers, obesity is associated with increased risk of breast 
cancer invasion [46, 47], development of distant metastases [48-50], tumor recurrence [51, 52], 
and mortality [24, 53-59] irrespective of molecular subtype. On the other hand, the role of 
obesity in risk of prostate cancer development remains equivocal [60-63], in part because, 
similar to breast cancer, prostate cancer risk in obese individuals also appears to vary by race 
[60, 64]. However, in confirmed prostate cancers, obesity is consistently associated with an 
elevated risk of cancer aggression (clinically advanced cases or high Gleason scoring, a 
grading system is used to inform the prognosis of men with prostate cancer) and prostate 
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cancer-associated mortality [65, 66]. Thus, rising obesity rates present an oncological crisis, 
both globally and within the US. 
Following a brief consideration of the anatomy of breast and prostate in humans and 
laboratory mice - a frequently used model in basic science and translational/pre-clinical cancer 
studies - potential mechanistic links between adipose tissue and breast and prostate cancer 
development or progression will be discussed in detail below through a comprehensive 
examination of the available literature regarding adipose-cancer interactions in each organ. 
 
Anatomy of the Breast and Prostate 
The laboratory mouse remains the most widely used animal model for the study of 
cancer pathophysiology. Consequently, integration of experimental findings with studies of 
human disease requires an understanding of human and veterinary pathology and anatomy, as 
well as developmental, molecular, and cellular biology. While this level of detail is beyond the 
scope of this review, this section will provide a brief comparative biology overview of the breast 
and prostate in humans and mice as a backdrop for the studies reviewed in subsequent 
sections.  
 
Mammary gland anatomy and adipose-cancer interaction in humans vs. mice 
In both mice and humans, the mammary gland is a unique, dynamic organ that 
continuously undergoes anatomic and functional changes over the life course [67]. In mice, the 
nascent mammary gland (“mammary tree”) consists of a network of epithelial ducts, each of 
which terminates in a stem cell-enriched structure called a terminal end bud (TEB; Figure 5A). 
During sexual maturation, inductive hormonal and growth factor-derived signals stimulate the 
proliferation of ectodermal cells within these TEBs, driving ductal elongation and branching [68-
70]. The mature mammary epithelium continues to undergo further differentiation during later life 
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stages such as pregnancy, lactation, and post-partum involution, or epithelial regression [70, 
71]. Development of the mammary tree and pregnancy/lactation-associated expansion and 
involution require remodeling of the surrounding stroma. In mice, mammary ductal-adjacent 
stroma is primarily comprised of adipose tissue, without a significant collagenous matrix layer 
(Figure 6).  
 
 
Figure 5. Comparison of mouse and human mammary gland anatomical structure. A) Murine ductal 
elongation and branching occur at the Terminal End Buds (TEBs). B) The human mammary gland is 
extensively branched, culminating in the functional terminal ductal lobular unit (TDLU). 
 
In comparison to mouse, the human mammary gland is a more extensively branching 
structure. Beginning at the nipple, the lactiferous sinus branches into segmental, or interlobular, 
ducts (Figure 5B). Segmental ducts branch further into terminal ducts and lobules, which 
together comprise the functional unit of the human mammary gland, the terminal ductal lobular 
unit (TDLU). Immediately surrounding the TDLU is a loose intra-lobular stroma, referred to as 
“specialized stroma”, which contains abundant fibroblasts (Figure 6) [71]. Dense, collagenous 
inter-lobular stroma surrounds the entire human TDLU structure, forming a thick layer between 
the TDLU and adjacent adipose tissue. Fibroblasts within the intra-lobular stroma exhibit 
phenotypic and functional differences from those found within inter-lobular stroma, including 
expression of select collagen isoforms [72] and ectoenzymes [73]. Surrounding the inter-lobular 
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stroma is a large depot of subcutaneous adipose, comprising 7 to 56% of the volume of the 
adult breast [74]. 
 
 
Figure 6. Comparison of mouse and human mammary gland histology. Left: Adult mouse mammary 
fat pad from nulliparous C57BL/6 mouse (4x and 10x, H&E staining). Right: H&E-stained normal human 
breast tissue. Arrowhead and asterisks in right panel refer to loose intra- and dense inter-lobular stroma, 
respectively. Human histology images courtesy of Melissa Troester and the UNC Normal Breast Study 
(unpublished). 
 
The most extreme example of tumor infiltration into adipose tissue is seen in breast 
cancer. Breast cancer most frequently begins in ductal epithelial cells, which proliferate to fill the 
ductal lumen and generate a pre-cancerous lesion called ductal carcinoma in situ (DCIS). 
Subsequently, invasive ductal carcinoma (IDC) cells invade the mammary stromal 
compartment. On the other hand, approximately 1 in 10 invasive breast cancers originate in the 
lobules, beginning as lobular carcinoma in situ and progressing to invasive lobular carcinoma. 
The lack of intra-lobular stroma in mice [71] and relatively thinner collagenous matrix means that 
tumor cell invasion in mouse models of breast cancer results in immediate encounter of 
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adipocytes and other adipose cell populations (Figure 7A), whereas human invasive breast 
carcinoma must invade through both intra- and interlobular stroma before direct interaction with 
an area rich in adipose tissue (Figure 7B).  
 
 
Figure 7. Adipose-breast cancer interactions in mice and humans. A) Early invasive lesions in H&E-
stained mammary gland tissue from the C3(1)-TAg genetically-engineered mouse model of spontaneous 
basal-like breast cancer (unpublished images). B) Human breast cancer - Female, 50 years, lobular 
carcinoma, grade 1, Elston-Ellis score 5. Image credit: The Human Protein Atlas [75, 76]. 
 
Prostate gland anatomy and adipose-cancer interaction in humans vs. mice 
Like the mammary gland, the prostate exhibits important inter-species differences 
between mice and humans. However, before progressing to a comparison of mouse and human 
prostate anatomy, it should be acknowledged that rat and canine models have generated 
important mechanistic knowledge in prostate cancer research, particularly in the context of the 
spontaneous development of prostate lesions [77]. With that said, genetically engineered or 
xenografted mice remain the most commonly used model in prostate cancer research. For an 
overview and critique of currently available mouse models of human prostate cancer, the reader 
is directed to [77, 78]. 
 In mice, the prostate is comprised of four lobes lying anterior and lateral to the urethra. 
These lobes are named after their spatial orientation (anterior, dorsal, ventral, and lateral lobes, 
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see diagram in Figure 8) and exhibit distinctive histology [77, 79]. The glandular acini of the 
prostatic lobes are surrounded by a thin fibromuscular tunica, and are embedded in a loose 
connective tissue stroma with minimal smooth muscle cells and sparse collagen fibers [79]. 
Individual mouse prostate lobes are surrounded by a delicate mesothelium-lined capsule, and 
are separated from each other by fibrous and adipose connective tissue [79].  
In contrast to mice, the human male prostate does not have exterior lobation, but instead 
contains distinct glandular regions (a peripheral zone, a central zone, and a transition zone; see 
diagram in Figure 8) [79], again with characteristic histology. Like the breast, a conspicuous 
histological difference between mouse and human prostate lies in the stromal component. In 
humans, the prostate gland bears an anterior, well-developed, non-glandular fibromuscular 
stromal region. Abundant adipose tissue is present surrounding most of the posterolateral 
aspects of the prostate [80], and is used as a marker of extraprostatic tissue in biopsy samples 
[81]. This region of adipose is referred to in subsequent sections as periprostatic adipose. 
Intraprostatic adipose, when present, consists of a small focus of a few adipocytes, and is rarely 
observed histologically [81]. 
 
 
Figure 8. Anatomical comparison of mouse (left) and human (right) prostate glands. 
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The most common type of prostate cancer is acinar adenocarcinoma, which originates 
from the glandular epithelium. Pre-neoplastic prostatic intraepithelial neoplasia (PIN) progresses 
to invasive adenocarcinoma, in which extension of prostatic carcinoma through the prostatic 
capsule (extraprostatic extension) and resulting interaction with the surrounding adipose is an 
indicator of malignant progression and advanced histopathological stage [82]. The periprostatic 
adipose depot unambiguously contributes to prostate cancer malignancy [83-85]. In fact, 
interaction with periprostatic adipose tissue has been suggested to be a more important 
determinant of cancer recurrence than an invasive phenotype [86]. Analogous to breast cancer, 
recent advances in molecular phenotyping by The Cancer Genome Atlas Research Network 
have identified several genomically distinct molecular subtypes of prostate cancers [87]. 
Whether these subtypes interact differentially with adjacent adipose remains to be determined. 
 
Microenvironmental Links between Adipose Tissue and Cancer 
Context matters: extracellular matrix in adipose tissue and cancer 
Adipocytes and stromal cells are embedded in a loose, three-dimensional ECM, the non-
cellular tissue component that provides both structural and biochemical support to surrounding 
cells, such as cell adhesion, paracrine communication, and differentiation signals. Maintenance 
of the adipose tissue ECM – primarily comprised of fibronectin and collagens [88] – involves a 
variety of cell types, including fibroblasts, macrophages, adipocytes, and preadipocytes. 
Importantly, adipocyte function and survival is tightly regulated by both the molecular 
composition and mechanical properties of the surrounding ECM [89].  
The structural flexibility of adipose tissue ECM facilitates transient volume changes in 
response to normal fluctuations in lipid stores throughout the feed-fast cycle. However, rapid 
adipocyte hypertrophy (increased adipocyte volume) during the development of obesity can 
result in intracellular or regional hypoxia. Reduced tissue oxygenation induces transcriptional 
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programs in adipocytes and other stromal cells that ultimately lead to excess deposition of 
fibrillar ECM components such as collagens I, III, and VI and development of tissue fibrosis [88, 
90]. Indeed, adipose depots of obese subjects often exhibit greater total fibrosis, and particularly 
pericellular fibrosis around adipocytes, than lean individuals [91, 92]. Importantly, hypoxia-
induced adipose tissue fibrosis is associated with onset of metabolic perturbations in adipocytes 
[88, 93], while dysregulation in visceral adipose function is linked to the pathogenesis of insulin 
resistance and type II diabetes mellitus [92-94]. Furthermore, as adipocytes become 
encapsulated in a shell of rigid ECM, impaired cellular function also results in apoptosis and 
necrosis [95]. Release of damage-associated molecular patterns (DAMPs) from dead and dying 
adipocytes and adjacent live adipocytes promotes recruitment of macrophages and other 
inflammatory cells; histologically, these macrophages can be observed within crown-like 
structures (CLS), foci of macrophages and other inflammatory cells surrounding dead and dying 
adipocytes [96]. Macrophages are fully integrated into all stages of the fibrotic process through 
secretion of soluble mediators and cytokines such as transforming growth factor β1 (TGF-β1), 
platelet-derived growth factor (PDGF), and chemokines that attract and activate fibroblasts and 
collagen-producing myofibroblasts [88, 97].  
Interestingly, while adipose tissue fibrosis in the context of obesity is well described, 
increased adipose ECM deposition, fibrosis, and immune cell infiltration are also observed in 
cancer-associated cachexia [98]. Abdominal subcutaneous adipose depots of lean cachectic 
subjects bearing gastrointestinal cancers displayed extensive adipose ECM remodeling, 
including a dramatic increase in deposition of collagens I, III, and VI as well as elastin and 
fibronectin [99]. These changes were associated with increased myofibroblast content and 
elevated activation of TGF-β/SMAD signaling pathways [99]. As described later in the 
Adipocytes and adipocyte-cancer interactions section, cancer-associated cachexia is also 
associated with metabolic dysfunction in adipocytes, which may be mediated in part by ECM 
modifications. 
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In addition to adipocytes, epithelial tissue homeostasis and tissue organization is also 
heavily dependent upon a dynamic dialogue with the surrounding ECM. Disruption of ECM 
structure or misinterpretation of ECM-derived signals due to alterations in signaling receptor 
profiles is associated with development of a malignant phenotype in transformed epithelial cells 
[100-102]. Enhanced ECM stiffness also triggers the process known as epithelial-to-
mesenchymal transition (EMT) in cancer cells, which is characterized by the loss of epithelial 
polarity, de-differentiation, and local migration and invasion [103-106]. Hence, modifications in 
the adipose tissue ECM that provide a hospitable environment to developing tumors, such as 
enhanced stiffness in obese breast tissue, may provide a link between adipose tissue and 
tumorigenesis.  
 
 
 
As discussed in later sections, chronic low-grade inflammation, macrophage infiltration, 
hypoxia, and aberrant wound healing responses, including an increase in myofibroblast and 
Figure 9. Desmoplasia and cancer-associated 
adipocytes. A) Mammary tumors from C3(1)-TAg 
mice stained with Hematoxylin/eosin (left) or 
Masson’s trichrome (right) (unpublished). Chronic 
activation of the wound-repair response results in 
excess collagenous extracellular matrix production 
(desmoplasia), within tumors. Asterisks (*) indicate 
desmoplastic stroma. B) Cancer-associated 
adipocytes (black arrows) at or near the tumor 
invasive front become smaller and exhibit 
decreased expression of adipocyte markers, while 
the number of fibroblast-like cells increases.   
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activated fibroblast content, are features of both the tumor and adipose tissue 
microenvironments [4, 102, 107]. Chronic activation of the wound repair response leads to 
excess deposition of ECM components and accumulation of scar-like fibrotic tissue in a process 
known as desmoplasia, or the desmoplastic reaction (Figure 9A). In both breast and prostate 
cancers desmoplasia is associated with poor outcomes [108, 109], and can facilitate cancer 
progression by interfering with drug delivery. Thus, ECM remodeling and the resultant 
disturbances in cytoskeletal tension and mechanotransduction have emerged as important 
factors that promote neoplastic transformation, cancer malignancy, and cancer metastasis [4, 
102, 110], and may provide another connection between adipose dysregulation and cancer.  
 
Adipose extracellular matrix composition and viscoelasticity: influence on the normal 
breast and breast cancer 
Mammographic density denotes the radiologic appearance of the breast, and is a metric 
of the fibroglandular (epithelial and non-fatty stromal) content in that tissue [111]. A number of 
qualitative and quantitative methods have been developed to estimate mammographic density, 
including Breast Imaging Reporting and Data System (BI-RADS) categories, Wolfe’s 
parenchymal patterns, Tabar’s classification scheme, and numerous two- and three-dimensional 
image analysis techniques [112]. Within heterogeneous breast tissue, tumors most frequently 
arise within the most mammographically dense regions of the breast, suggesting that denser 
fibroglandular tissue directly influences carcinogenesis [113]. Indeed, regardless of the reporting 
method [111], high mammographic density is consistently and strongly associated with both 
elevated risk of breast cancer [114] and more aggressive tumor characteristics [115], even after 
adjustment for other risk factors such as age and BMI [116].  
At the molecular level, high mammographic density reflects the development of a dense, 
collagenous stroma rich in type I and/or type III collagen [117, 118]. Similar stromal changes are 
also observed in breast cancers [119], wherein they are orchestrated by a heterogeneous, 
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reactive population of so-called “cancer-associated fibroblasts” (CAFs). CAFs display 
remarkable plasticity, and frequently differentiate into myofibroblasts, a cell type exhibiting 
properties of both fibroblasts and smooth muscle cells [120-122]. In non-malignant tissue, 
myofibroblasts play an important role in wound healing responses, secreting a fibronectin- and 
collagen type I-rich ECM characterized by fibrillary architecture and increased cross-linking and 
density [123]. They are also the predominant source of fibrogenic and/or inflammatory cytokines 
in fibrotic lesions [124]. Despite the utility of this cell type to normal wound healing programs, 
however, the presence of myofibroblasts in tumors contributes to pathological desmoplasia 
[122], and may thus promote cancer progression [125]. 
In addition to fibroblasts, local (adipose-derived) mesenchymal stem cells, bone marrow-
derived mesenchymal stem cells, myeloid precursors, and cells derived from EMT may also 
present alternative sources of myofibroblasts in tumor stroma [126-128]. Furthermore, in tumors 
growing in an adipose tissue-rich microenvironment, cancer cell-induced reprogramming of local 
adipocyte gene expression and function has been observed to promote adipocyte delipidation 
and atrophy/regression [129]. This process occurs concurrently with the accumulation of 
fibroblast-like cells and a desmoplastic stroma; this synchronicity raises the possibility that some 
CAFs might be derived from dedifferentiated adipocytes [129] (Figure 9B). However, the extent 
to which their specific lineages determine the contribution of CAFs to tumor progression remains 
inconclusive. 
Although obesity is associated with reduced mammographic density – in part because 
fat is radiolucent – several studies have unveiled close links between chronic inflammation and 
the development of fibrosis and associated ECM rigidity in obese mammary adipose tissue 
[123, 130, 131]. Myofibroblasts are typically absent from normal, uninflamed breast tissue [132]. 
However, Seo et al. showed that obesity elevated matrix rigidity in non-cancerous breast tissue 
by enhancing myofibroblast content in mammary adipose [123]. Adipose stromal cells (ASCs, 
also called adipose-derived stem cells) isolated from obese mice exhibited increased 
expression of α-smooth muscle actin (α-SMA, a myofibroblast marker), as well as increased 
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fibronectin and a more fibrillar, partially unfolded, and stiffer ECM [123], implicating ASCs as a 
source of myofibroblasts in obesity. Furthermore, obese ASCs also exhibited enhanced 
proliferative capacity and secreted increased quantities of matrix components [123], thereby 
mimicking characteristics of tumor-associated stromal cells [122, 133]. Consistent with findings 
in mice, histologically normal breast tissue from obese patient mastectomies exhibited 
increased α-SMA staining and collagen fiber length and thickness relative to tissue from lean 
individuals [123]. Obesity-associated increases in α-SMA levels also correlated with formation of 
CLS, further implicating macrophages in the development of mammary adipose tissue fibrosis 
[123]. However, distinct from tumors [133], obesity-associated increases in myofibroblast 
content and matrix rigidity occurred in a TGFβ-independent manner [123], suggesting that ECM 
composition and stiffness may be differentially regulated in benign obese and malignant breast 
tissue. 
Increased matrix rigidity in breast adipose tissue may be an important mediator of 
cancer initiation and progression in obese individuals. To test the effects of obesity and ECM on 
tumor cell behavior, Seo et al. cultured pre-invasive human MCF10AT cells upon decellularized 
matrices produced by ASCs isolated from lean or obese mice. The authors reported that, 
relative to ECMs deposited by lean ASCs, obesity-associated ECMs increased MCF10AT cell 
motility and promoted the formation of disorganized three-dimensional acini, indicative of 
greater tumorigenic potential [123]. Additionally, ECM generated by obese mammary ASCs 
significantly enhanced the proliferation of the highly invasive MDA-MB-231 cancer cell line by 
altering mechanotransduction through enhanced RhoA/ROCK-mediated cell contractility and 
YAP/TAZ transcription factor activity [123]. Collectively, these results are suggestive of a 
relationship between obesity-associated mammary adipose tissue fibrosis and accelerated 
tumor initiation and/or proliferative capacity.  
In addition to fibroblasts/myofibroblasts, adipocytes play a vital role in defining the ECM 
environment through secretion and processing of factors such as collagen VI, an ECM 
component with both structural and signaling roles that is highly enriched in adipose tissue [93, 
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134, 135].  Excess adipocyte collagen VI expression in obesity is associated with adipose tissue 
fibrosis and metabolic dysregulation, while the absence of collagen VI in mouse models of 
obesity allowed for uninhibited adipocyte expansion and an improved metabolic phenotype [93]. 
Increased adipocyte collagen VI expression is also associated with elevated local 
concentrations of endotrophin, the collagen VI α3 chain cleavage product, which has been 
identified as a driving factor in adipose tissue fibrosis, macrophage chemotaxis, and 
inflammation, and appears to mediate adipose metabolic dysregulation in obesity (Figure 10) 
[131, 135]. Unsurprisingly, increased collagen VI production also coincides with increased 
adipose tissue macrophage content [130, 135].  
To further illustrate parallels in the obese adipose and tumor microenvironments, 
collagen VI and its cleavage product have also been implicated in the initiation and progression 
of breast cancers. Collagen VI is abundantly expressed by breast cancer-associated adipocytes 
(discussed at greater length in the Adipocytes section below), and its increased deposition in 
the ECM promotes tumorigenesis and malignant progression both in vitro and in vivo by 
inducing alterations in cancer cell signaling programs, gene expression patterns, and post-
translational modifications [136, 137]. For example, treatment of MCF-7 human invasive breast 
cancer cells with collagen VI significantly elevated activity of the oncogenic Akt-GSK3β–β-
catenin–Tcf/Lef pathway, ultimately resulting in cyclin D1 protein stabilization and enhanced cell 
proliferation [136, 137]. Accordingly, expression of the proto-oncogenes GSK3β and cyclin D1 in 
mammary tumors exhibited a steep immunohistochemical gradient, with increased staining 
intensities observed proximate to adipocytes. A similar gradient in collagen VI expression was 
also observed, further implicating adipocyte-derived collagen VI in the induction of mitogenic 
signaling pathways [136]. In addition, collagen VI-derived endotrophin induces markers of EMT 
in cancer cells and acts as a potent adipokine that exerts growth-stimulatory and pro-survival 
effects on developing tumors [135]. In the breast tumor microenvironment, endotrophin 
overexpression is associated with increased rate of metastasis [135] and resistance to the 
platinum-based chemotherapeutic cisplatin [138]. Thus, increased collagen VI deposition and 
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endotrophin concentration in obese adipose may influence both early tumor development and 
treatment outcomes.  
 
 
Figure 10. Obesity-associated modifications in the adipose tissue microenvironment. Adipose tissue 
expansion in obesity occurs in association with extracellular matrix changes such as fibrosis. Adipocyte 
hypertrophy and hypoxia trigger macrophage infiltration and crown-like structure formation, which further 
exacerbates development of fibrosis and inflammation. 
 
Adipose extracellular matrix-derived factors: direct effects on epithelial cells 
In addition to modulating composition and viscoelasticity of the breast ECM, stromal 
cells within the obese breast microenvironment secrete numerous soluble signaling mediators 
that have direct effects on epithelial cells. In particular, HGF is an excellent candidate for 
stromal-mediated breast cancer promotion in the context of obesity. Although HGF is classified 
as an adipokine [139], it is produced by a number of breast cell types including stromal 
fibroblasts and has been detected in both normal and malignant breast tissue [140]. In 
advanced tumors, HGF signaling through its receptor cMET initiates an invasive growth 
program that promotes cell migration, invasion, proliferation, and angiogenesis (Figure 11) 
24 
 
[141]. HGF is also elevated in the serum of breast cancer patients and correlates with advanced 
disease [142-145]. However, HGF signaling impacts the phenotypes of both early- and late-
stage breast cancers. With respect to early-stage lesions, we have reported that treatment of 
pre-malignant basal-like breast cells with HGF-blocking antibodies inhibited 3D morphogenesis, 
reflecting a reduction in epithelial malignant potential [142]. An HGF gene expression signature 
generated via treatment of pre-malignant breast cells with recombinant HGF was also found to 
correlate with both basal-like subtype and poor survival in >700 breast cancer samples from 
three publicly available datasets [142].    
 
 
Importantly, basal-like breast cancer is a clinically intractable TNBC subtype that is more 
prevalent in obese individuals [37-41], while serum HGF is also elevated in obese individuals 
and is reduced with weight loss [146-148]. Our laboratory previously demonstrated that high fat 
diet-induced obesity increased HGF concentration and enhanced expression and activation of 
cMET in the mammary fat pad of C3(1)-T-antigen (TAg) mice, a unique genetically engineered 
mouse model (GEMM) of spontaneous basal-like breast cancer [43, 149, 150]. We also reported 
that obesity increased HGF production by primary murine fibroblasts isolated from both normal 
mammary glands and tumors, and that CAFs isolated from obese animals induced epithelial cell 
Figure 11. 
HGF/cMET: an 
oncogenic 
signaling 
cascade. HGF 
secretion by 
stromal cells 
such as 
fibroblasts, 
adipocytes, and 
macrophages 
initiates an 
invasive growth 
program in 
epithelial cells. 
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migration in an HGF-dependent manner [43]. Obesity-mediated regulation of HGF secretion 
from other stromal cell types such as adipocytes is currently under investigation. 
 
Adipose extracellular matrix in prostate cancer 
Despite being a common feature of mouse models of prostate cancer, histologically 
conspicuous reactive stroma is much less prevalent in human prostate tumors compared to 
breast cancers [77]. However, like the breast, induction of a myofibroblastic phenotype and 
degree of reactive stroma carry important prognostic value for prostate cancer malignancy [109, 
151, 152]. Notably, as the literature regarding the contribution of adipose tissue to breast cancer 
onset and progression has greatly outpaced that of prostate cancer, obesity-associated ECM 
modifications are currently better characterized in the mammary, relative to the periprostatic, fat 
pad. Additionally, conflicting data exist regarding the association between periprostatic fat 
density (measured by magnetic resonance imaging or computed tomography) and tumor 
aggressiveness in prostate cancer patients [153-155]. Our literature search also revealed no 
publications reporting that periprostatic adipose tissue fibrosis occurs in obesity, but whether 
this is due to a lack of occurrence or a lack of examination is unknown. Furthermore, no studies 
investigating links between adipocyte-derived endotrophin and prostate cancer were available at 
the time of writing this review. Therefore, future obesity-prostate cancer studies may be 
informed by the sundry findings linking breast cancer and adipocyte-associated fibrosis, 
modifications in ECM dynamics, and endotrophin release. 
 
Adipocytes and adipocyte-cancer interactions 
Adipocytes are specialized connective tissue cells that constitute a major cell type in 
both the normal-weight and obese breast. The majority of adipocytes in adult humans are white 
adipocytes, which contain a large, unilocular lipid droplet and are specialized for storage of 
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neutral lipids. However, brown and/or beige adipocytes (also called “brite” or “inducible” 
adipocytes [9]) have also been reported in adults, and likely play important roles in 
thermogenesis [156]. More recently, “pink” adipocytes have been described in murine mammary 
gland, arising exclusively during pregnancy and lactation due to a process wherein white 
adipocytes progressively transdifferentiate to acquire secretory, epithelial-like features [9]. 
Adipocytes secrete a broad range of signaling molecules that exert local and/or systemic effects 
with the potential to influence tumor growth. Among the better studied adipocyte-derived factors 
are metabolic factors such as leptin, adiponectin, resistin, visfatin, and plasminogen activator 
inhibitor-1 (PAI-1); hematopoietic factors such as GM-CSF; growth factors such as 
angiopoietins, HGF, vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-
1), and TGF-β; and a variety of cytokines, including interleukin-6 (IL-6) and TNF-α and the 
chemokine monocyte chemoattractant protein (MCP-1) [also referred to as chemokine (C-C 
motif) ligand 2 (CCL2)] (Figure 12) [157, 158].  
 
 
 
 
Figure 12. Adipocyte subtypes and 
secreted factors. White adipocytes contain 
a large, unilocular lipid droplet and are 
specialized for storage of neutral lipids. 
Brown and/or beige adipocytes have 
increased mitochondrial content relative to 
white adipocytes and play important roles in 
thermogenesis. “Pink” adipocytes have been 
described in murine mammary gland, arising 
exclusively during pregnancy and lactation. 
Collectively, adipocytes secrete a broad 
range of signaling molecules. 
 
27 
 
Several of the aforementioned adipocyte-derived growth factors influence development 
of a tumor vascular supply (tumor angiogenesis), as discussed in the Endothelial 
Cells/Lymphendothelial Cells section below. Whereas leptin and adiponectin are considered 
true adipokines, many of the other signaling molecules, including resistin, visfatin, TNF-α, IL-6, 
MCP-1 and PAI-1, are not, as they are expressed by both adipocytes and immune cell 
populations such as macrophages, and play a variety of well-known roles in immunity [157]. 
Thus, select functions for several of these signaling molecules will be discussed within the 
section titled Adipose Tissue Immune Populations in Cancer Development and Progression. 
Finally, although there are clear and important roles for leptin and adiponectin in tumorigenesis 
and malignancy, these roles have been reviewed extensively by others [139, 159-162] and will 
be addressed only briefly within this review. 
Adipocytes exhibit both short- and long-range interactions with cancer cells, and may be 
found in close proximity to tumors, along tumor margins, and within the tumor body. These 
cancer-associated adipocytes (CAAs; also referred to as peritumoral, intratumoral, or tumor-
infiltrating adipocytes) influence tumor biology in a number of ways, including by promoting 
angiogenesis and inflammation [reviewed in 163, 164, 165]. Although it is reasonable to 
hypothesize that proliferation and invasion of tumor cells into cancer-adjacent adipose may 
account for the presence of CAAs within the tumor body, the origin of CAAs in fact remains 
unclear. As explained in further detail in the section on Adipose-derived Stromal Cells below, 
several cell types may give rise to intratumoral CAAs. 
 In addition to indirect mechanisms of tumor growth promotion (e.g., stimulation of 
angiogenesis, production of proinflammatory cytokines), the proximity of CAA to growing tumors 
may also provide direct metabolic benefits to cancer cells. In the phenomenon known as 
metabolic symbiosis, cancer cells within hypoxic regions of a tumor undergo metabolic shifts 
that facilitate increased utilization of fuel sources such as lactate, glutamine, and fatty acids 
released by surrounding cells, including other cancer cells [166, 167] and adipocytes [168, 169]. 
As mentioned previously, CAAs have been frequently observed to undergo delipidation. Lipid 
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droplet size within mature white adipocytes is the net result of several processes, including fatty 
acid uptake or de novo fatty acid synthesis, esterification, and lipolysis. Interestingly, Nieman et 
al. showed that co-culture of primary omental adipocytes with ovarian cancer cells, which 
frequently metastasize to the omentum, induced lipolysis in adipocytes, upregulation of β-
oxidation in cancer cells, and direct transfer of lipids between the two cell types [170]. Notably, 
the transfer of lipids from adipocytes to cancer cells has also been observed in prostate cancer 
[171] and breast cancer [172]. These findings indicate that active heterotypic cellular 
interactions between cancer cells and adipocytes induce metabolic symbiosis.  
CAAs may also influence cancer cell phenotypes through the shedding of exosomes, 
small vesicular bodies released from cells as a form of short- or long-range communication. 
Lazar et al. [173] reported that exosome shedding by mature human adipocytes induced 
increased migratory and invasive behavior in melanoma cells, which grow in proximity to the 
hypodermal adipose layer. Proteomic analysis of adipocyte-derived exosome composition 
revealed enrichment for proteins involved in mitochondrial lipid metabolism, particularly fatty 
acid oxidation. Remarkably, their results suggested that these enzymes were incorporated and 
utilized by melanoma cells. Melanoma cells pre-treated with exosomes exhibited an increased 
ability to form lung metastases in mice and an increase in fatty acid oxidation without a 
concomitant change in glycolysis, indicating that augmentation of lipid oxidation pathways 
occurred in the absence of complete metabolic reprogramming. In further support of these 
findings, administration of the mitochondrial fatty acid oxidation inhibitors etomoxir or 
trimetazidine reversed exosome-induced enhancement of migration without affecting basal 
migration levels. Importantly, increasing adiposity in obese individuals enhanced both the 
number of exosomes released from adipocytes as well as the potency of their effect on 
melanoma cell migration. Collectively, these studies reveal important roles for adipocytes in 
regulating cancer cell metabolism, migration, and metastatic potential. 
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Adipocytes in the normal breast and breast cancer 
Mouse models have revealed that adipocytes act as local regulators of normal mammary 
epithelial cell growth and function. In fact, mammary epithelial cells require adjacent adipocytes 
during embryonic and postnatal development, as well as throughout later life stages such as 
pregnancy, lactation, and involution [174]. Indeed, using the novel FAT-ATTAC mouse, a model 
of inducible and reversible adipocyte loss developed by Scherer and colleagues, Landskroner-
Eiger et al. showed that adipocytes play crucial roles in normal growth and development of 
mammary ductal epithelium [175, 176], contributing both to ductal branching morphogenesis 
during puberty and to maintenance of normal alveolar structures in adulthood [176].  
Due to the proximity of the adipose pad to the mammary glandular organ, ductal tumor 
invasion results in interaction of breast cancer cells with adipocytes (Figures 6 & 7), with 
dramatic implications for tumor cell biology. Carter and Church reported that mature breast 
adipocytes, but not preadipocytes, increased motility of both normal and malignant breast 
epithelial cell lines through secretion of PAI-1 [177]. Similarly, higher levels of CAA-specific IL-6 
expression in human breast tumors were associated with larger tumor size and more extensive 
lymph node involvement [178]. Co-culture with adipocytes also induced mesenchymal features 
in human breast cancer cells, including repolarization of vimentin and downregulation of E-
cadherin, thereby promoting tumor cell invasion and metastasis [178]. Furthermore, adipocytes 
co-cultured with malignant breast epithelial cells exhibited the profound phenotypic changes 
associated with CAA, including delipidation and decreased expression of adipocyte markers 
[178]. Hence, bidirectional communication between adipocytes and breast tumor cells also 
alters adipocyte biology.  
For example, reminiscent of findings in melanoma [173], prostate [171], and ovarian 
cancers [170] (discussed in the Adipocytes and adipocyte-cancer interactions intro section 
above), following co-culture of breast cancer cells with adipocytes Wang et al. reported 
increased lipolysis by adipocytes and concomitantly increased fatty acid oxidation by breast 
cancer cells [172]. Importantly, the signal released by tumor cells to induce adipocyte 
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delipidation was not identified, although IL-6 and β-adrenergic stimulation – factors previously 
implicated in lipolytic induction in cancer-associated cachexia [179] – were eliminated as 
potential candidates [172]. Similar to Lazar et al. [173], Wang et al. reported that co-culture with 
adipocytes increased both in vitro invasion toward a stimulus and formation of breast cancer 
lung metastases in vivo, each of which were restored to basal levels by administration of the 
fatty acid oxidation inhibitor etomoxir [172]. In vitro etomoxir administration also reduced the 
morphological hallmarks of EMT. Remarkably, the increase in fatty acid oxidation by breast 
cancer cells appeared to be dependent on an upregulation of both adipocyte triglyceride lipase 
(ATGL) and the carnitine palmitoyltransferase 1 (CPT1) isoform CPT1A, enzymes not 
expressed at appreciable levels in noncancerous human breast epithelial cells. Short-hairpin 
(sh)RNA-mediated knockdown of CPT1A and ATGL reduced hallmarks of EMT and invasive 
potential, respectively.  
In addition to oxidizing transferred fatty acids, breast cancer cells also esterified free 
fatty acid from adipocyte lipolysis [172], incorporating the newly synthesized triglyceride into 
lipid droplets within the cancer cells themselves. Breast cancer cell lipid droplet accumulation 
was supported by both in vitro co-culture experiments employing radiolabeled palmitate and the 
observation of lipid droplet accumulation in breast cancer cells along the tumor margin in 
histological sections (i.e., in close proximity to adipocytes). Interestingly, despite increased fatty 
acid oxidation, breast cancer cells also showed reduced ATP content and activation of AMP-
activated protein kinase (AMPK). AMPK activation following co-culture with adipocytes was 
associated with increased mitochondrial biogenesis and function, indicated by increased levels 
of PGC-1α and its associated transcription factor PPARα as well as an increase in the ratio of 
mitochondrial to genomic DNA. AMPK also inhibited acetyl-CoA carboxylase, the rate limiting 
enzyme in fatty acid oxidation, ensuring uninterrupted flux of fatty acids into mitochondria. 
Furthermore, breast cancer cell fatty acid oxidation was determined to be uncoupled from ATP 
production and, unlike in melanoma [173], occurred with a concurrent increase in anaerobic 
glycolysis, consistent with activation of AMPK [172]. Collectively, these findings provide new 
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insight into mechanisms of metabolic symbiosis between adipocytes and cancer cells in breast 
tumors. 
Interactions between cancer cells and adjacent adipose may also increase breast cancer 
stem cell abundance and facilitate metastatic progression. Picon-Ruiz et al. isolated human 
adipocyte stem cells and used adipogenic differentiation media to generate “immature” 
adipocytes. Co-culture of these “immature” adipocytes with both primary breast cancer cells and 
established cancer lines conferred stem-like features to the epithelial cells, including elevated 
expression of the pluripotency markers Sox2, c-Myc, and Nanog [180]. Co-culture with 
adipocytes also increased mammosphere-forming capacity, indicating a more stem-like 
phenotype due to a greater ability to grow under non-adherent conditions. Furthermore, when 
co-cultured breast cancer lines were orthotopically injected into mouse models, the resulting 
tumors exhibited reduced latency, increased abundance of tumor-initiating cells, and an 
enhanced capacity to form distant metastases. Taken together, this study demonstrates that 
interactions between immature adipocytes and breast cancer cells drive initiation of highly 
metastatic cancers by enhancing epithelial cell tumor-initiating potential. 
Due to the practice of autologous fat grafting as a method of breast reconstruction 
(oncoplastic surgery) following breast-conserving tumor excision, the impact of adipocytes on 
tumor malignancy may be a consideration for recurrence following treatment. Indeed, using a 
model of autologous fat grafting, Massa et al. reported increased proliferation of several breast 
cancer lines co-cultured with either induced adipocytes (i.e., differentiated from fibroblasts) or 
intact adipose tissue samples obtained from liposuction patients [181]. However, a recently 
published prospective matched case-control analysis found no significant differences in 
locoregional recurrence in patients who received autologous fat grafting vs. those who did not 
[182]. Although cases and controls were matched for hormone receptor status in this study, no 
analysis was conducted to evaluate potential differences in recurrence by tumor molecular 
subtype, potentially due to the limited sample size and low locoregional event rate. However, 
based on the aforementioned complex relationships between obesity status and risk of specific 
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breast cancer subtypes, as well as the reported roles for adipocytes in regulating breast 
epithelial tumorigenicity and metastatic potential, additional studies are needed to address 
concerns regarding the potential risks associated with fat grafting in breast reconstructive 
surgery. Stratification by BMI and/or molecular tumor subtype may be necessary to fully assess 
the influence of fat grafting on breast cancer recurrence rates.  
 
Adipocytes and prostate cancer 
Bidirectional communication between adipocytes and prostate epithelial cells also 
influences prostate tumor biology, particularly with regard to chemokine activity. Chemokines, or 
chemotactic cytokines, are small secreted signaling proteins that induce directed, gradient-
driven migration (chemotaxis) in nearby cells that express the appropriate chemokine receptor. 
The functions of chemokines in malignancy depend on both tumor characteristics and the 
specific chemokine in question, but are frequently associated with leukocyte infiltration as well 
as metastatic potential and site-specific spread of tumor cells [183]. Adipose tissue-specific 
expression of many CC subfamily chemokines and their receptors is upregulated in human 
obesity [184]. For example, Laurent et al. [185] identified a CCR3/CCL7 axis regulated by 
obesity, through which secretion of CCL7 by mature periprostatic adipocytes supported the 
directed migration of prostate cancer cells, thereby promoting cell migration toward the 
periprostatic fat pad and the spread of cancer cells outside of the prostate gland. This process 
appeared to be augmented in obesity by both enhanced secretion of CCL7 by hypertrophic 
adipocytes and increased expression of the CCL7 receptor, CCR3, by prostate cancer cells 
[185].  
Adipocyte-derived CCL2 is also implicated in prostate cancer progression. Ito et al. 
reported that adipocyte-derived CCL2 directly stimulated prostate cancer cell proliferation, 
promoting invasion and migration through induction of matrix metalloprotease (MMP)-2 activity 
and ultimately leading to enhanced tumorigenesis and metastasis [186]. Importantly, increased 
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production of CCL2 by bone marrow adipocytes and other stromal cells is also strongly 
implicated in the propensity of prostate cancer cells to metastasize preferentially to bone [187, 
188]. An increase in bone marrow adipocyte content with age, obesity, and obesity-associated 
metabolic pathologies [189, 190], suggests a potential link between obesity and elevated rates 
of prostate cancer metastasis [187, 188]. 
Interestingly, prostate cancer-adipocyte crosstalk also appears to induce tumor-
promoting changes in periprostatic adipocytes. Treatment of periprostatic adipose tissue 
organotypic explants with PC3 prostate carcinoma cell-conditioned medium activated a cancer-
promoting secretory profile, including increased secretion of osteopontin, TNF-α, and IL-6, and 
reduced production of adiponectin [191]. These changes were not observed upon treatment of 
cells comprising the periprostatic adipose stromal vascular fraction (i.e., all stromal populations 
except adipocytes) with PC3 cell-conditioned medium, suggesting that the observed increase in 
pro-tumorigenic factor production by explanted tissue was due specifically to tumor-mediated 
education of adipocytes [191]. Indeed, adipocytes appear to be a major source of 
microenvironmental IL-6 in prostate cancer. Periprostatic adipose tissue harvested from patients 
undergoing radical prostatectomy secreted IL-6 at concentrations 375 times greater than that in 
patient-matched serum and correlated with histological grade [192]. Additionally, Tang et al. [83] 
recently showed that co-culture of prostate cancer cells increased production of the cysteine 
protease cathepsin B by adipocytes. Further probing revealed that adipocyte co-culture induced 
secretion of the peptide hormone cholecystokinin (CCK) by prostate cancer cells, resulting in 
establishment of an autocrine/paracrine amplification loop in which CCK, acting through the 
CCK receptor CCKBR, induced expression of cancer stem cell markers such as CD49f and 
Sca-1 in prostate cancer cells and further production of cathepsin B by adipocytes. Importantly, 
cathepsin B has been shown to facilitate prostate cancer invasion and metastasis via 
degradation of ECM and basement membrane components [193, 194]. Collectively, these 
studies demonstrate that prostate cancer cell-induced alterations in adipocyte function are 
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important mediators of tumor progression. Figure 13 briefly summarizes adipocyte-cancer cell 
crosstalk findings described above.  
 
 
 
 
Adipocytes and adipose wasting in cancer-associated cachexia 
An example of long-range adipocyte-tumor interactions can be observed in cancer-
associated cachexia (referred to hereafter as cancer cachexia or simply cachexia). Cancer 
cachexia is a fatal energy-wasting syndrome that is estimated to be the immediate cause of 
death in approximately 20-40% of end-stage cancer patients [195]. A key feature of cancer 
cachexia is white adipocyte “browning”, characterized by greatly increased levels of brown fat-
mediated thermogenesis in white adipose depots [196, 197]. Accordingly, cachectic patients 
exhibit irreversible, pathologically elevated basal energy expenditure levels, adipocyte lipolysis 
and adipose tissue wasting, rapid weight loss, and eventually, death [196-199]. Although 
prolonged systemic inflammation plays a well-established role in cachexia-associated adipose 
tissue wasting [198, 199], tumor-derived factors have also been shown to contribute to the 
Figure 13. Adipocytes promote 
tumor progression and 
metastasis. Adipocytes may 
provide metabolic substrates 
directly to cancer cells, or may 
indirectly influence cancer 
metabolism through exosome 
secretion. Adipocytes also 
secrete a variety of factors that 
promote tumor growth, EMT 
(epithelial-mesenchymal 
transition), acquisition of stem-
like features, invasive behavior, 
and metastasis. 
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pathophysiology of this syndrome. For example, in a murine model of Lewis lung carcinoma, Kir 
et al. [196] demonstrated that tumor-derived parathyroid hormone-related protein (PTHrP) 
induced the expression of thermogenesis-associated genes in adipose tissue, implying a crucial 
role for this hormone in energy expenditure and tissue wasting. Accordingly, administration of a 
PTHrP neutralizing antibody prevented cachexia-associated weight loss and ablated 
thermogenic gene expression in white and brown adipose tissue. Furthermore, compared to 
cancer patients lacking detectable levels of blood PTHrP, patients with detectable blood PTHrP 
levels exhibited significantly higher resting energy expenditure levels per kilogram of lean body 
mass, implying a clinically relevant association between this hormone and wasting.  
On the other hand, Rohm et al. [200] reported that browning and associated 
thermogenesis in major white adipose depots was not the primary mechanism of adipose tissue 
wasting in mouse models of colon cancer-induced cachexia. Although the brown adipose-
associated protein cell death activator (CIDEA) was upregulated in both brown and white 
adipose depots of cachectic mice relative to healthy controls, this upregulation occurred in the 
absence of changes in other proteins implicated in adipocyte browning and thermogenesis, 
such as uncoupling protein 1 (UCP-1). Furthermore, while increased free fatty acid release was 
observed in primary mouse adipocytes exposed to serum from cachectic mice, this increase in 
lipolysis was not associated with well-characterized lipolytic inducers such as increased 
expression of lipases (e.g., hormone-sensitive lipase and ATGL), or increased β-adrenergic 
receptor activation. Instead, CIDEA-mediated degradation of AMPK, evidenced by a reduction 
in AMPK protein and enzymatic activity, contributed to adipocyte metabolic dysfunction. For 
example, although increased lipolysis was observed, decreased AMPK activity also resulted in 
reduced inhibitory phosphorylation of acetyl-CoA carboxylase, suggesting the establishment of 
a futile cycle in adipocytes characterized by simultaneous increases in both lipolysis and 
lipogenesis. Microinjection of white adipose depots with a peptide designed to interfere with the 
AMPK-CIDEA interaction (termed AMPK–CIDEA-interfering peptide, or ACIP), followed by 
implantation of the cachexia-inducing colon cancer cell line C26, resulted in approximately 30% 
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greater retention of adipose depot mass and greater adipocyte lipid droplet size compared to 
the contralateral control-injected depot. No significant effect was observed from ACIP injection 
into adipose depots of control, non-cachectic mice, suggesting that the augmented AMPK-
CIDEA interaction and downstream influences on lipid metabolism in adipocytes may be a 
cachexia-specific phenomenon.  
These findings by Rohm et al. are particularly interesting in light of the reportedly 
opposite regulation of AMPK in breast cancer cells co-cultured with adipocytes that was 
highlighted in the previous section [172]. Also interesting to note is the lack of a role for β-
adrenergic signaling in either of these two studies [172, 200], as catecholamines are well-
established regulators of lipolysis, while lipid mobilizing factor – a tumor-derived factor 
frequently implicated in cachexia [179, 201] – also signals through beta receptors. Thus, 
although the causes of cachexia are multifactorial and systemic, it is clear that adipocyte-cancer 
cell interactions are key players in the pathophysiology of this syndrome. Future work should 
seek to identify additional tumor-derived paracrine and hormonal signals that contribute to 
cachexia pathogenesis and progression. 
 
Adipose-derived Stem Cells 
Human adipose tissue stroma is a rich source of multipotent mesenchymal stem cells, 
termed adipose stromal cells or adipose-derived stem cells (ASCs), that can differentiate toward 
the osteogenic, adipogenic, myogenic, and chondrogenic lineages [202]. Interestingly, several 
recent studies reviewed below suggest that ASC recruitment substantially contributes to stromal 
populations in both breast and prostate cancers. Due to the abundance of adipose tissue, as 
well as the minimally invasive procedures required to collect it, ASCs are a celebrated approach 
for tissue engineering and regenerative medicine. For example, lipoaspirate preparations may 
be “enriched” by the addition of ASCs to improve graft volume retention [203, 204]. However, 
the findings described below suggest that caution may be advised in use of ASCs in patients 
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with a history of cancer. Notably, factors such as age and menopausal status have been found 
to influence the proliferation and differentiation capacities of ASCs [205]. Future studies on the 
impact of age on ASC recruitment to tumors will yield interesting findings. 
 
Adipose-derived stem cells in breast cancer 
The varied stromal components of the tumor microenvironment must be recruited from 
either adjacent tissue or from distant precursor sources such as bone marrow. Kidd et al. [206] 
investigated the relative contribution of ASCs versus bone marrow-derived stem cells to stromal 
populations in mouse models of ovarian and breast cancers, and found that the majority 
(greater than 70%) of intratumoral myofibroblasts, pericytes, and endothelial cells were recruited 
from neighboring adipose tissue. However, CAF subpopulations were recruited from multiple 
distinct sources, with fibroblasts positive for fibroblast specific protein and fibroblast activation 
protein originating from bone marrow-derived mesenchymal stem cells, while α-smooth muscle 
actin+/chondroitin sulfate proteoglycan 4+ (α-SMA+/NG2+) CAFs were recruited from adjacent 
adipose. While the factors contributing to ASC recruitment to tumors are still ambiguous, 
Gehmert et al. have demonstrated that the PDGF-BB/PDGFR-β signaling pathway may be 
involved in ASC recruitment to breast cancers [207]. Together these results imply that the 
diversity of the tumor microenvironment can be attributed, at least in part, to the heterogeneous 
origin of stromal constituents.  
 Although ASCs are primarily localized to fat depots, circulating ASCs have also been 
detected in obese individuals and cancer patients, with greater levels observed in obese 
patients bearing colon, prostate, or breast cancers (relative to lean) [208-211]. Additionally, 
relative to ASCs from lean adipose, ASCs isolated from obese adipose show enhanced 
potential to traffic to breast tumors in both humans and mice [212, 213]. Similarly, Zhang et al. 
[213] recently reported hematogenous seeding of breast and ovarian tumors by ASCs in obese 
mice, resulting in infiltration and subsequent differentiation to pericytes and intratumoral 
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adipocytes/CAA. This process occurred in an obesity-dependent manner, with a 6-fold increase 
in “shedding” of precursors from adipose depots in obesity contributing to tumor cell survival and 
angiogenesis. It will be interesting to note in future studies whether specific adipose depots 
shed ASCs to the circulation at different rates. Ultimately, these findings reinforce the need to 
more comprehensively evaluate the risk of breast cancer recurrence after autologous fat 
grafting (see above), particularly in obese individuals.  
 
Adipose-derived stem cells in prostate cancer 
Similar to breast cancer, local and circulating ASCs have been reported in prostate 
cancer patients. Ribiero et al. observed higher levels of circulating ASCs in the blood of 
overweight or obese compared to lean prostate cancer patients [208]. The authors also reported 
that periprostatic adipose tissue of prostate cancer patients bore significantly higher numbers of 
ASCs than nearby visceral adipose tissue, independent of BMI. However, increased recruitment 
of ASCs into prostate tumors in obesity has been reported, and was recently attributed to 
secretion of the chemokines CXCL1 and CXCL8 by cancer cells (Figure 14) [210, 213]. CXCL8 
expression was restricted to malignant cells and was obesity-independent; on the other hand, 
secretion of CXCL1 by non-malignant epithelium was exclusively observed in histological 
sections from obese individuals, while CXCL1 expression in tumor cells was found in a 
significantly higher percentage of tumor sections from obese as compared to lean patients 
[210]. The extent to which periprostatic ASCs, as opposed to circulating ASCs released from 
other adipose depots, contribute to the cellular composition of prostate tumor stroma was not 
quantified in the highlighted studies and requires further investigation. 
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Adipose and Endothelial/Lymphendothelial cells 
Vascularization mechanisms in adipose tissue and tumors 
Expansion of adipose tissue during progression to obesity requires concomitant 
expansion of the adipose vascular bed through the process known as angiogenesis, the 
formation of new blood vessels from pre-existing vessels. In fact, administration of anti-
angiogenic agents in models of both genetic and diet-induced obesity either prevented weight 
gain [214] or induced dose-dependent, reversible weight reduction and adipose tissue loss [215, 
216]. When expansion of the vasculature does not occur in proportion to the expansion of 
adipocyte volume (hypertrophy), cellular and/or regional hypoxia develops, resulting in 
activation of the transcriptional complex hypoxia-inducible factor 1 (HIF-1) through stabilization 
of the HIF-1α subunit. HIF-1-mediated upregulation of inflammatory and pro-angiogenic 
signaling pathways in adipocytes, endothelial cells, and immune cells induces vascular growth, 
facilitating further tissue expansion [8, 217, 218]. In this way, the microenvironment during 
Figure 14. Obesity, cancer 
increase circulating ASCs. 
Human adipose tissue 
stroma is a rich source of 
multipotent ASCs, which 
enter the circulation and 
traffic to other tissues. This 
“shedding” process is 
increased in obese and/or 
tumor-bearing individuals. 
Tumor chemokine secretion 
(e.g., CXCL1, CXCL8) is 
influenced by obesity and is 
implicated in ASC 
recruitment to developing 
tumors and differentiation 
into stromal populations 
such as fibroblasts, 
pericytes, and adipocytes.   
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accumulation of adipose tissue resembles the tumor microenvironment during tumor 
vascularization, described in detail below (Figure 15). The extensive list of signaling factors 
contributing to angiogenesis in both adipose tissue and tumors includes VEGF isoforms, 
angiopoietins 1 and 2, leptin, adiponectin, TNF-α, fibroblast growth factor (FGF) isoforms, 
TGFβ, HGF, and cytokines such as IL-6 and IL-8 [158, 219, 220]. Among these, the 
VEGF/VEGFR system - one of the best characterized and most potent of the known pro-
angiogenic signaling pathways - is the main mediator of angiogenic activity in adipose tissue 
[219, 221, 222]. The VEGF-A ligand in particular is abundantly expressed by adipocytes and 
other adipose stromal populations [219, 221]. An additional shared factor of particular 
importance is angiopoietin-2, which signals through the receptor tyrosine kinase TIE2 to induce 
ECM degradation and disruption of endothelial-pericyte interactions during sprouting 
angiogenesis [223, 224]. Importantly, several of the pro-angiogenic factors listed above, 
including multiple VEGF isoforms, leptin, HGF, and angiopoietin-2, are also elevated in the 
serum of obese subjects and are implicated in systemic effects of obesity on cancer progression 
[147, 225, 226].  
Similar to adipose tissue, growth of solid tumors is also heavily dependent upon 
synchronous expansion of their vascular beds. In early stage solid tumors, rapid proliferation 
leads to diffusion limited hypoxia, wherein cells within the tumor mass end up at a distance from 
the surrounding vasculature that is beyond the diffusion limit of oxygen. Resulting hypoxia-
induced apoptosis and necrosis limit further tumor growth unless an intratumoral vascular 
system is established. The shift in developing primary or metastatic tumors from avascular to 
vascularized is termed the “angiogenic switch”, and is a discrete and requisite step for 
exponential tumor growth and progression to malignancy (Figure 15) [227-229]. Accordingly, 
tumor microvessel density is a powerful and independent prognostic indicator for several human 
cancers, including breast, prostate, melanoma, ovarian, gastric, and colon cancers [229]. 
However, in light of the myriad options for tumor vascularization described below, it is 
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interesting to note that the microvessel density in solid tumors is often lower than in their normal 
tissue counterparts [230]. 
 
 
 
New tumor vessel formation can occur through a number of non-mutually exclusive 
mechanisms, including sprouting and migration of endothelial cells (“classical” sprouting 
angiogenesis) or intussusceptive (non-sprouting) microvascular growth, a process in which 
tumor cells induce splitting and rapid remodeling of existing endothelial vessels [229]. 
Remarkably, along with endothelial cells, tumor cells themselves may integrate into newly 
forming blood vessels, resulting in mosaicism [229]. Tumor cells may also engage in a process 
known as vasculogenic mimicry, the arrangement of tumor cells into vascular channels which 
anastomose with adjacent blood vessels [229, 231, 232]. An additional mechanism for perfusion 
of tumors is vessel co-option, wherein tumor cells simply track alongside existing vessels for 
their own oxygen and nutrient gain, thereby exploiting nearby mature vessels in the host organ 
Figure 15. Hypoxia & the 
Angiogenic Switch. An extensive 
list of pro-angiogenic factors is 
involved in both induction of the 
angiogenic switch in developing 
solid tumors and expansion of 
adipose tissue during progression 
to obesity. As tumor cells proliferate 
or adipocytes hypertrophy, hypoxia 
develops and triggers stabilization 
of the HIF-1 complex, a 
transcription factor which promotes 
increased production of growth 
factors such as VEGF-A, FGF1, 
TGF-β, HGF, and angiopoietins 1 
and 2. Additional proangiogenic 
factors include the adipokines leptin 
and adiponectin; cytokines such as 
TNF-α, IL-6, and IL-8; and matrix 
metalloproteases, which degrade 
the extracellular matrix. Ultimately, 
increased vascularization alleviates 
regional hypoxia and facilitates 
further tissue expansion. 
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[229]. Given that adipose tissue is one of the most vascularized tissues in the body [164, 219], it 
is unsurprising that co-option of adipose tissue vascular beds was recently shown to promote 
accelerated tumor growth and intratumoral vascularization [233].  
Among other abnormal features, tumor vasculature is characterized by enhanced 
permeability, including transcellular holes and fenestrae, which drives further angiogenesis and 
increases nutrient and oxygen delivery, immune cell infiltration, and tumor cell extravasation 
during metastasis [234, 235]. Similar to adipose tissue, the VEGF/VEGFR system – and 
particularly VEGF-A – is highly expressed in tumors and is a potent inducer of tumor vascular 
permeability [236]. Given the extensive similarities of the pro-angiogenic signaling networks in 
adipose and tumors, it is unsurprising that the vasculature in these two tissue types is 
structurally similar. For example, adipose tissue capillaries also contain fenestrations, the 
presence of which depends upon a poorly understood synergistic relationship between VEGF, 
leptin, and FGF-2 signaling [237]. It is tempting to speculate that the fenestrations within 
adipose vasculature may provide a convenient means of escape for tumor cells invading into 
adipose tissue. 
 In addition to hematogenous metastasis, a tumor cell can also escape from its primary 
location through lymphatic dissemination. In a number of cancer types, including breast cancer, 
melanoma, and prostate cancer, metastasis to the tumor draining lymph node(s), also referred 
to as the “sentinel” lymph node(s), is a common initial route for the metastatic dissemination 
from solid tumors [238]. For this reason, sentinel lymph node biopsy in newly detected and 
early-stage cancers is a frequent and evidence-based clinical practice required for staging of 
disease, determination of prognosis, and development of the treatment approach. In a process 
similar in principle to classical sprouting angiogenesis, secreted factors in some solid tumor 
types and other inflamed tissues can also initiate lymphangiogenesis, the formation of new 
lymphatic vessels from preexisting vessels. These newly formed lymphatic vessels exhibit 
morphological differences from those in their healthy tissue counterparts, including structural 
disorganization [238]. Interestingly, tumor-associated lymphangiogenesis appears to involve 
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both incorporation of bone marrow-derived endothelial progenitors and endothelial mimicry by 
CD11b+ tumor-associated macrophages, although there are conflicting reports regarding the 
extent to which the latter occurs [239-242]. 
Although peritumoral lymphatic vessel density can act as a prognostic indicator in 
several cancer types, including cervical, colorectal, breast, and prostate cancers [243-247], 
several studies have suggested that intratumoral lymphatic vessels in solid tumors may be 
either collapsed due to intratumoral pressure, occluded by infiltrating tumor cells and therefore 
nonfunctional, or simply absent altogether [248-251]. Thus, the high frequency of cancer cell 
detection in regional lymph nodes implicates peripheral, peritumoral lymphatic vessels in 
mediating tumor metastasis in these tumor types [250, 252]. However, results showing non-
functional intratumoral lymphatic vessels have not been uniformly supported [253]. 
Consequently, the role of tumor lymphangiogenesis and the relative contribution of intratumoral 
versus peritumoral lymphatics to lymph node metastasis remains controversial.  
 
Adipose and breast cancer angiogenesis 
In vivo tumor models have demonstrated the ability of breast tumors to obtain a blood 
supply through all of the aforementioned processes: vessel co-option, intussusceptive growth, 
vasculogenic mimicry, and classical sprouting angiogenesis [254, 255]. Additional mechanisms 
have also been described for breast cancers, such as vasculogenesis and glomeruloid 
angiogenesis, albeit to a lesser extent [255]. Nevertheless, remodeling of existing vessels 
appears to be the dominant mechanism for establishing new vasculature in human breast 
cancers [256, 257]. In support of this assertion, Lim et al. [233] demonstrated that implantation 
of the E0771 murine mammary tumor line into either brown or white adipose tissue resulted in 
accelerated tumor growth rates and increased intratumoral vessel densities as compared to 
tumors grown subcutaneously. These results were attributed to co-option of pre-existing 
adipose vascular beds, as tumor growth and vascularity reflected the differential degree of 
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vascularity within the respective adipose types. Furthermore, adjacent adipose tissue fostered 
both reduced pericyte coverage and enhanced permeability in tumor vessels, features 
associated with worse prognosis.  
In obesity, both the increased abundance of white adipose and the resulting chronic 
inflammatory conditions of the microenvironment may promote tumor vascularization. Indeed, 
enhanced tumor angiogenesis in the context of obesity is observed in both mice and humans 
[45, 213, 258-260]. In one compelling study, Arendt et al. [45] developed a novel humanized 
mouse model wherein human adipose stromal populations overexpressing CCL2 were injected 
into cleared mammary fat pads (cleared of endogenous mammary epithelium) to generate an 
obese-like microenvironment. Prior to tumor formation, the authors reported enhanced 
angiogenesis in CCL2-overexpressing mammary fat pads, which was shown to be mediated by 
elevated levels of macrophage recruitment and activation. Upon transplantation of transformed 
human breast epithelial cells, the obese-like microenvironment augmented macrophage-
associated angiogenesis in early premalignant lesions as well as tumor-adjacent adipose 
following tumor formation, which induced the formation of larger and higher-grade tumors. 
Whether the observed tumor-promoting effects were due to specific macrophage phenotypes in 
“obese” vs. lean mammary adipose or simply to an increase in macrophage numbers was not 
explored. Moreover, this study did not differentiate whether increased tumor-associated 
macrophage content in obesity was due to accelerated recruitment of bone marrow-derived 
macrophages or to co-option of nearby mammary adipose tissue macrophages. Nevertheless, 
similar results were reported by Cowen et al., who demonstrated that high-fat diet-induced 
obesity in the MMTV-PyMT model of spontaneous breast cancer resulted in mammary adipose 
tissue inflammation, enhanced macrophage recruitment, and increased mammary tumor 
vascular density [44].  
As described in the previous section, obesity is also associated with elevated levels of 
circulating and infiltrating ASCs [213] which produce a range of proangiogenic factors, including 
VEGF and HGF [261]. Our lab has demonstrated that inhibition of the HGF receptor, cMET, via 
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the small molecule kinase inhibitor crizotinib significantly reduced tumor burden and tumor 
vascularity in both lean and obese C3(1)-TAg mice [262].  Reversal of high fat diet-induced 
elevation of HGF/cMET expression in both normal mammary gland and tumors was also 
observed with weight loss, which significantly blunted the effects of obesity on both pre-
neoplastic lesion formation [263] and tumor progression [264] (Figure 16). Importantly, 
endothelial cell upregulation of cMET is one mechanism attributed to inherent or acquired 
resistance to anti-angiogenic therapies targeting VEGF [265, 266]. In fact, the HGF/cMET 
pathway has been reported to act synergistically with VEGF [265, 267], and clinical trials 
investigating crizotinib alone (ClinicalTrials.gov: NCT 02101385 [268]) or in combination with 
anti-VEGF therapy (ClinicalTrials.gov: NCT 02074878 [269]) for the treatment of advanced 
TNBC are currently underway at the time of preparation of this review.     
 
 
 
However, one response to anti-angiogenic therapies is vessel pruning and regression, 
leading to intratumoral hypoxia. Such hypoxic conditions induce an influx of tumor-associated 
macrophages and other myeloid cells, triggering tumor revascularization and tumor relapse 
[270-273]. In addition, peritumoral adipose tissue is characterized by a dense macrophage 
infiltrate and a high degree of vascularization. Indeed, Wagner et al. demonstrated that 
inflamed, tumor-associated adipose tissue acts as a source of both vascular endothelium and 
Figure 16. Mammary 
HGF/cMET signaling in the in 
C3(1)-TAg mouse model of 
basal-like breast cancer. 
Obesity increased HGF 
production by stromal cells, 
promoting tumor growth and 
angiogenesis. HGF/cMET-
mediated tumor promotion was 
reversible by weight loss or 
cMET inhibition. 
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activated pro-angiogenic macrophages, thereby fueling the growth of malignant cells [259, 274]. 
Importantly, the presence of macrophages within adipose tissue increases considerably in 
obesity [275]. Thus, obesity-associated mammary adipose inflammation and resulting 
macrophage infiltration and angiogenesis may contribute to tumor relapse following anti-
angiogenic therapies. 
 
Adipose tissue and lymphangiogenesis in breast and prostate cancers 
Lymphatic vessels in the normal breast are dispersed throughout the interlobular stroma 
and adipose tissue [249], the latter of which acts a source of molecules that directly affect the 
lymphatic endothelium. For example, the lymphangiogenic factors VEGF-C and VEGF-D are 
chemotactic for macrophages in mice, and their blockade in a diet-induced obesity model 
attenuated macrophage infiltration, adipose tissue inflammation, and onset of insulin resistance 
[276]. An increase in circulating levels of pro-lymphangiogenic factors such as HGF and VEGF-
C in obesity may also alter lymphatic vessel density or function by enhancing capillary 
permeability and inducing lymphendothelial hyperplasia [226, 277]. Indeed, obesity is 
associated with dysfunction of the adipose lymphatic system, including decreased lymph node 
size and number [278], reduced drainage of macromolecules [279], increased perilymphatic 
inflammation [280], and altered lymph node immune cell composition [278]. These changes 
were recently attributed to the condition of obesity per se – specifically injury to lymphatic 
endothelial cells caused by inflamed adipose tissue – rather than the high fat diet used to 
generate the obese phenotype [281]. Interestingly, using a model of Prox1 haploinsufficiency, 
Harvey et al. demonstrated that lymphatic vascular defects and resulting abnormal lymph 
leakage into surrounding tissues induced adult-onset obesity [282]. A follow-up study by 
Escobedo, et al. further reported that the obese mutant phenotype of Prox1+/- mice could be 
rescued with tissue-specific restoration of Prox1 in lymphatic endothelial cells [283]. Whether 
lymphatic vessel density is altered in peritumoral adipose, either normal or obese, has not been 
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reported. However, Yamaguchi et al. observed a >3-fold increase in lymph node metastasis with 
adipose tissue invasion at the tumor margin in patients with invasive breast carcinoma [36]. 
The role of adipose tissue in prostate carcinoma angiogenesis and lymphangiogenesis is 
not well understood. However, as mentioned previously, ASCs are abundant in periprostatic 
adipose tissue [208] and are a source of lymphangiogenic factors [284]. Indeed, implantation of 
ASCs has been used successfully in mice to induce lymphangiogenesis in a model of 
lymphedema [285, 286]. Importantly, obesity may influence the degree of pro-
angiogenic/lymphangiogenic factors released from the periprostatic adipose depot. 
Venkatasubramanian et al. reported that conditioned media generated via explant culture of 
human obese periprostatic adipose stimulated prostate cancer cell proliferation and 
angiogenesis to a significantly greater degree than explants from lean patients, providing a 
potential link between obesity and worse prostate cancer prognosis [287]. Paradoxically, 
elevated leptin concentration in obese mouse models is associated with attenuated tumor cell 
proliferation and reduced angiogenesis and lymphangiogenesis in prostate cancers in vivo [288, 
289]. Furthermore, rate of lymph node metastasis in patients with clinically localized prostate 
cancer does not appear to be altered by obesity [290]. Thus, there are lingering questions 
surrounding the role of periprostatic adipose tissue in prostate tumor progression in both lean 
and obese individuals, particularly with regard to its influence on tumor angiogenesis.  
 
Adipose Tissue Immune Populations in Cancer Development and Progression 
Acute inflammatory responses, such as those that occur in the context of pathogen 
infections, are usually self-limiting and are characterized by an “acute inflammatory infiltrate” 
consisting primarily of neutrophils and sometimes eosinophils [291]. However, when triggering 
factors persist or inflammatory resolution mechanisms fail, a shift occurs in the immune profile 
to a “chronic inflammatory infiltrate”, predominantly comprised of lymphocytes and mononuclear 
cells such as macrophages and dendritic cells. Chronic inflammation is consistently associated 
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with increased risk of carcinogenesis and is a well-known hallmark of cancer [291, 292], leading 
Dvorak to describe tumors as “wounds that do not heal” [107]. Solid tumors frequently contain a 
dense infiltrate of immune cells, including lymphocytes, neutrophils, macrophages and mast 
cells, each of which directly or indirectly influence the course of tumor progression. In fact, many 
of the changes that occur in the tumor microenvironment are orchestrated by immune cells 
[293-295]. Chronic inflammation is also highly prevalent in obesity, and as discussed in previous 
sections, plays pivotal roles in adipose tissue (lymph)angiogenesis and development of fibrosis. 
Thus, the final section of this review will focus on adipose tissue immune populations. We will 
emphasize the changing immune profile during adipose accumulation and progression to 
obesity and the potential impact of these alterations on adipose-adjacent tumor progression. 
However, it should be noted that the immune profile of adipose tissue depends upon both the 
degree and the duration of adiposity, as well as a variety of other factors that are beyond the 
scope of this review, including physical activity, dietary intake, the microbiome, and certain 
therapeutics such as thiazolidinediones [296].  
Healthy adipose tissue contains a wide variety of innate and adaptive immune cells, 
including macrophages, dendritic cells, mast cells, eosinophils, neutrophils, and lymphocytes, 
which collectively constitute ~25-45% of stromal cells in humans [12]. In lean adipose, these 
“resident” immune cells maintain tissue homeostasis by clearing apoptotic cells, suppressing 
inflammation, and mediating basal ECM remodeling and angiogenesis in response to routine 
fluxes in caloric availability [114]. However, during progression to obesity, rapid expansion of 
adipose tissue and associated adipocyte dysfunction trigger a dynamic infiltration of innate and 
adaptive immune populations (Figure 17). These immune cells act as potent sources of 
inflammatory cytokines, chemokines, growth factors, and matrix-degrading enzymes such as 
MMPs, which rapidly remodel the tissue microenvironment and result in chronic low-grade, or 
“smoldering”, inflammation [88]. A decrease in relative influence of select adipose resident 
populations known for their anti-inflammatory action (e.g., immunosuppressive macrophages, 
eosinophils, regulatory T cells, and innate lymphoid cells [ILC2s]) may further exacerbate 
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adipose inflammation in obesity and associated sequelae, thereby indirectly mediating 
differential immune responses during tumor-adipose interactions in lean vs. obese individuals.  
 
 
Figure 17. Summary of changes in immune cell profile during progression to obesity.  In the lean 
state, adipose tissue contains a variety of immunoregulatory cells such as M2-like tissue-resident 
macrophages, regulatory T cells, and eosinophils.  Neutrophils infiltrate adipose within days of exposure to 
an obesogenic diet. Over weeks to months, an increase in CD8+ T cells, macrophages, and myeloid-
derived suppressor cells (MDSCs) results in a mix of pro- and anti-inflammatory cells. In prolonged obesity, 
adipose mast cell content may also increase. 
 
Despite a surge in research over the past 15 years on the roles of immune cells in 
adipose tissue biology, many fundamental lines of investigation remain incompletely 
understood. For example, a growing understanding of the complexity of innate lymphocyte 
subsets and their remarkable parallels with adaptive lymphocyte subsets [297] complicates 
interpretation of innate vs. adaptive influence. In addition, data regarding roles for select 
immune cell types, such as basophils, in adipose tissue remain in short supply. Notably, while 
comparing the immune response to tumor growth in lean and obese individuals many studies 
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have failed to take into account co-morbidities associated with obesity which may alter the 
immunometabolic milieu. For example, type II diabetes is a metabolic condition in which insulin 
resistance, often due to prolonged obesity and associated inflammation, results in 
hyperinsulinemia, hyperglycemia, and dyslipidemia. In addition to elevating risk of both cancer 
development and cancer mortality in several solid tumor types [298, 299], metabolic 
dysregulation in type II diabetics shifts availability of metabolic substrates such as glucose and 
fatty acids, which can alter immune cell number and behavior [300-302]. Furthermore, 
medications prescribed for glucose control in type II diabetics, such as metformin, may have 
profound and confounding effects on anti-tumor immunity through suppression of inflammation 
in macrophages [303] or augmentation of the cytotoxic T cell response [304].  
With these caveats acknowledged, the increased presence of adipose inflammatory cells 
in obesity may provide a link between adipose tissue and the pathophysiology of adipose-
associated cancers. Thus, when considering the effects of adipose tissue on cancer 
development, the potential for cross-talk between adipose immune populations and the 
developing tumor is paramount. Due to a current dearth of literature addressing immune 
populations in periprostatic adipose, the structure for this final section of our review will diverge 
from the format above, which emphasized breast and prostate adipose pads individually, and 
instead focus more generally on literature regarding immune populations in a variety of adipose 
depots.  
T cells in Adipose and Cancer  
T cell diversity in the tumor microenvironment 
T lymphocytes, or T cells, are central to cell-mediated immune responses and mediate 
exquisitely specific adaptive immune defenses within a given disease context, including cancer. 
Broadly speaking, T cells can be classified into CD4+ helper T (Th) and CD8+ cytotoxic T (Tc) 
cell subsets. CD4+ Th cells can be further subdivided into pro-inflammatory effector Th1 cells or 
immunoregulatory Th2 cells, which influence both generation and activity of CD8+ Tc cells and 
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antigen-presenting cells (APCs), such as macrophages and dendritic cells, within the tumor 
microenvironment. Other T cell subsets include Th17 cells, γδT cells, and certain types of 
natural killer (NK) cells, the latter of which exhibit cytotoxic activity and play a role in antitumor 
immune defense. While each of these T cell subsets, along with other, less well-characterized 
populations, influence both tumor progression and adipose immunity [305, 306], a 
comprehensive review of T cell function in these contexts is beyond the scope of this review. 
However, several of the most well characterized subsets will be addressed below, with 
particular emphasis on how adiposity-associated alterations in CD8+ T cells and a subset of 
CD4+ T cells termed “classical T regulatory cells”, or Tregs, may contribute to cancer 
development in obese individuals.  
CD8+ Tc cells and CD4+ Tregs generally exhibit opposing immunologic functions in both 
the tumor microenvironment and normal tissues. CD8+ Tc cells are a critical component of 
antitumor immune defense, directly killing tumor cells through release of cytotoxic granules 
containing perforin and granzyme B, and indirectly promoting tumor rejection by stimulating 
APC activity. On the other hand, Tregs are a subset of CD4+ T cells identified by expression of 
the cell surface markers CD4 and CD25 and the transcription factor forkhead box P3 (FOXP3), 
which acts as the master regulator of the Treg phenotype [307, 308]. Tregs directly regulate the 
activity of other T cells through suppression of CD8+ Tc cell proliferation following T cell 
receptor (TCR) stimulation and activation of immune checkpoint pathways, which provide a 
critical defense against T cell-mediated responses to self-antigens (autoimmunity). Specifically, 
in T cells, the amplitude and duration of TCR-mediated immune responses are determined by 
immune checkpoint proteins, which exert co-stimulatory and/or inhibitory signals to effectively 
“tune” the immune response and curtail collateral tissue damage. For example, FOXP3-
mediated constitutive expression of the immune checkpoint protein CTLA4 by Tregs inhibits 
development of self-reactive CD8+ Tc cells in secondary lymphoid organs such as lymph nodes 
[309]. In peripheral tissue, including tumors, expression of the inhibitory checkpoint protein 
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Programmed Death-1 (PD-1) by “exhausted” or chronically activated T cells impairs cell-
mediated responses. Binding of ligands to the PD-1 receptor triggers T cell senescence, 
apoptosis, or conversion to a Treg phenotype [310, 311], thereby attenuating cell-mediated 
immune responses [312]. Additionally, Tregs potently suppress the function of other immune 
cells such as APCs, NK cells, and CD8+ Tc cells through production of cytokines including IL-10 
and TGF-β [305, 306, 312]. While these immune-regulatory functions provide a critical defense 
against rampant immune responses, by suppressing immunosurveillance and promoting 
immune tolerance in the tumor microenvironment Tregs actively prevent robust elimination of 
developing cancers. Accordingly, the density of Tregs in solid tumors is correlated with adverse 
clinical outcomes in melanoma, as well as ovarian, gastric, pancreatic, hepatic, breast, and 
prostate cancers [313-315]. 
 
Differential T cell content and activation in lean and obese adipose tissue: links to cancer 
In addition to their well-established roles in the tumor microenvironment, Tregs have also 
recently been shown to contribute to the maintenance of adipose tissue metabolic homeostasis. 
Feuerer et al. [316] demonstrated that nearly half of the CD4+ T cells in lean visceral adipose of 
male mice expressed FOXP3. In fact, visceral adipose in 30-week old mice contained a greater 
abundance of Tregs than lymphoid tissues such as spleen and lymph nodes. Interestingly, 
these adipose-resident Tregs were frequently detected in CLS, which are typically associated 
with inflammatory cells. Expression profiling of isolated adipose Tregs revealed a gene 
signature distinct from that of “conventional” T cells from spleen and lymph nodes. Divergent 
transcription patterns in adipose Tregs included a relative increase in chemokines involved in 
leukocyte migration and extravasation and greatly elevated IL-10 expression (>100-fold) as 
compared to lymph node Tregs. Adipose-resident Tregs also exhibited limited TCR diversity 
relative to spleen or lymph node Tregs [316]. Similarly, Yang et al. reported that adipose T cells 
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displayed a TCR profile distinct from that of splenic T cells, further demonstrating that depot-
specific microenvironments modulate lymphocyte phenotypes [317].  
Feuerer et al. [316] also noted that the presence of Tregs in visceral adipose declined 
with increasing adiposity in three mouse models of obesity, although the abundance of lymphoid 
tissue Tregs was unaffected. Subsequent mechanistic studies employing Treg stimulation and 
depletion suggested that IL-10 secretion by Tregs dampens inflammation in adipose tissue, 
thereby safeguarding insulin sensitivity. A second study published the same year by Nishimura 
et al. [318] also reported a decrease in Treg content in obese murine visceral adipose, with a 
simultaneous and substantial increase in the presence of CD8+ Tc cells displaying markers of 
activated effector T cells. Of note, in obese mice the accumulation of CD8+ Tc cells preceded 
macrophage infiltration by 3-4 weeks, indicating that T cells may affect microenvironmental 
changes enabling macrophage recruitment (Figure 17). An increase in CD8+ Tc cells, 
particularly within CLS, was also observed in subcutaneous adipose. Genetic or antibody-
mediated depletion of CD8+ Tc cells during the course of high-fat feeding attenuated the onset 
of insulin resistance, prevented macrophage infiltration, and blunted obesity-associated 
increases in TNF-α and IL-6 expression in whole adipose tissue; these phenotypes were 
“rescued” upon reintroduction of CD8+ Tc cells via adoptive transfer. Similarly, CD8+ T cell 
depletion in established obesity reduced the presence of pro-inflammatory macrophages and 
CLS density in adipose tissue. These findings were confirmed in vitro, as co-culture of CD8+ T 
cells from obese adipose with macrophages induced significantly greater macrophage-specific 
TNF-α expression than did CD8+ T cells from lean adipose. In sum, these studies illustrate that 
reduced Treg content and increased CD8+ T cell presence promote macrophage-specific 
expression of pro-inflammatory mediators, thereby contributing to adipose inflammation and 
metabolic dysfunction in obesity, both of which are drivers of tumor malignancy. 
However, the nature of these reported shifts in T lymphocyte profiles of obese murine 
adipose has not been consistent in human studies. In fact, the opposite has been observed. In 
obese adults, the expression of Treg activation markers and Treg cytokines increased with 
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increasing adiposity, particularly in subcutaneous as compared to visceral adipose [319, 320]. 
One potential explanation for these observed increases in Treg activation relates to increased 
local estrogen concentration in adipose tissue of obese subjects. Indeed, Subbaramaiah et al. 
provided evidence that elevated cyclooxygenase-2 (COX-2)-induced prostaglandin E2 (PGE2) 
production by CLS-associated inflammatory cells mediates increased risk of breast cancer in 
obesity by inducing activity of aromatase in mammary adipose tissue [321, 322]. Increased 
aromatase activity in adipose tissue increases the conversion of circulating androgens to 
estrogens, and thus is of particular concern for development of estrogen receptor-positive 
breast cancers in postmenopausal women, a population in which obesity is strongly linked to 
elevated risk of cancer [323, 324]. Estrogen also exerts a positive effect on both expansion of 
Tregs and augmentation of their immunosuppressive activities [325, 326]. Elevated PGE2 also 
induces FOXP3 expression and Treg function [327-329]. Paradoxically, however, elevated 
aromatase and PGE2 levels are also present in adipose of obese mice. Thus, the significance of 
interspecies differences in obesity-associated Treg abundance and/or activation is unclear.  
Interspecies differences in T cell content are not exclusive to Tregs. For example, 
although increases in Tc and Th1 cell content are frequently reported in murine models of 
obesity, the prevalence of these cell types in obese human adipose is controversial. Indeed, 
while Yang et al. reported that the stromal-vascular fraction of abdominal subcutaneous adipose 
from obese human subjects displayed an increased percentage of both CD4+ and CD8+ T cells 
compared to lean individuals [317], two additional studies profiling T cells in obese human 
adipose did not reach the same conclusions [319, 320]. Accordingly, although CD8+ T cells 
appear to contribute to adipose inflammation in mice, their role in human obese adipose 
remains ambiguous. Furthermore, in addition to identifying potentially critical cross-species 
differences in adipose T cell function, these results also suggest that, in humans, an increase in 
pro-inflammatory cell abundance in adipose occurs with a parallel protective response driven by 
Tregs. Should this be the case, an elevated presence of Tregs in human obese adipose may 
contribute to immunosuppression of anti-tumor responses in adipose-adjacent cancers.  
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In addition to influencing Treg-mediated immunosuppression, obesity may also impair T 
cell-mediated antitumor responses through systemic mechanisms. For example, obesity 
reportedly accelerates age-associated declines in immune function, including thymic atrophy. 
The thymus is a specialized primary lymphoid organ located in the mediastinum that houses 
maturing T lymphocytes. Beginning at puberty, the thymus undergoes involution, or atrophy, 
exhibiting fibrotic and fatty changes that culminate in its replacement by adipose tissue [330]. 
Following thymic involution, the peripheral T cell pool is primarily maintained independently of 
thymic lymphopoiesis, such as by expansion of existing T cell populations; however, it should be 
noted that some studies in humans have reported that the aged thymus retains a limited 
capacity to produce naïve T cells [331]. Eventually, the age-related decline in naïve T cell 
production, in combination with steady exposure to antigenic challenge and resulting expansion 
of effector-memory T cells, depletes the naïve T cell pool and reduces diversity of the TCR 
repertoire [332]. Thus, these processes reduce the capability of the adaptive immune system to 
respond to new antigenic challenges, increasing susceptibility to infection, autoimmune 
responses, and cancer. Importantly, Yang et al. [333] reported that prolonged obesity in mice 
increased perithymic adipose tissue content, reduced thymocyte counts, and enhanced 
thymocyte apoptosis relative to lean animals, each of which are associated with thymic aging. 
Similarly, increased frequencies of CD4+ and CD8+ effector-memory cells in subcutaneous 
adipose of obese mice, concomitant with a notable decrease in TCR diversity and depletion of 
the CD4+ and CD8+ naïve T cell pools, further supported an acceleration of the immune aging 
process. Moreover, splenic T cells isolated from obese mice exhibited reduced expression of 
pro-inflammatory mediators important for antitumor immune defenses, including interferon-γ and 
TNF-α. Finally, in humans, analysis of mature thymus-derived T cells demonstrated that 
increasing adiposity significantly correlated with a reduction in thymic output in overweight and 
obese middle-aged subjects. These obesity-related restrictions in TCR diversity and T cell 
function may account for reports of impaired adaptive immunity in obese patients [334, 335] and 
suggests a reduced capacity to mount an effective antitumor immune response. 
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Finally, recent clinical successes with tumor immunotherapies targeting the PD-1 
immune checkpoint pathway have increased interest in the regulation of this pathway in the 
context of obesity. As described above, PD-1 expression by T cells is an important driver of 
immunosuppression and reduced cytotoxic T cell response in the tumor microenvironment 
[336], prompting development of PD-1-targeting monoclonal antibodies (e.g., pembrolizumab 
and nivolumab) for clinical use. Recently, Shirakawa et al. reported B cell-dependent 
accumulation of CD4+ T cells constitutively expressing PD-1 within visceral adipose of obese 
mice and human omental adipose from obese patients [337], further suggesting that tumor-
adjacent adipose in obese individuals may present an immunosuppressive environment. In light 
of the accelerated thymic aging and naïve T cell depletion reported in obese patients, it will be 
interesting to see whether adipose contributes to increased PD-1+ T-cell content in the solid 
tumor microenvironment. 
 
Macrophages and myeloid-derived suppressor cells 
Macrophage ontogeny and activation   
Macrophages, or “big eaters”, are myeloid-lineage immune cells typically classified 
within the innate immune system, yet they bridge innate and adaptive immunity through 
extensive interactions with adaptive immune cells such as T cells. Conventionally, macrophages 
have been classified according to the “M1/M2” dichotomy, wherein “M1” polarized, or 
“classically-activated”, macrophages are pro-inflammatory, and “M2” polarized, or “alternatively-
activated”, macrophages are anti-inflammatory. M1 macrophages are generated in vitro upon 
exposure to Th1 cytokines (e.g., IFN-γ) or stimuli such as bacteria and lipids [338-340]. In 
contrast, M2 macrophages are most commonly generated by culture in the presence of Th2 
cytokines such as IL-4 and/or IL-13 [341]. However, a variety of other compounds may also be 
used for M2 macrophage polarization, including TGF-β, IL-10, glucocorticoid hormones, M-CSF, 
and PGE2 [342].  
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Figure 18.  Macrophage activation as a spectrum. Unstimulated macrophages can be polarized in vitro 
to generate M1 macrophages (right) or M2 macrophages (left) using single cytokines or cytokine and other 
stimuli cocktails. However, tissue macrophages are exquisitely plastic, often expressing one or more 
markers of both M1 and M2 subtypes. Thus, tissue macrophage activation lies along a spectrum, resulting 
in mixed phenotype with specific expression and function varying by tissue type and timing of residence. 
 
Importantly, a lack of standardized nomenclature and macrophage polarization strategy 
[343], coupled with the multifarious nature of tissue macrophages and their exquisite ability to 
respond to context-dependent cues [344], has resulted in a tremendous influx of literature about 
the respective roles of M1 vs M2 macrophage subsets in disease that is often contradictory and 
difficult to reconcile [345]. Furthermore, while much of our understanding of the M1 and M2 
phenotypes have come from animal and in vitro studies, genomic profiling of human and mouse 
macrophages treated with M1 or M2 stimuli revealed that only approximately 50% of 
macrophage polarization markers are shared across both species [346]. With these caveats 
acknowledged, despite their utility to in vitro research, truly polarized macrophages are rare in 
vivo. Instead, tissue macrophages display a diverse array of functional phenotypes and often 
express one or more markers of both M1 and M2 subtypes, resulting in a mixed phenotype with 
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specific expression and function varying by tissue type and timing of residence, as discussed 
below (Figure 18) [347-350]. 
Over the past few decades, macrophage ontogeny studies have revealed multiple 
origins for what are now referred to as “tissue resident” macrophage populations (for two 
excellent reviews on macrophage ontogeny the reader is referred to [348, 351]). During primitive 
hematopoiesis in early embryonic development, macrophages arise in the blood islands of the 
yolk sac from an erythromyeloid precursor, differentiating to macrophages without passing 
through a monocyte stage [352, 353]. These early embryonic macrophages are followed by a 
second wave derived from fetal monocytes and originating in the fetal liver [352, 353]. 
Collectively, macrophages within these waves of early hematopoiesis populate tissues 
throughout the body and develop specialized functions based on their tissue of residence (e.g., 
microglia in the brain, Kupffer cells of the liver, etc.) [348, 351]. Tissue-resident macrophages 
persist through adulthood and, in most tissues, self-maintain through local proliferation without 
significant contribution from circulating monocytes (exceptions include the intestine and the 
dermis) [354, 355]. Only in later stages of embryonic development and postnatally do 
macrophages develop from bone marrow-derived circulating monocytes, which are recruited to 
tissues as needed when insults arise.  
Although the embryonic origin of many specialized tissue macrophage populations has 
been identified, the precise origin of adipose tissue macrophages (ATMs), and the degree to 
which resident ATM populations are replaced by circulating monocytes, remains unclear 
(Figure 19). In one recent study, Franklin et al. demonstrated that ablation of the CCL2 
receptor, CCR2, significantly reduced mammary fat pad macrophage content in lean mice [356]; 
CCL2 mediates egress of monocytes from bone marrow and thereby augments the abundance 
of circulating monocytes [357]. This study by Franklin and colleagues therefore suggests that 
mammary-specific ATMs in lean mice are replenished throughout adulthood by circulating 
monocytes. Whether this replenishment also occurs in other lean adipose depots under 
physiologic conditions has not been reported.  
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Figure 19.  Adipose tissue macrophage ontogeny. Lineage tracing studies have revealed multiple 
embryonic sources for tissue-resident macrophages (e.g., Kupffer cells, microglia) including the yolk sac 
and fetal liver. However, the contribution of bone marrow monocyte-derived macrophages to tissue-resident 
populations remains ambiguous. Moreover, the relative contribution of yolk sac, fetal liver, and bone 
marrow-derived macrophages within adipose tissue depots has not been established, although the overall 
proportion of inflammatory, bone-marrow derived macrophages increases in obese adipose. 
 
Macrophage content and phenotypes in obesity 
Macrophages are the most highly represented immune cells in adipose tissue, and their 
numbers increase considerably in both visceral and subcutaneous adipose in obesity. However, 
the increased presence of ATMs in obesity appears to arise from multiple tissue sources. For 
example, using bone marrow transplant studies employing CD45.2-expressing recipient mice 
and syngeneic CD45.1-expressing donor mice, Weisberg et al. reported that adipose-infiltrating 
macrophages in obesity had differentiated from bone marrow-derived, circulating monocytes 
[275]. However, Amano et al. demonstrated that elevated CCL2 in visceral adipose drove local 
proliferation of macrophages in obesity, which contributed to ATM accumulation [358]. Local 
ATM proliferation was also observed by Hasse et al., with live imaging of adipose explants 
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showing that macrophages expressing M2-identifying markers underwent mitosis within CLS, 
followed by migration to interstitial spaces between adipocytes [359]. Moreover, in vivo 
proliferation in a subset of bone marrow-derived macrophages has also been described, a 
surprising finding as bone marrow-derived macrophages were long believed to be terminally 
differentiated and thus non-proliferative [360]. Importantly, however, recruitment of bone 
marrow-derived macrophages and local ATM proliferation need not be mutually exclusive, and 
future studies should examine obese ATM ontogeny in a longitudinal fashion.   
Regardless of their tissue of origin, the increased presence of macrophages in obese 
adipose tissue can be best observed histologically as an increase in CLS formation. Indeed, 
Weisberg et al. demonstrated that macrophage influx and CLS formation in both mice and 
humans were significantly correlated with both adipocyte diameter and BMI [275]. Time course 
studies probing the changing immune profile in obesity report that this macrophage 
accumulation occurs subsequent to neutrophil and T cell infiltration [318, 361]. However, there 
is variability in both the reported timing of macrophage influx and the degree of infiltration across 
adipose depots. For example, Elgazar-Carmen et al. observed an increase in CLS formation in 
murine visceral adipose tissue as early as 3 weeks into high fat feeding, which increased in 
density over time until the study endpoint at 16 weeks of diet exposure [361]. On the other hand, 
Nishimura et al. reported that the presence of macrophages in the stromal-vascular fraction of 
visceral adipose tissue did not increase until 10-12 weeks of high-fat feeding [318]. These 
temporal differences may be due to variation in the age at which obesity was induced and the 
dietary composition used to generate adiposity (i.e., both the percent kilocalories obtained from 
lipids as well as the lipid profile), as each are important considerations in diet-induced obesity 
studies. Nevertheless, although the initial timing of macrophage infiltration varies across studies, 
macrophage accumulation continues with prolonged obesity, with ATMs eventually comprising 
up to 50% of adipose stromal-vascular cells [275, 362-364]. Due to sexual dimorphism in mice 
with regard to degree of adiposity in response to high-fat feeding, as well as differential 
contribution of adipose depots to obesity-associated metabolic dysregulation, many obesity 
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studies have preferentially quantified changes in macrophage content in abdominal adipose 
depots of male mice (i.e., inguinal and periepididymal). However, we and others have also 
demonstrated obesity-associated CLS formation in the mammary fat pad of female mice, as well 
as human breast adipose tissue [321, 322, 365, 366].  
As mentioned in previous sections of this review, obese adipose tissue frequently 
exhibits elevated levels of pro-inflammatory cytokines such as TNF-α and IL-6. Although obese 
adipocytes have been shown to contribute to the secretion of these factors [367], macrophages 
and other stromal-vascular cells are thought to be the primary source of pro-inflammatory 
mediators in both mice [275] and humans [368, 369].  Following initial reports of adipose 
macrophage influx in 2003 [275, 364], early characterization of ATMs reported the appearance 
of a CD11c-expressing population of ATMs in adipose tissue of obese, but not lean, mice [370, 
371], as well as a phenotypic switch in the collective ATM population from an anti-inflammatory 
(M2) polarized state in lean animals to a pro-inflammatory (M1) state in obese animals [370]. 
Importantly, however, more recent research indicates that the nature of ATM phenotypes in 
obesity is more dynamic and complex than originally expected. For example, the pro-
inflammatory phenotype of CD11c-expressing ATMs appears to be malleable and may be 
modulated by degree of insulin sensitivity in obese animals [372]. In addition, more extensive 
profiling of ATMs in obese adipose of mice and humans has revealed that these cells harbor a 
“mixed” pro- and anti-inflammatory phenotype [373, 374]. For example, in human abdominal 
subcutaneous adipose, ATMs accumulating in CLS expressed both CD11c and the commonly 
used M2 marker mannose receptor C type 1 (CD206), as well as both pro- and anti-
inflammatory interleukins (IL-1β, IL-6, IL-8, and IL-10) [375]. These results are further supported 
by Nakajima et al., who reported accumulation of ATMs expressing both CD11c and CD163, the 
latter of which is commonly associated with M2-like macrophages, in abdominal visceral and 
subcutaneous adipose of obese subjects [376]. Shaul et al. [373] also described a mixed M1/M2 
phenotype in obese murine CD11c+ visceral ATMs, suggesting phenotypic and functional 
similarities between murine and human ATMs in obesity. Interestingly, in the latter study, these 
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mixed phenotype ATMs exhibited a shift toward a more M2-like transcriptional profile as obesity 
progressed.  
Due to the phenotypic overlap between ATMs and canonical M1- and M2-polarized 
macrophages, the precise stimuli that activate ATMs, as well as the specific surface marker 
profile of this cell population, have only recently been described. Using a membrane proteomics 
approach, Kratz et al. [377] described a unique, ‘‘metabolically-activated’’ phenotype in visceral 
ATMs from obese mice, which displayed surface markers distinct from those of classically-
activated macrophages generated in vitro. When these metabolically-activated ATMs were 
recapitulated in vitro by exposure to conditions characteristic of the metabolic syndrome (high 
glucose, insulin, and palmitate), they were further found to exhibit increased surface expression 
of M2-associated lipid metabolizing proteins, but not other M2-defining markers. Metabolically-
activated ATMs also exhibited increased PPARγ activation, as well as a strong and selective 
induction of protein sequestome-1/p62, a scaffold protein with a variety of signaling roles 
including activation of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) [377, 378]. Importantly, PPARγ is a transcription factor crucial in the 
generation of the M2-like macrophage phenotype, while the NF-κB transcription factor family 
mediates several aspects of the M1 inflammatory response. Moreover, ablation of PPARγ or 
p62 in metabolically activated macrophages increased expression of several pro-inflammatory 
mediators, indicating that PPARγ and/or p62 attenuate pro-inflammatory responses in ATMs in 
obesity [377]. Moreover, Ferrante and colleagues [379] observed elevated lysosome biogenesis 
and lipid metabolism in visceral adipose ATMs from obese mice relative to lean, without 
concomitant activation of inflammatory pathways. In fact, the authors suggested that the driving 
force for the chronic low-grade inflammation observed in obesity may simply be due to the 
increased density of macrophages in obese adipose, rather than a shift in the inflammatory 
potential of individual macrophages. Thus, questions remain regarding our understanding of 
ATM phenotype and degree of plasticity within adipose tissue.   
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Adipose tissue macrophages: connections to cancer 
Increased ATM content in obesity suggests a clear inflammatory link between obese 
adipose and initiation of adipose-adjacent cancers. For example, as mentioned previously, 
macrophage infiltration into obese breast adipose tissue and resulting inflammation are linked to 
increased risk of mammary carcinogenesis [321, 322]. Additionally, in various sections of this 
review we have addressed roles for ATMs in development of adipose tissue fibrosis [88, 97], 
which may influence early stages of tumor initiation. Macrophages are also highly represented 
within the body and margins of many solid tumor types, and directly promote progression of 
both early and established tumors [380, 381]. Indeed, macrophages are implicated in every 
aspect of tumor progression, including induction of the angiogenic switch [382]; generation of an 
immunosuppressive environment [342]; ECM degradation to facilitate invasion and migration of 
tumor cells into surrounding tissue; and physical participation in tumor cell metastasis [380, 
383]. Macrophages have also been shown to negatively influence response to anticancer 
therapies in breast and prostate cancers [384-388]. Accordingly, in human breast tumors, 
degree of macrophage infiltration is an independent prognostic indicator strongly associated 
with high vascular grade, reduced relapse-free survival, and decreased overall survival [258, 
380, 389].  
Differences in phenotype and trophic potential between embryonic-resident, locally-
proliferating, and bone marrow-derived ATM populations may influence tumor development and 
ATM participation in the tumor microenvironment. Collectively, macrophages found both along 
the solid tumor periphery and within the tumor mass are referred to as tumor-associated 
macrophages (TAMs). Studies investigating the origins of TAMs in mice have reported that 
circulating bone marrow-derived monocytes are the primary source of TAMs in syngeneically 
grafted [390] and spontaneously arising mammary tumors [356], as well as in breast cancer 
pulmonary metastases [391]. Furthermore, Franklin et al. reported that monocyte-derived TAMs 
in the MMTV-PyMT mouse model of spontaneous breast cancer proliferate within the tumor site 
and are phenotypically and functionally distinct from the resident mammary tissue macrophages 
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present before tumor development [356]. Together these observations argue against 
recruitment of local tissue-resident macrophage populations. However, studies probing TAM 
ontogeny have investigated this question exclusively in lean animals. The term “tissue-resident 
macrophages” is often used to refer to embryonic macrophages but may also refer to any 
macrophages residing in a given tissue before an insult induces recruitment of bone marrow-
derived inflammatory monocytes. Both expansion of adipose tissue in obesity and the presence 
of a developing tumor act as inflammatory insults; thus, the marked increase in ATM content in 
obesity, as well as their variable tissues of origin and distinct phenotypic differences from 
macrophages in lean adipose, requires an evaluation of the ATM-TAM relationship in the 
context of obesity. 
 
Similarities between adipose tissue macrophages and tumor-associated macrophages 
In a similar vein to ATMs, discrepancies exist between reports of the defining “TAM 
phenotype”. Conventionally, TAMs have been described as resembling alternatively-activated 
M2 macrophages [342, 392, 393]. However, large-scale transcriptome analyses of TAMs in 
breast cancer suggest that TAMs collectively exhibit a mixed phenotype, expressing both M1-
like and M2-like markers [394]. Interestingly, this same study also showed that the gene 
signature of breast TAMs resembled that of fetal macrophages, with increased abundance of 
transcripts for genes regulating angiogenesis, tissue remodeling, and immune response [394]. 
On the other hand, Franklin et al. recently reported that TAMs in the MMTV-PyMT model of 
metastatic, luminal-B breast cancer did not resemble M2-like macrophages, nor were they 
dependent upon tumor-elicited Th2 immune response [356]. Together these studies indicate 
that, at least in breast cancer, TAMs are highly heterogeneous, and their phenotypes depend on 
tumor type, subtype, and location within the tumor (i.e., margins vs. periphery and extent of 
hypoxia) [383]. Alterations in TAM phenotypes may also occur over the course of tumor 
development and progression, as Qian and Pollard have described a shift in TAMs throughout 
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tumorigenesis from an “inflammatory” type during tumor initiation to an anti-inflammatory, M2-
like trophic type in later stages of tumor progression [383]. As mentioned previously and 
discussed further in the following section on Myeloid-derived suppressor cells, a similar shift has 
been described in ATMs over the course of prolonged obesity [373]. 
Shared characteristics between the tumor and obese adipose microenvironments, such 
as fibrosis, elevated ECM stiffness, angiogenesis, and regional hypoxia, may foster similarities 
between ATMs and TAMs. In particular, transient hypoxia activates the NF-κB transcription 
factor family [395]. While numerous molecules are involved in generating inflammation, NF-κB 
has long been considered to lie at the center of the inflammatory response. However, due to the 
plurality of NF-κB family members, as well as the sheer number of combinatorial interactions 
within canonical and non-canonical signaling pathways, NF-κB activation can have both pro- 
and anti-inflammatory effects. Inflammatory mediators controlled by canonical NF-κB signaling 
include the TNF superfamily, IL-1β, IL-6, several chemokines, COX-2, 5-lipooxygenase, MMPs, 
VEGF, and cell surface adhesion molecules [396]. Some of these gene products also activate 
NF-κB, with TNF-α being a particularly potent stimulus [396]. On the other hand, non-canonical 
NF-κB activities, such as regulation of IL-10 and TGF-β, play a role in inflammation resolution 
[397, 398]. As discussed throughout this review, many of these signaling mediators also 
contribute to tumor malignancy through a variety of mechanisms, including growth promotion, 
matrix degradation, and tumor angiogenesis. In fact, NF-κB signaling is a known mediator of the 
tumor promoting activities of both early-stage, pro-inflammatory TAMs, and late-stage 
immunosuppressive TAMs [399-402]. A study by Mayi et al. [403] provided direct evidence 
underscoring the similarities between ATMs and TAMs. Specifically, ATMs from obese 
individuals expressed several of the same cancer-promoting genes as TAMs, including 
angiogenic factors, chemokines, cytokines, proteases, and growth factors. In fact, many of 
these pro-tumoral genes, including VEGF-C and CXCL12, were expressed to an equal or 
greater extent in obese ATMs compared with TAMs [403], and are known targets of non-
canonical NF-κB signaling [404]. Taken together, these findings indicate that chronically 
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activated NF-κB signaling and dysregulated immune responses are likely unifying themes 
between ATMs and TAMs. 
 
Myeloid-derived suppressor cells 
For reasons that are not well understood, abnormalities in myelopoiesis under conditions 
of prolonged inflammation such as chronic infections and cancer generate a poorly 
differentiated group of myeloid lineage cells collectively termed myeloid-derived suppressor 
cells (MDSCs) [405]. MDSCs include immature monocytes, neutrophils, dendritic cells, and 
macrophages, and are defined by their expression of the myeloid lineage markers CD11b and 
Gr1 and their potently immunosuppressive properties [405-407]. Although they are comprised of 
multiple myeloid cell types, MDSCs are often described as immature macrophages, as MDSCs 
in mice are frequently reported to lack markers of mature macrophages such as major 
histocompatibility complex II (MHCII) and/or F4/80 [407, 408].  
Factors implicated in promoting the egress of MDSCs from bone marrow, as well as their 
arrest in an immature state and their immunosuppressive nature, include PGE2, IL-6, TNF-α, IL-
1β, and VEGF [407]. Of these factors, PGE2 is a particularly potent inducer of MDSCs that 
triggers upregulation of arginase metabolism, thereby suppressing T cell function [409-411]. 
Several of these signaling molecules are in turn produced by MDSCs, resulting in a positive 
feedback loop of MDSC recruitment. Notably, as discussed in various sections throughout this 
review, each of these factors is also elevated in obese adipose tissue, and increased MDSC 
content in adipose tissue of obese mice has recently been reported. Indeed, Xia et al. [408] 
demonstrated that increased MDSC content in peripheral tissues (e.g., adipose and liver) of 
obese mice acted as an important safeguard of insulin sensitivity in both genetic and diet-
induced models of obesity. Depletion of Gr1-expressing cells exacerbated symptoms of glucose 
intolerance and increased the presence of CD8+ T cells in adipose tissue. On the other hand, 
adoptive transfer of MDSCs improved fasting glucose and insulin levels in obese mice and 
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reduced levels of circulating pro-inflammatory cytokines. Interestingly, the onset of MDSC 
accumulation coincided with previously reported windows of CD8+ T cell and pro-inflammatory 
macrophage recruitment, supporting the putative role of MDSCs in suppression of a rampant 
inflammatory response. Accordingly, the percentage of CD11b+ Gr1+ MDSCs in adipose tissue 
increased with the duration of obesity [408]. Factors contributing to the accumulation of adipose 
MDSCs in obesity are poorly understood, but may include development of insulin resistance or 
increased local concentrations of estrogen and IGF-1, each of which have been found to 
influence MDSC biology [412]. Importantly, influx of MDSCs into adipose in prolonged obesity 
may provide a partial explanation for reports of a shift in overall ATM phenotype over the course 
of obesity from pro-inflammatory M1-like to that of more immunosuppressive M2-like 
macrophages [373]. For example, isolated MDSCs cultured with media conditioned by 
explanted obese adipose tissue displayed a greater shift toward an M2-like macrophage profile 
than MDSCs exposed to lean adipose explant-conditioned media [408]. Future studies should 
examine the extent to which MDSCs in obese adipose differentiate to M2-like macrophages in 
vivo.  
While the presence of MDSCs in obese adipose tissue is a relatively recent finding, a 
large body of literature supports the immunosuppressive functions of MDSCs within the tumor 
microenvironment. However, similarities in marker expression and immunosuppressive 
activation states may complicate a clear distinction between TAMs and MDSCs. Moreover, 
MDSCs can also differentiate into mature TAMs upon entry into the tumor microenvironment 
[413]. Functional similarities between MDSCs and certain TAM subsets have also been 
documented. For example, MDSCS suppress the function of critical antitumor defense cells 
(e.g., CD8+ cytotoxic T cells and NK cells) through expression of cytokines such as IL-10 and 
TGF-β and through arginine metabolism via the enzymes arginase-1 or inducible nitric oxide 
synthase (iNOS) [407]. Interestingly, simultaneous expression of arginase-1 and iNOS is a 
hallmark of MDSCs that is rarely observed in other immune cells [407].  
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As described in the T lymphocytes section above, activation of the PD-1 pathway in T 
cells is a critical checkpoint promoting immunosuppression in the tumor microenvironment [414]. 
Prima et al. reported that co-culture of bone marrow-derived myeloid cells with bladder tumor 
cells elevated production of PGE2 by both MDSCs and TAMs, and induced expression of the 
PD-1 ligand, programmed death-1 ligand (PD-L1), in these populations in a PGE2-dependent 
manner [415]. Increased expression of PD-1 and its ligands PD-L1 and PD-L2 were also more 
highly expressed in prostate tumors of obese mice compared to those from lean animals [416]. 
Importantly, hypoxia-induced HIF-1α activation in TAMs was also recently shown to control 
TAM-specific PD-L1 expression [417]. Whether regional hypoxia in obese adipose and resulting 
HIF-1α activation increases PD-L1 expression by ATMs remains to be seen. However, the 
presence of MDSCs in prolonged obesity, as well as their influence on ATM activation, further 
suggests that adipose-adjacent cancers in obese individuals may encounter an environment 
conducive to suppressed immunosurveillance.  
 
Neutrophils 
Neutrophils infiltrate adipose tissue early in progression to obesity 
Neutrophils are the most abundant white blood cells in human circulation and are 
typically the first immune cells recruited in response to infection or sterile tissue injury. Upon 
arrival, neutrophils secrete a variety of pro-inflammatory cytokines and participate in 
presentation of antigen to, and activation of, T cells, while helping to recruit additional 
inflammatory cells such as macrophages [418]. In lean animals, neutrophils represent a small 
fraction of total adipose tissue immune cells (<1%) [419]. However, Elgazar-Carmon and 
colleagues [361] demonstrated that transient neutrophil infiltration into visceral adipose depots 
occurs early during the course of adipose tissue expansion in diet-induced obesity models, 
suggesting induction of an acute inflammatory response. Indeed, neutrophils accumulated in 
visceral (periepididymal) adipose of male mice as early as 3 days after initiating high-fat feeding 
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- well before weight gain - with a corresponding increase in the neutrophil enzyme 
myeloperoxidase. Maximal myeloperoxidase was detected within 3-7 days, followed by a slow 
decline and return to baseline levels within 2-3 weeks of high fat feeding, and neutrophils were 
no longer detectable histologically at 16 weeks on diet. Talukdar et al. [420] also reported a 
rapid and dramatic increase in adipose tissue neutrophil content by 3 days of high fat feeding. 
This increase was maintained for up to 90 days by fluorescence-activated cell sorting (FACS) 
analysis of immune cells within the periepididymal adipose stromal-vascular fraction of obese 
male mice, with a corresponding increase in neutrophil elastase mRNA. However, the exact 
adipose tissue-derived chemoattractant(s) that mediate neutrophil recruitment so early during 
the course of adipose tissue expansion remain unclear, as adipocyte hypertrophy and death do 
not typically occur until several weeks into diet-induced obesity studies. In either case, once 
inflammation is established, neutrophils in inflamed adipose engage in bidirectional interactions 
with macrophages, dendritic cells, natural killer cells, lymphocytes, and mesenchymal stem 
cells, with important implications for adipose metabolic homeostasis. For example, neutrophil 
elastase appears to be an important mediator in the development of obesity-associated insulin 
resistance in response to adipose inflammation, signaling through Toll-like receptor 4 and 
downstream NF-kB activation to influence both recruitment and inflammatory activation state of 
infiltrating immune cells in obesity, including neutrophils themselves [420]. 
 
Tumor-associated neutrophils 
Within the tumor microenvironment neutrophils exhibit varied content and multiple 
phenotypes and have been found to exert both pro- and anti-tumoral effects. Similar to the 
M1/M2 dichotomy long used for macrophages (but now transitioning out of favor as described 
above), tumor-associated neutrophils (TANs) have been described as either “N1” (anti-tumoral) 
or “N2” (pro-tumoral) (Figure 20) [421]. The N1 neutrophil profile is reported to be promoted by 
increased levels of interferon-β [422] and pro-inflammatory cytokines such as IL-1β and TNF-α 
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[422, 423], while transforming growth factor β (TGF-β) is an important determinant of the N2 
phenotype [421]. Relative to N2 neutrophils, N1 neutrophils display elevated oxygen radical-
dependent cytotoxicity and increased expression of the chemokine CCL3 and the cell adhesion 
molecule ICAM [421], which recruit additional inflammatory cells and act to increase adherence 
and extravasation, respectively.  
 
 
Figure 20. Tumor-associated neutrophils have N1 and N2-like phenotypes. A) Neutrophil content and 
phenotype is both pro- and anti-tumoral with cytokines such as IFNβ, IL-1β, TNF-α activating the N1 or pro-
inflammatory phenotype and TGF-B driving the N2 immunomodulatory phenotype. The N1 neutrophil 
releases reactive oxygen species (ROS) and proteins that increase cell recruitment and extravasation 
(ICAM and CCL3 (MIP-1-alpha)). N1 neutrophils support cytotoxic CD8+ T cell activity. N2 neutrophils have 
a less segmented nucleus than typical and secretes many angiogenic and immunosuppressive mediators, 
expressing arginase 1 for example.  ROS secreted by both N1 and N2 may both promote genotoxicity in 
tumor initiation, or in contrast, can be cytotoxic to growing tumors. B) Neutrophils infiltrate adipose early 
during progression to obesity. Neutrophil production of reactive oxygen species, for example, through 
myeloperoxidase (MPO) expression, contributes to oxidative stress and fibrotic changes. 
 
Pro-inflammatory N1 neutrophils promote CD8+ cytotoxic T cell recruitment and 
activation by producing T-cell attracting chemokines and pro-inflammatory cytokines [424]. The 
N2 subpopulation can be distinguished morphologically, with less pronounced segmentation of 
the nuclei than N1 neutrophils and elevated expression of pro-angiogenic mediators including 
chemokines (e.g., CXCR4, CCL2), growth factors (e.g., VEGF), and remodeling factors such as 
MMP9 [423, 425]. For example, neutrophil-derived MMP9 was shown to contribute to the 
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angiogenic switch in early-stage pancreatic adenocarcinoma [426]. Additionally, tumors formed 
by highly disseminating variants of prostate carcinoma recruited elevated levels of MMP9-
positive TAN, which correlated with tumor cell dissemination and increased levels of 
angiogenesis and intravasation [425]. N2 neutrophils are also immunosuppressive; elevated 
expression of the enzyme arginase-1 by N2 neutrophils contributes to depletion of arginase 
within the tumor microenvironment, inhibiting T-cell receptor expression and antigen-specific T-
cell responses [427]. 
 
Adipose tissue neutrophils and cancer 
Potentially due to the minimal presence of neutrophils in lean adipose, very few studies 
have addressed the influence of adipose tissue on neutrophils specifically in tumors that are 
adipose-adjacent or adipose-invading. Wagner et al. reported that melanoma cell lines 
implanted within white adipose tissue of lean mice showed significantly greater infiltration of 
CD11b+ cells than tumors implanted at a site distant from adipose [259]. Although these cells 
were initially described as monocytes and/or macrophages, CD11b is expressed by multiple 
myeloid lineage cells, including neutrophils [428]. Furthermore, inflamed peritumoral adipose 
exhibited increased expression of pro-inflammatory cytokines and chemotactic factors 
implicated in both macrophage and neutrophil recruitment, including CXCL1, macrophage-
inflammatory protein-2 (MIP-2), and CCL2 [259]. Moreover, in obese adipose, neutrophils likely 
contribute to both tumor initiation and tumor progression. In addition to facilitating recruitment of 
additional inflammatory cells, neutrophils participate in establishment of the mutagenic pro-
inflammatory microenvironment associated with cancer initiation. Indeed, neutrophil-derived 
reactive oxygen species and myeloperoxidase are genotoxic, and are recognized mutagens in 
certain tumor types, such as lung cancer [429]. Furthermore, the skewed cytokine profile of 
inflamed obese adipose, such as elevated CCL2, may influence recruitment of neutrophils to 
developing tumors.  
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Alternatively, tumor-adjacent adipose may impinge upon the phenotype of TANs. Incio et 
al. [430] reported that pancreatic tumors from obese animals contained higher concentrations of 
adipocyte-derived IL-1β than those from lean animals, resulting in increased TAN recruitment, 
TAN-induced activation of pancreatic stellate cells, and enhanced deposition of fibrillary 
collagen (i.e., desmoplasia). Obesity was also associated with greater tumor weight, which was 
reverted to lean levels by TAN depletion. Importantly, tumor formation in this study was induced, 
via orthotopic cell injection or tumor fragment implant, following 10 weeks on a high fat diet – a 
period during which, as illustrated above, the presence of neutrophils in visceral adipose depots 
is elevated [361, 420]. Reversion of tumor growth rate was only observed when TAN depletion 
was initiated on day 1 following tumor induction, as opposed to day 7 [430]. Thus, it is unclear 
whether neutrophils recruited from the visceral adipose, as opposed to newly trafficked 
peripheral blood neutrophils, were the primary contributors to induction of the desmoplastic 
response.  
Taken together, the balance of N1/N2 TAN subtypes is an important factor in tumor 
progression, and future studies should consider the functions of adipose tissue neutrophils in 
initiation and/or progression of adipose-adjacent or adipose-invading tumors in obese 
individuals. Notably, although the presence of neutrophils in visceral adipose is clearly 
enhanced in early stage obesity, it is important to acknowledge that the time course studies 
described above regarding neutrophil adipose infiltration used exclusively male mice, and 
therefore it is unknown to what extent, or when, neutrophils also infiltrate the obese mammary 
fat pad. 
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Mast cells 
Mast cell content and activation states in adipose tissue 
An understudied immune cell in both adipose and tumor biology is the mast cell. 
Historically described as mediators of allergic hypersensitivity reactions [431], mast cells are 
found in virtually all tissues and are frequently classified into one of two subtypes: those residing 
in connective tissues, which express both tryptase and chymase, and those residing in mucosal 
tissues, which express only tryptase [432]. However, similar to other immune cells, mast cells 
exhibit plasticity based on microenvironmental conditions, and thus several phenotypic subtypes 
may exist [433]. 
Accumulation of mast cells in visceral white adipose in obesity has been reported in both 
mice [434, 435] and humans [435, 436], with documented heterogeneity across specific adipose 
depots. Altintas et al. found that mast cell density in the epididymal fat pad of male mice 
increased up to 230-fold under conditions of prolonged obesity, with mast cells intermingled with 
macrophages in the interstitial spaces between adipocytes [434]. A similar study published the 
same year by the same group also found dramatically increased mast cell infiltration in 
mesenteric and perirenal adipose, but no significant obesity-induced changes in mast cell 
density in inguinal subcutaneous adipose [437]. However, Liu et al. reported increased numbers 
of mast cells in abdominal subcutaneous adipose tissue from obese human subjects, as well as 
significantly elevated serum tryptase levels, relative to lean individuals [435]. Many of these 
mast cells were found in association with microvessels [435], implicating mast cells in the 
regulation of endothelial cell biology and angiogenesis in adipose tissue. Interestingly, increased 
serum tryptase levels were not found in obese children and adolescents, suggesting an adult-
specific window of susceptibility to adipose-mast cell interactions [438]. 
Degree of mast cell activation is also affected by obesity. Divoux et al. [436] reported 
that mast cells isolated from omental and subcutaneous adipose depots of obese subjects 
exhibited a more activated state than mast cells isolated from lean subjects, secreting increased 
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levels of pro-inflammatory cytokines, chemokines, and growth factors. Histological sections also 
revealed that mast cells in obese subjects preferentially localized to fibrotic bundles or 
proximate to endothelial vessels and showed increased degranulation relative to those in lean 
tissue (Figure 21A). Collectively, these results suggested that mast cells in obesity harbor a 
pro-inflammatory profile, a phenotype which was recapitulated by culture of mast cells in a 3D 
matrix designed to mimic fibrotic conditions. Furthermore, a positive correlation was observed 
between mast cell density and both fasting glucose and glycated hemoglobin, suggesting a role 
for mast cells in altered glycemic status in obese subjects. Finally, Zhou et al. recently showed 
that mast cells in both white adipose and bone marrow of obese mice express elevated levels of 
leptin, potentially in response to increased regional concentrations of IL-6 or TNF-α in obesity 
[439]. 
 
 
Figure 21. Mast cells: Unappreciated players in adipose and tumor biology. A) Mast cell content in 
adipose tissue increases with obesity, with mast cells localized to blood vessels and/or within fibrotic 
bundles. Obesity is also associated with increased mast cell degranulation, an indicator of a mast cell 
activation. B)  In cancer, mast cells contribute to tumor progression through release of pro-angiogenic 
factors (MMP9, VEGF), immunosuppressive mediators (histamine), or growth factors such as PDGF.  Mast 
cells also secrete cytokines that may promote (arrow) or inhibit (line) tumor progression.  Mast cell influence 
on tumor progression appears to be dependent upon mast cell localization as peri- versus intratumoral. 
 
Similar to the other immune cell populations described above, mast cells have been 
ascribed both pro- and anti-tumoral roles. Tumor promotion by mast cells has been attributed to 
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secretion of proangiogenic factors such as MMP9 and VEGF, immunosuppression through 
release of histamine, or growth promotion by mitogenic factors including PDGF [440].  Mast 
cells also secrete IL-1, TNF-α, IL-6, IL-10, and IL-4 [440], each of which plays complex – and 
sometimes controversial – roles in solid tumor biology [441-446]. Thus, below we consider the 
potential relevance of adipose mast cells to cancer progression with regard to potential changes 
induced with increased adiposity and prolonged obesity. 
 
Mast cells in breast cancer 
In breast cancer, mast cell tryptase levels are linked to angiogenesis and 
lymphangiogenesis [447, 448], lymph node metastasis [449], and myofibroblast differentiation 
[450]. Samoszuk et al. [451] reported elevated serum tryptase in the blood of breast cancer 
patients as compared to healthy controls, as well as mast cell infiltration and mast cell tryptase 
expression adjacent to or within the stroma of every breast cancer patient sample examined, 
including DCIS specimens. Interestingly, in patients with invasive breast cancers, tryptase was 
found more frequently as extracellular deposits, suggesting mast cell degranulation, whereas in 
patients with early stage breast cancer, tryptase was located intracellularly, within intact mast 
cells [451].  
Remarkably, mast cell activation state and influence on the course of tumor 
development appear to also depend upon their localization within the tumor microenvironment 
(Figure 21B). For example, correlation between mast cell density and lymphatic microvessel 
density varied based on breast cancer subtype and peritumoral versus intratumoral mast cell 
location [447]. As discussed in an earlier section of this review, peritumoral lymphatic vessel is a 
prognostic indicator in several cancer types, including cervical, colorectal, breast, and prostate 
cancers [243-247]. Indeed, peritumoral mast cell density was significantly positively correlated 
with lymphatic density in luminal A and basal-like breast carcinomas; on the other hand, 
intratumoral mast cell density showed a low inverse correlation with lymphatic density in both 
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luminal A and HER2+ breast cancer subtypes, yet a positive correlation with basal-like 
carcinomas [447]. In addition, Rajput et al. investigated over 4,000 clinically annotated tissue 
microarrays from invasive breast cancer patients with long-term follow-up, and reported that 
intratumoral mast cell infiltration was a strong marker of favorable prognosis independent of 
age, tumor grade, tumor size, lymph node status, and ER or HER2 status [452]. Future work 
should address the molecular significance of the differential prognostic implications based on 
mast cell localization observed across breast cancer subtypes. 
 
Mast cells in prostate cancer 
Mast cell location also appears to influence prognosis in prostate cancers. Indeed, 
Nonomura et al. reported that increased peritumoral mast cell count was associated with 
reduced recurrence-free survival and higher Gleason scores in prostate cancer patients treated 
with radical prostatectomy, irradiation therapy, or androgen deprivation therapy [453]. Androgen 
deprivation therapy, also called castration therapy, is the gold standard for treatment of patients 
with metastatic prostate cancer. However, despite high initial response rates, nearly all men 
eventually develop progressive disease, referred to as “castration-resistant” prostate cancer. 
Johansson et al. [454] found that androgen deprivation therapy increased mast cell recruitment 
to the peritumoral tissue compartment of locally relapsing human prostate tumors, but not to the 
tumor itself. Peritumoral mast cells also promoted tumor growth and tumor angiogenesis, which 
were further exacerbated by mast cell degranulation. Moreover, patients with higher peritumoral 
mast cell density had higher Gleason scores and significantly shorter cancer-specific survival, 
while patients with low numbers of intratumoral mast cells exhibited the same patterns. Low 
intratumoral mast cell count was also associated with high tumor stage, higher tumor cell 
proliferation index, and metastatic spread [454]. Similar results have been reported by others, 
with poorest outcomes in prostate cancer patients lacking intratumoral mast cells [455]. These 
studies raise several important questions: how different are peritumoral vs intratumoral mast 
77 
 
cells, and what are the factors determining which phenotype develops? Are these factors tumor-
intrinsic or determined by the surrounding tissue, particularly adipose tissue? 
 
Impact of obesity on peritumoral mast cells 
Given consistent reports regarding the increased mast cell content and altered mast cell 
activation state in obese adipose, we were surprised to find not a single publication addressing 
the impact of obesity or adipose tissue on the density or phenotype of peritumoral mast cells. In 
fact, the only study found even peripherally linking mast cells in adipose tissue to cancer 
outcomes addressed the frequency of metastatic ovarian cancer colonization within “milky 
spots”, vascularized accumulations of mononuclear cells in human omental adipose that include 
mast cells [456]. It must also be noted that BMI was not included as a variable in any of the 
aforementioned studies addressing mast cell function in breast and prostate tumors.  
Increased adipose tissue mast cell density in obesity suggests the potential for elevated 
peritumoral mast cell concentrations in adipose-infiltrating tumors of obese individuals. 
However, although increases in adipose mast cell density have been reported in visceral 
adipose tissue of obese mice [434] and abdominal subcutaneous adipose of obese patients 
[435], whether obesity influences mast cell density in breast subcutaneous or periprostatic 
adipose tissue has not been reported. Ishijima et al. demonstrated that mast cells influence 
preadipocyte-adipocyte transition under both physiological and pathological conditions [457], 
suggesting a possible role for mast cells in adipose expansion. Furthermore, adipose tissue 
hematopoietic progenitor cells contain a population committed to the mast cell lineage, allowing 
white adipose tissue to act as a reservoir for mast cells that traffic to other tissues such as skin 
and, potentially, developing tumors [458]. Thus, considering the differential associations 
between peritumoral vs. intratumoral mast cells and cancer outcomes, future studies should 
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investigate the positioning and granulation status of peritumoral mast cells in relation to adipose 
tissue in lean and obese patients.   
 
Eosinophils 
Eosinophils are granulocytes typically associated with allergy and asthma that play key 
immunoregulatory roles in antigen presentation, suppression of inflammation, and maintenance 
of metabolic homeostasis [459, 460]. Under physiologic conditions, circulating eosinophils are 
rare however, eosinophils comprise ~4-5% of cells in the stromal-vascular fraction of lean 
adipose [461]. Indeed, Wu et al. [461] demonstrated that eosinophils are the primary source of 
IL-4 in adipose tissue, as ~ 90% of IL-4-expressing cells recovered from visceral adipose of lean 
mice were eosinophils [461]. Interestingly, they also noted an inverse relationship between 
adiposity and adipose eosinophil content in both genetic and diet-induced models of obesity. 
Furthermore, mice engineered to be eosinophil-deficient developed significantly greater 
adiposity and impaired glucose tolerance in response to high-fat diet feeding. These results 
were attributed to impaired eosinophil-mediated maintenance of alternatively activated, anti-
inflammatory macrophages, which are generated upon exposure to IL-4 and/or IL-13 and are 
generally considered to be protective against diet-induced obesity and associated metabolic 
dysregulation. Subsequent studies have revealed that visceral adipose eosinophil populations, 
and thus alternatively activated macrophages, are in turn dependent upon innate lymphoid type 
2 cells (ILC2s) through their production of IL-13 and IL-5, an eosinophil colony-stimulating factor 
[462]. In light of their direct or indirect anti-inflammatory effects, it is tempting to speculate that 
the presence of eosinophils and ILC2s in lean adipose, and their relative absence in inflamed 
obese adipose, may be a contributing factor to the differential cancer risk profile in lean vs. 
obese individuals.  
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In light of the role of eosinophils in the maintenance of alternatively activated 
macrophages in normal, uninflamed adipose, it may seem surprising that these cells appear to 
promote pro-inflammatory macrophage polarization in tumors. Accordingly, an E1/E2 
classification scheme analogous to the macrophage M1/M2 and T helper cell Th1/Th2 subsets 
has been proposed [463]. Eosinophil peroxidase enhances TNF-α and hydrogen peroxide 
release by human monocyte-derived macrophages, suggesting that paracrine signaling 
between eosinophils and macrophages within the tumor microenvironment may be relevant in 
promoting activity of certain tumoricidal TAM populations [464]. In agreement with this 
proposition, injection of exogenous eosinophils in a mouse melanoma model reportedly 
reprogrammed TAMs toward a pro-inflammatory, tumoricidal phenotype, a result attributed to 
increased production of eosinophil-derived IFN-γ [465]. However, it should be noted that while 
eosinophils facilitate tumor rejection in numerous cancer models, increased levels of circulating 
eosinophils are associated with poor prognosis in some hematologic malignancies, such as 
non-Hodgkin’s and T cell lymphomas [463]. Therefore, future research should systematically 
address relationships between local and circulating eosinophil content, site-specific tumor 
promotion vs. rejection, and eosinophil-mediated modulation of macrophage polarization. 
Although little research has addressed these functions in the context of obesity, it is 
clear that eosinophils also facilitate anti-tumor immune reactions independent of their effects on 
macrophage polarization. For example, Carretero et al. [465] recently reported that eosinophil-
mediated production of the chemoattractants CCL5, CXCL9, and CXCL10 promoted cytotoxic T 
cell recruitment in developing melanomas. Antibody-mediated depletion of eosinophils reduced 
CD8+ T cell infiltration, impaired tumor rejection, and severely reduced animal survival. 
Moreover, injection of melanoma cells together with exogenous eosinophils resulted in tumor 
vessel normalization, as evidenced by reduced permeability, enhanced perfusion, and reduced 
tumor hypoxia, alterations sometimes associated with reduced tumor aggression and more 
efficient vascular delivery of chemotherapies. In addition to their effects on other immune cells 
within the tumor microenvironment, eosinophils may also exhibit direct cytotoxicity. Tepper et al. 
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[466] reported that mouse melanoma and plasmacytoma cells engineered to express IL-4 
exhibited reduced or absent tumorigenicity in transplant studies due to elicitation of an 
inflammatory infiltrate comprised predominantly of macrophages and cytotoxic eosinophils. 
Accordingly, administration of a monoclonal antibody with granulocyte-specific cytotoxicity 
depleted eosinophils and restored tumorigenicity of IL-4-producing cells. However, these results 
were called into question by a subsequent study in which eosinophil-deficient IL-5-knockout 
mice showed similar degrees of IL-4-expressing melanoma rejection as wild-type animals, a 
phenotype attributed to a neutrophil-mediated response [467]. Ultimately, the conflicting results 
of these two studies indicate that the putative cytotoxic functions of eosinophils in anti-tumor 
immunity warrant further study. Moreover, additional investigation into eosinophil content in lean 
vs. obese adipose and their potential influence on adipose-tumor interactions should yield 
interesting findings.  
 
Conclusion 
Although adipocytes comprise the bulk of adipose tissue volume, adipose also contains 
a rich variety of stromal and vascular cells, as well as matrix and signaling components, which 
together constitute the adipose tissue microenvironment. A growing body of literature indicates 
that reciprocal, heterotypic interactions between developing tumors and the local adipose milieu 
influence the course of solid tumor progression. Herein, we have provided an overview of 
interactions between select adipose tissue components and developing adipose-adjacent 
cancers, emphasizing breast and prostate cancers and the known or potential impact of 
changes that occur in the adipose tissue microenvironment during progression to obesity. As 
described throughout this review, obesity-associated adipose modifications often resemble 
aberrations observed within the tumor microenvironment. For example, similar to tumors, 
dysregulated, obese adipose tissue is characterized by chronic low-grade inflammation, 
macrophage infiltration, hypoxia, and aberrant wound healing responses, including an increase 
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in myofibroblast and activated fibroblast content. Obese adipose tissue is also a harbor for 
soluble mediators of cancer development, including metabolites, exosomes, cytokines, growth 
factors, and extracellular matrix scaffolding proteins, which collectively provide a critical link 
between adiposity and tumorigenesis. Thus, we posit that adipose-adjacent epithelium in obese 
individuals encounters an environment particularly conducive to tumor initiation and 
progression.  
Despite a recent increase in research regarding the contributions of adipose tissue in 
cancer development, many questions still remain. For example, the identities of many adipose-
derived microenvironmental signaling mediators that modify tumor biology are largely unknown. 
Furthermore, while immune cells in both adipose tissue and cancer biology have been 
characterized individually, few studies have attempted to quantify recruitment of immune cells 
originating in adipose tissue adjacent to tumors. This potential for recruitment becomes 
especially important in the context of obesity, wherein adipose tissue immune cell content is 
greatly increased, yet the relative immune composition and phenotype shifts dramatically. Thus, 
the extent to which specific adipose-derived cell lineages contribute to tumor development 
and/or progression remains inconclusive. Ultimately, given the rising global prevalence of 
obesity, a better understanding of the molecular interactions between adipose tissue 
components and tumor cells is critical for the identification of novel targets for prevention and/or 
treatment of obesity-associated cancers.
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CHAPTER 2: CMET INHIBITOR CRIZOTINIB IMPAIRS ANGIOGENESIS AND REDUCES 
TUMOR BURDEN IN THE C3(1)-TAG MODEL OF BASAL-LIKE BREAST CANCER2 
Background 
Basal-like breast cancer (BBC) accounts for 15-20% of total breast cancers, with a 
higher prevalence in young and minority women such as African Americans and Hispanics [468, 
469]. BBC is typically estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor-2 (HER2) negative (so called “triple-negative”) and is highly aggressive, 
exhibiting an early pattern of metastasis and poor overall prognosis. Thus, BBC presents a 
formidable challenge, as it lacks the molecular targets for current targeted drug treatments. High 
body mass index (BMI) is associated with poorer prognosis in breast cancer patients, including 
increased risk of lymph node metastasis, vascular invasion, disease recurrence, and mortality 
[24, 52, 53]. Epidemiologic studies indicate that obesity is strongly associated with the BBC 
subtype in both pre- and post-menopausal women [52, 469]. Obesity mediates, and can 
exacerbate, both normal and tumor microenvironment dysfunction [296, 470]. In obesity, rapid 
expansion in mammary adipose tissue leads to alterations in the stroma that mediate normal 
and tumor microenvironment dysfunction yet are poorly understood in breast cancer risk and 
progression [296, 470-472]. Given that obesity has increasing prevalence and is one of few 
modifiable risk factors for breast cancer, it is important to better elucidate the mechanisms for 
this obesity-associated cancer. 
                                                          
2This chapter previously appeared as an article in the journal SpringerPlus, in a special Breast Cancer Edition. The 
original citation is as follows: Cozzo AJ, Sundaram S, Zattra O, et al. cMET inhibitor crizotinib impairs angiogenesis 
and reduces tumor burden in the C3(1)-TAg model of basal-like breast cancer. SpringerPlus. 2016; 5:348. 
doi:10.1186/s40064-016-1920-3. 
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We have shown that BBC is characterized by unique epithelial-stromal interactions, 
which likely play a role in BBC etiology [142, 473-475]. An elevated level of hepatocyte growth 
factor (HGF), a pleiotropic growth factor that signals through the receptor tyrosine kinase cMET, 
is characteristic of BBC [476]. Elevation of circulating HGF is also seen in obese patients [147].  
HGF/cMET signaling initiates an invasive growth program that promotes cell migration, invasion, 
proliferation, and angiogenesis [141]. Endothelial cell upregulation of cMET has also been 
attributed to inherent or acquired resistance to antiangiogenic therapies targeting vascular 
endothelial growth factor (VEGF) in patients [265, 266]. Marking the first work in preclinical 
models paralleling human epidemiologic BBC findings, we used C3(1)-TAg mice, a unique 
GEMM of spontaneous BBC, to demonstrate that high fat diet (HFD)-induced obesity 
accelerated onset of tumor development and increased tumor aggressiveness as compared to 
low fat diet (LFD)-fed lean controls [43]. HFD also increased mammary gland HGF 
concentration and enhanced expression and activation of cMET. Using primary murine 
fibroblasts isolated from mammary glands or tumors, we further reported that obesity increased 
HGF production by mammary gland normal- and cancer-associated fibroblasts (NAF and CAF) 
[43]. Through signaling inhibition via an HGF blocking antibody, we showed that obese CAF-
induced epithelial cell migration occurred through an HGF-dependent mechanism. Furthermore, 
using the intervention strategy of weight loss prior to tumor latency, we reported that weight loss 
blunted effects of HFD-induced obesity on multiple tumor parameters compared to mice 
maintained on HFD. Importantly, HFD-induced elevation of HGF/cMET signaling in normal 
mammary gland and cMET in tumors was significantly reversed with weight loss in C3(1)-TAg 
mice, with a concomitant and complete reversal of HFD-driven tumor progression [264].  
Given the precedent for the role of HGF signaling in invasive breast cancer [477], a 
better understanding of HGF’s role in BBC tumorigenesis was necessary. We hypothesized that 
inhibition of cMET signaling through crizotinib therapy (PF-02341066) would reduce HFD-
induced BBC. We first sought to inhibit tumor progression in existing tumors and began 
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crizotinib treatment upon identification of the first palpable tumor. Crizotinib significantly reduced 
total tumor burden in both LFD- and HFD-fed C3(1)-TAg mice, with a corresponding reduction in 
microvascular density. We next investigated whether we could inhibit or delay tumorigenesis by 
treating C3(1)-TAg mice with crizotinib prior to tumor development. Crizotinib treatment 
paradoxically increased progression of the initially detected tumor in both diet groups. However, 
at sacrifice there were no differences between diet or treatment groups in total preneoplastic 
lesions, total tumor progression or tumor burden. In summary, cMET inhibition disrupted tumor 
vascularization and limited subsequent BBC tumor development in tumor-bearing mice. Our 
results suggest that reduction of microvascular density through cMET inhibition may be a viable 
therapeutic target in the treatment of BBC.     
 
 
Methods 
Antibodies and drugs  
Crizotinib (PF-2341066 [(R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-
yl-1H-pyrazol-4-yl)-pyridin-2-ylamine) was purchased from Selleck Chemical (Catalog No. 
S1068). Primary antibodies include: Rabbit anti-mouse CD31 (Abcam #ab28364, Lot 
GR212364-5; 1:400); Rabbit anti-mouse phospho-cMET (Abcam #ab5662, Lot GR159296-1; 
1:4000); Goat anti-mouse cMET (R&D Systems #AF527, Lot CTB0310091; 1:1000)) diluted in 
Renoir Red Diluent (BM #PD904H). Additional reagents included biotin-conjugated Goat anti-
rabbit IgG (Jackson #111-065-144, Lot 110335; 1:500); Donkey anti-goat IgG (Jackson #705-
065-147, Lot 110544; 1:1000). ABC Elite (Vector #PK-6100, 1:50) and 3,3' Diaminobenzidine 
(DAB) (Thermo Scientific #TA-125-QHDX). 
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Animals and diet  
Animal studies were performed with approval and in accordance with the guidelines of 
the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel 
Hill.  Animals were cared for according to the recommendations of the Panel on Euthanasia of 
the American Veterinary Medical Association. The veterinary care provided at UNC is in 
compliance with the Public Health Service Policy on Humane Care and Use of Laboratory 
Animals and meets the National Institutes of Health standards as set forth in the Guide for the 
Care and Use of Laboratory Animals (DHHS Publication No. (NIH) 85-23 Revised 1985). The 
animal facility is Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) approved and is responsible for the health and husbandry of animals. UNC also 
accepts as mandatory the PHS Policy on Humane Care and Use of Laboratory Animals be 
Awardee Institutions and NIH Principles for the Utilization and Care of Vertebrate Animals Used 
in Testing, Research, and Training. Animal studies comply with the ARRIVE guidelines. Mice 
were housed in a climate controlled Department of Laboratory Animal Medicine facility with a 12 
hour light:dark cycle and ad libitium access to food and water or special diets as defined below. 
Female C3(1)-TAg mice were obtained in collaboration with the UNC Lineberger 
Comprehensive Cancer Center (LCCC) Mouse Phase I Unit (MP1U). C3(1)-TAg mice [150], a 
model of BBC, were generated by crossing heterozygous male mice with FVB/N non-transgenic 
female mice.  
For the tumor treatment study, N= 46 female C3(1)-TAg mice were bred and maintained 
on chow diet (Harlan 2918) until nulliparous female were randomly assigned to LFD (N=24) and 
HFD (N=22) at 10 weeks of age. Diets obtained from Research Diets Inc. (New Brunswick, NJ, 
USA) were matched for protein, vitamins, and minerals, and provided 10% kcal (“LFD”; # 
D11012202); and 60% kcal (“HFD” ; # D11012204) derived from fat. Diets were sucrose-free, 
and soy-free. Additional details of diet components are provided in Sundaram et al. [43]. For the 
prevention study, during breeding and after weaning mice were put on Prolab Isopro RMH 3000 
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chow from LabDiet (St. Louis, MO, USA). At 8 weeks of age, nulliparous female C3(1)-TAg mice 
were randomly assigned to LFD (N=43) and HFD (N=45) diet.  
Tumor latency, number, and progression  
Mice were monitored for tumor development by palpating twice weekly. Tumor latency 
was defined as age in weeks at detection of first tumor. Tumor volumes were measured twice 
weekly over 3 weeks using calipers to measure the width (short diameter) and length (long 
diameter) in millimeters for each tumor. Tumor volumes were calculated using the formula: 
length × width2 × 0.5. Tumor progression is reported as percent change in volume from latency 
to sacrifice 3 weeks later. Primary tumor progression refers to the first tumor identified; total 
tumor progression includes all tumors palpated. The total number of visible tumors per mouse 
was counted at sacrifice for total tumor burden (multiplicity).  
Crizotinib treatment  
Crizotinib dosage was 50 mg crizotinib/kg of body weight [478]. In the treatment study, 
crizotinib administration by oral gavage began at identification of the first palpable tumor and 
persisted for 3 weeks until sacrifice (5 days on drug, 2 days rest). Briefly, drug was prepared by 
dissolving 20 mg of crizotinib powder in 200 µL 1 N hydrochloric acid (HCl), then brought to a 
total volume of 1 mL with vehicle (0.5% glucose in phosphate-buffered saline) to yield a 2x 
crizotinib solution. Immediately prior to gavage administration, the 2x solution was diluted with 
an equal volume of vehicle to yield a 1x solution.  In the prevention study, drug was prepared as 
a 1x solution by dissolving 10 mg of crizotinib powder in 200 µL 1 N HCl, then brought to a total 
volume of 1 mL with vehicle; crizotinib treatment began for all mice at 9 weeks of age and 
continued for 3 weeks (5 days on drug, 2 days rest).  
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Body weight & composition  
Body weight was measured at start of diet and weekly until sacrifice. Body composition 
including lean mass, fat mass, free water content and total water content of non-anesthetized 
mice was measured using EchoMRI-100 quantitative magnetic resonance whole body 
composition analyzer (Echo Medical Systems, Houston, TX). Fat mass is presented as (fat 
mass/total body weight)×100% [43, 264]. There were no significant changes in absolute lean 
mass in grams (data not shown). 
Tissue and blood collection  
Three weeks after detection of the first palpable tumor, mice were fasted for six hours 
and anesthetized by an intraperitoneal (i.p.) injection of avertin (tribromoethanol/amylene 
hydrate, 1.25%) (Sigma Aldrich, St. Louis, MO). Blood was collected via cardiac puncture using 
an EDTA-coated syringe into 5µL of 250mM EDTA. Plasma was separated from other blood 
components by centrifugation at 10,000xg for 2 minutes at 4°C. Mammary tumors, unaffected 
inguinal mammary gland, liver, spleen, and lungs were flash frozen in liquid nitrogen or were 
placed into a cassette and formalin-fixed for immunohistochemistry (IHC) and H&E analysis. All 
frozen samples were stored at -80°C until analyzed. 
Immunohistochemistry  
Briefly, formalin-fixed and paraffin-embedded tissues were sectioned at 5 microns and 
mounted for histological staining [43]. Tissues were baked, deparaffinized, and hydrated. 
Following heat-induced epitope retrieval (Rodent Decloaker BM#RD913L)), slides were treated 
with 3% hydrogen peroxide in de-ionized water. Tissues were treated with Avidin/Biotin Block 
(Vector #SP-2001) and exposed to primary antibodies (anti-CC3, anti-Ki67 anti-CD31; anti-
phospho-cMET; anti-cMET) diluted in Renoir Red Diluent at 4°C overnight. Following incubation 
with biotin-conjugated secondary antibodies [Goat anti-rabbit IgG; Donkey anti-goat IgG] tissue 
sections were treated with ABC Elite and DAB. Digital immunohistochemistry quantification was 
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performed following the protocol previously described in Sundaram et al.[43]. Stained slides 
were scanned into the Aperio Scanscope CS system (Aperio Technologies, Vista, CA, USA) at 
a magnification of 40× and were quantified using the Aperio Imagescope software. Scanned 
slides were analyzed using algorithms as described previously [42]. N = 5-6 random areas from 
sections (n = 2 sections per mouse) were quantified and averaged per tumor per animal (n = 9-10 
mice per diet or exposure group). Images shown are representative.  
Statistical Analysis  
Data are expressed as mean ± standard error of the mean (SEM). All means were 
compared by 2-way analysis of variance (ANOVA) with Tukey’s post-hoc test for statistical 
differences using GraphPad Prism 5 software (GraphPad Software, Inc. La Jolla, CA). Kaplan-
Meier analyses were conducted using GraphPad Prism 5 software to estimate tumor latency. 
Log rank and chi-square tests were used to investigate differences among groups. P values < 
0.05 were considered statistically significant. 
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Results 
Diet-induced adiposity accelerated tumor latency in C3(1)-TAg mice 
In the treatment arm of our study, adult female C3(1)-TAg mice were randomly assigned 
to diet groups at 10 weeks of age (N=11-15; see Figure 22, Model of Treatment study design). 
Body weight and body composition were monitored, as were tumor latency and progression (by 
palpation and calipers).  
 
 
Body weight was not significantly altered by diet or drug treatment group for the study 
duration (Figure 23A). Adiposity as measured by MRI was increased with HFD exposure but 
did not reach significance (Figure 23B). This result may in part have been due to daily oral 
gavage of vehicle or drug, as adiposity initially declined in all groups following onset of the 
treatment protocol, irrespective of diet or treatment (i.e., vehicle vs. control) (Figure 23B). 
However, gonadal fat pad mass was significantly greater in mice fed HFD compared to mice fed 
LFD (P = 0.0173, Figure 23C). Consistent with our previously reported results [43], C3(1)-TAg 
mice fed HFD exhibited significantly accelerated tumor latency compared with mice fed LFD 
(LFD median 17.3 weeks; HFD median 15.5 weeks; P < 0.0001, Figure 23D). Using a log-rank 
(Mantel-Cox) chi-square test with a degree of freedom of 1, LFD vs HFD equaled 15.72. 
Figure 22. Model of 
Treatment Study 
design. At 10 weeks of 
age female mice were 
randomized to LFD or 
HFD and palpation 
began for identification of 
tumor onset. Vehicle or 
crizotinib treatment by 
daily oral gavage began 
at detection of first 
palpable tumor and 
lasted for 3 weeks, 5 
days on and 2 days off. 
Mice were sacrificed at 3 
weeks past tumor onset. 
Metabolic and other 
parameters were 
measured as indicated.  
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Figure 23. High-fat diet exposure accelerated basal-like tumor latency in C3(1)-TAg mice. A) Body 
weights did not differ by diet or treatment group. B) Body composition was measured at diet start, tumor 
latency (week 0 of crizotinib), 1.5 weeks on crizotinib treatment, and 3 weeks on crizotinib treatment (at 
sacrifice). C) Gonadal fat pad mass was weighed at sacrifice (LFD vs. HFD N = 11–13 per group *P = 
0.017).  D) Tumor latency was reported as age at detection of the first palpable tumor (LFD median 17.3 
weeks, N = 24; HFD median 15.5 weeks, N = 22; P < 0.0001. 
 
Crizotinib treatment inhibited secondary tumor development, reduced overall tumor 
burden 
Tumor progression of the primary (first detected) tumor and all subsequent palpable 
tumors was monitored via electronic calipers throughout the 3-week measurement period 
between latency and sacrifice. No differences by diet or treatment group were detected in either 
primary tumor progression (Figure 24A) or total tumor progression (total percentage volume 
change in all palpable tumors throughout 3-week monitoring period) (Figure 24B).  However, 
Crizotinib treatment significantly reduced total tumor burden (multiplicity) by 27.96% and 
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37.29% in LFD- and HFD-fed C3(1)-TAg mice, respectively, compared to mice treated with 
vehicle (P = 0.0085, Figure 24C). A minor diet effect on tumor burden was also detected: HFD-
fed animals in both vehicle- and crizotinib-treated groups exhibited lower overall tumor burden 
at sacrifice compared to LFD-fed mice (P = 0.0491, Figure 24C).  
 
 
Figure 24. Crizotinib treatment inhibited subsequent tumor development. No significant differences 
were observed in A) primary or B) total tumor progression, measured as percentage volume change during 
monitoring period C) Total number of visible tumors was assessed at sacrifice (LFD vs HFD *P = 0.0491; 
Vehicle (a) versus crizotinib (b) P = 0.0085). 
 
Crizotinib treatment disrupted tumor vascularization 
We next measured expression of CD31, a marker of endothelial and lymphendothelial 
cells [479], in tumors using immunohistochemistry (IHC) (Figure 25A-E). CD31 expression was 
reported as percent CD31-positive area out of total tissue area analyzed. Crizotinib 
administration significantly reduced mean intratumoral CD31 expression by 35.04% and 33.52% 
in LFD and HFD groups, respectively (P = 0.014, Figure 25F). There were no detected diet 
effects on CD31 positivity. Also quantified was total tumor cMET and phosphorylated (active) 
cMET protein expression, also by IHC. Although total intratumoral cMET positivity did not differ 
by diet or treatment group (Figure 26A), phosphorylated cMET was significantly higher in mice 
fed HFD (P = 0.014, Figure 26B). 
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Figure 25. Crizotinib impaired tumor vascularization. A-E) Representative photomicrographs (40×) of 
CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. 
F) CD31 was quantified on 5–6 randomly selected 20x regions of n = 2 sections each from each mouse. 
N = 9–10 mice (a vs b, Veh vs Criz, P = 0.014). 
 
 
 
Figure 26. High fat diet exposure increased active cMET in tumors. A) Total MET staining did not differ 
by diet or treatment group. B) Phosphorylated (active) MET was significantly higher in mice fed HFD (2-
way ANOVA *P = 0.0141). 
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Prophylactic crizotinib administration did not affect body weight or adiposity 
As crizotinib treatment reduced tumor multiplicity in tumor-bearing mice, we next 
investigated whether we could inhibit or delay tumorigenesis by treating with crizotinib prior to 
tumor development. C3(1)-TAg tumors progress along the following approximate timeline: 
atypical hyperplasia (AH) of the mammary ductal epithelium at 8 weeks of age, mammary 
intraepithelial neoplasia (resembling human carcinoma in situ [CIS]) at 12 weeks of age, and 
invasive carcinomas at 16 weeks of age with 100% penetrance [150]. Thus, in the prevention 
arm of the study, mice were started on diet 2 weeks earlier than in the treatment study above to 
ensure crizotinib administration occurred within the primary window of AH/CIS precursor 
lesions. Starting at 8 weeks of age, mice were randomly assigned to LFD or HFD, with crizotinib 
treatment beginning at 9 weeks of age and continuing until 12 weeks of age (see Figure 27, 
Model of Prevention Study design).  
 
 
Mice fed HFD diet gained significantly more weight than the LFD mice, with greater body 
weights from 9-16 weeks of age (P < 0.05, Figure 28A). Body composition differed significantly 
between LFD- and HFD-fed mice beginning at 1 week on diet (9 weeks of age) and remained 
significant until sacrifice (P < 0.0001 for all data points, Figure 28B). Crizotinib- and vehicle-
Figure 27. Model of 
Prevention Study 
design. At 8 weeks of age 
female mice were 
randomized to LFD or 
HFD. At 9 weeks of age 
vehicle or crizotinib 
treatment by oral gavage 
began and lasted for 3 
weeks, 5 days on and 2 
days off. Palpation began 
for identification o of tumor 
onset also began at 9 
weeks of age. Mice were 
sacrificed at 3 weeks past 
tumor onset. Metabolic and 
other parameters were 
measured as indicated. 
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treated mice fed HFD had significantly greater gonadal fat pad mass when compared to LFD-
fed mice (P < 0.0001, Figure 28C). No difference was detected in body weight or adiposity 
between the crizotinib and vehicle treated mice. 
 
 
Prophylactic crizotinib administration increased primary tumor progression without 
significantly altering tumor burden or precursor lesion development 
Upon initiation of crizotinib or vehicle administration (9 weeks of age), mice were 
palpated twice weekly for detection of tumor onset. Median tumor latency did not vary 
significantly between diet or treatment groups (LFD vehicle-treated median 15.0 weeks; LFD 
crizotinib-treated median 16.1 weeks; HFD vehicle median 16.0 weeks; HFD crizotinib median 
16.2 weeks, Figure 29A). Progression of the primary, initially detected tumor was significantly 
increased with crizotinib treatment in both diet groups (P = 0.04, Figure 29B). However, when 
all tumors were considered there were no differences between diet or treatment groups in total 
Figure 28. Crizotinib prophylactic treatment did 
not affect body weight or adiposity. Diet was 
started at 8 weeks of age. A) Mice fed HFD diet 
gained significantly more weight than LFD-fed 
mice, with greater body weights from 9 to 16 weeks 
of age  (LFD vs HFD *P  < 0.05). B) Body 
composition was measured by MRI (LFD vs. HFD 
*P < 0.0001). C) Gonadal fat pad mass was 
determined at sacrifice (LFD vs. HFD *P < 0.0001).  
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tumor progression (Figure 29B) or tumor burden (Figure 29D) at sacrifice. Non-tumor 
mammary tissue was analyzed for AH and CIS premalignant lesions in of HFD-fed vehicle- or 
crizotinib-treated mice. There were no significant diet- or crizotinib-mediated effects on 
precursor lesion formation detected (Figure 29E). 
 
Figure 29.  Preventive administration of crizotinib prior to tumor onset did not alter tumor latency 
or overall tumor burden. A) Median tumor latency did not differ across diet or treatment groups. B) 
Progression of the primary (first detected) tumor was significantly increased with crizotinib treatment (a vs 
b, P = 0.036 by 2-way ANOVA). C) Crizotinib treatment did not significantly influence total tumor progression 
or D) total tumor burden, assessed at sacrifice. (N = 21-22).  E) There were no significant diet- or crizotinib-
mediated effects on precursor lesion formation within the mammary fat pad (AH: atypical hyperplasia, CIS: 
carcinoma in situ) n = 7/diet + treatment group. 
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Discussion 
We have previously demonstrated that HFD exposure during adulthood increased cMET 
expression and activation in normal mammary and tumors [43]. Diet-induced upregulation of 
cMET in tumors was also evident in mice fed HFD from weaning and could be reversed by 
weight loss [264]. Our previous work further revealed that HFD-induced weight gain resulted in 
increased mammary adipose HGF that was reversed with weight loss [264]. Reduction in HGF 
due to weight loss correlated with diminished tumor progression or deceleration of tumor 
latency, depending on whether the diet was initiated at weaning or adult onset, respectively. 
Altogether, our previously published studies implicated HGF/cMET signaling as a mediator of 
obesity-driven BBC tumor aggression. Therefore, the studies herein aimed to specifically inhibit 
cMET signaling as a potential BBC treatment or prevention strategy, hypothesizing that 
disruption of HGF/cMET signaling would mimic the effects of weight loss on BBC tumorigenesis.  
C3(1)-TAg mice are a GEMM that develop BBC in 100% of female mice [150]. Initial 
characterization of the C3(1)-TAg model reported grossly palpable tumors at ~16 weeks of age; 
in our hands, median tumor latency occurs between 15-19 weeks, dependent on diet 
composition and age at diet start [42, 264, 470].  As shown here, in the crizotinib treatment arm 
of our study, initiating diets at 10 weeks of age resulted in detection of tumor latency two weeks 
earlier in mice that were fed HFD compared to mice fed LFD, consistent with our previous 
C(3)1-TAg studies in which identical diets were initiated at the same age [43]. However, in the 
crizotinib prevention arm of our study, in which HFD was initiated at 8 weeks of age, we did not 
see this diet effect of accelerated latency – these results parallel our second previously 
published study, in which female C3(1)-TAg mice were weaned onto LFD or HFD and no 
difference in latency was observed [264].  Several groups have reported “windows of 
susceptibility” during which HFD and/or obesity may play a disproportionately greater role in 
promoting breast cancer onset [470, 480]. Interestingly, pubertal exposure to HFD has been 
linked to stunted mammary duct elongation and reduced mammary epithelial cell proliferation in 
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murine models [481], a finding that was not seen in mice started on diet at 10 weeks of age or 
older. Collectively, our results here and in our previous studies support the concept that 
exposures extrinsic to the cancer cell (i.e., diet-induced alterations in the mammary 
microenvironment) can impact tumorigenesis, while age at diet start is an important variable 
contributing to diet effects on tumor latency.   
Herein, we showed that crizotinib treatment after BBC latency inhibited subsequent 
tumor formation such that total tumor burden was reduced at sacrifice, regardless of diet. The 
degree of tumor inhibition was paralleled by a similar degree of suppression of MVD, also 
irrespective of diet. Reduction in MVD in our crizotinib-treated tumor-bearing C3(1)-TAg mice 
could explain the significant reduction of tumor burden compared to vehicle-treated controls. In 
tumors, an “angiogenic switch” occurs, in which an increase in MVD in and near the tumor 
allows for exponential growth of cancer cells, tumor survival, and metastasis [482]. Increases in 
HGF in the tumor microenvironment contribute to this angiogenic switch [483, 484], while cMET 
signaling in cancer cells facilitates invasion and migration away from the hypoxic interior of the 
tumor, entry into the new and leaky vessels, and metastasis to distant locations [477]. Indeed, 
obesity-promoted HGF production by fibroblasts, adipocytes, macrophages, and endothelial 
cells [43, 141, 142, 264, 485] may be a unique mechanism to increase blood vessel density and 
alleviate the hypoxia of obese adipose tissue. The fact that no changes were detected in MVD 
in the prevention arm of our study suggests that the HGF/cMET axis may play a greater role in 
invasive BBC carcinoma than in earlier stages of BBC progression.  
The HGF/cMET signaling pathway has long been studied in ductal morphogenesis 
during mammary gland development [486] as well as invasive breast cancer [140, 487-491] and 
invasive biology of several other cancers due to its angiogenic, mitogenic, and morphogenic 
effects [492, 493]. Notably, single nucleotide polymorphisms in the MET gene may be 
associated with metastatic breast cancer [494]. HGF/cMET signaling is also relevant in BBCs, 
specifically. In patients, we demonstrated through gene expression analyses that 86% of BBCs 
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expressed an HGF/cMET activation signature [142]. Furthermore, a comprehensive meta-
analysis including over 6,000 cases showed a significant association between cMET over-
expression and poor survival in breast cancer patients, particularly among patients with triple-
negative breast cancers [495]. HGF is also an excellent candidate mediator of obesity-induced 
effects on cancer, as serum HGF is elevated in obese individuals and reduced with weight loss 
[146-148]. Moreover, adipose-derived HGF has been detected in normal and malignant breast 
tissue [140]. 
Inhibition of cMET as an effective anti-angiogenic agent has been shown in initial 
mechanism-of-action studies for crizotinib, in which dose-dependent inhibition of cMET in 
gastric carcinoma, glioblastoma, and prostate carcinoma resulted in reduction of microvessel 
density (CD31) [478]. Angiogenic suppression by cMET inhibition has also been shown in 
xenograft models of aggressive cancers such as lung [496] and pancreatic cancers [497]. 
Moreover, the use of other cMET inhibitors in triple-negative breast cancer models such as ours 
has yielded promising results in preclinical studies [498]. However, to date clinical trials using 
the cMET inhibitors tivantinib or onartuzamab in isolation or in combination with chemotherapy 
have demonstrated little therapeutic benefit in metastatic breast cancer [499-501]. At the time of 
publication, clinical trials investigating crizotinib alone (ClinicalTrials.gov:NCT 02101385 [268]) 
or in combination with anti-VEGF therapy (ClinicalTrials.gov:NCT 02074878 [269]) for the 
treatment of advanced triple negative breast cancer are currently underway. Breast cancer 
ranks as the fifth cause of death from cancer overall and is now the second cause of cancer 
death among women following lung cancer [502, 503]. With the growing global prevalence of 
obesity and the notable racial and ethnic disparities in BBC outcomes [502], it is imperative that 
approaches are identified to effectively address the increased risk of breast cancer onset and 
progression to malignancy for an increasingly overweight and obese US population.
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CHAPTER 3: WEIGHT LOSS NORMALIZES OVERWEIGHT-ASSOCIATED CLAUDIN-LOW 
BREAST CANCER PROGRESSION: ROLE OF MAMMARY FAT PAD INFLAMMATION AND 
MYELOID CELL INFILTRATES3 
Background 
Over the past four decades the worldwide prevalence of obesity has more than doubled 
among women [17]. Within the United States, 77.3% of adult women are overweight or obese 
[504], defined as having a body mass index (BMI) of 25.0-29.9 and >30 kg/m2, respectively. 
Importantly, among breast cancer patients overweight and obesity are associated with 
increased risk of invasive cancer, development of distant metastases, tumor recurrence, and 
mortality [505].  
Interactions with the local adipose milieu are important mediators of malignancy in triple-
negative breast cancers (TNBCs), a heterogeneous collection of highly proliferative and 
invasive breast cancers primarily comprised of the basal-like (BBC) and claudin-low (CLBCs) 
molecular subtypes. TNBCs represent approximately 15-20% of breast cancer cases [506], are 
typically poorly differentiated and highly enriched for vascular and immune response genes 
[507, 508], and exhibit elevated recurrence and metastasis rates relative to other breast cancer 
subtypes [509]. Importantly, in the context of TNBC overweight and obesity are negatively 
associated with both breast cancer-specific and overall survival in premenopausal women [510]. 
Animal studies also indicate that excess weight and dietary energy intake promote progression 
of both BBC and CLBC. For example, we have previously demonstrated that high fat diet-
induced weight gain accelerated pre-neoplastic lesion formation [263], tumor onset (latency) 
[43, 263] and tumor progression [264] in the transgenic C3(1)-TAg model of spontaneous BBC. 
                                                          
3 A modified version of this manuscript has been submitted for review, and the final published version is likely to 
differ from that which is included here. 
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On the other hand, weight loss before tumor onset in this transgenic model reversed the effects 
of mammary adiposity on both pre-neoplastic lesion formation [263] and tumor progression 
[264]. Similarly, obesity enhanced CLBC tumor progression, as evidenced by upregulation of 
migration and invasion markers associated with the epithelial-mesenchymal transition [511, 
512]; however these studies were conducted in the postmenopausal setting. Accordingly, the 
impacts of premenopausal weight gain, overweight without frank obesity, and weight loss on 
mammary inflammation and CLBC progression remain underexplored.  
The mechanisms whereby overweight and obesity exacerbate TNBC progression are 
likely multifactorial, yet inflammation plays a pivotal role. In visceral (intra-abdominal) adipose 
tissue depots, obesity is associated with a dynamic infiltration of innate and adaptive immune 
cells that produce inflammatory cytokines, chemokines, growth factors, and matrix-degrading 
enzymes, triggering chronic low-grade adipose inflammation and development of metabolic 
dysfunction (reviewed in detail in [505]). We and others have demonstrated that obesity-
associated inflammatory changes, including formation of crown-like structures (CLS), foci of 
macrophages and other inflammatory cells surrounding dead and dying adipocytes, also occurs 
in mouse mammary fat pad and human breast adipose tissue [321, 322, 366]. Importantly, 
increased breast CLS density has been observed in both overweight and obese patients with 
early-stage breast cancers, demonstrating that macrophage influx into breast adipose occurs in 
response to even minor changes in adiposity [366, 513].  
In addition to altering macrophage-associated inflammation, adipose accumulation also 
appears to increase both content and activation of mast cells in multiple adipose tissue depots 
[435, 436]. In the normal breast, mast cells play a significant role in pubertal mammary gland 
branching morphogenesis, promoting proliferation in ducts and terminal end buds through 
secretion of growth factors and tissue-remodeling proteases [514]. However, an increase in 
mast cell content and/or activation within the overweight or obese breast also has potential to 
influence the course of a developing breast cancer, as multiple mast cell-derived products are 
known mediators of tumorigenesis [505]. Remarkably, mast cell influence on the course of 
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tumor development appears to differ considerably depending upon their localization relative to 
the tumor. For example, tryptase-positive mast cells are found at high density along the tumor 
invasive front and are associated with tumor progression and angiogenesis [515]. Increased 
peritumoral mast cell density also significantly correlated with lymphatic density – a prognostic 
indicator in several cancer types – in luminal A breast cancers and BBC [452]. Conversely, 
increased intratumoral mast cell infiltration in invasive breast cancer was a strong marker of 
favorable prognosis independent of age, tumor grade, tumor size, lymph node status, or 
hormone receptor status [452]. As invasive breast cancers frequently interact with breast 
adipose tissue [505], these studies collectively raise important questions regarding the impact of 
overweight and obesity on the relative abundance and activation states of peritumoral and 
intratumoral mast cells in invasive breast cancers. However, despite consistent reports 
regarding increased mast cell content and altered mast cell activation state in obese adipose 
tissue [435, 436], the impact of excess adiposity on the density or activation phenotype of mast 
cells in breast adipose tissue has not been explored.  
To elucidate associations among changes in weight status, inflammatory changes within 
the mammary fat pad and CLBC tumor progression, we conducted syngeneic orthotopic 
transplant studies in female FVB/NJ mice, a model of overweight as opposed to frank obesity 
[516]. A C3(1)-TAg-derived CLBC cell line (C3-Tag-luc) was orthotopically injected into mice 
that remained lean, mice fed a high-fat diet to induce weight gain (Overweight), and mice in 
which a period of overweight was followed by weight loss (Weight Loss, WeLo) induced by a 
diet switch. Collectively, our results demonstrate that overweight induces inflammatory changes 
within mammary adipose that are akin to frank obesity and reversible with weight loss. 
Importantly, weight loss also normalized CLBC growth and reduced intratumoral expression of 
pathways associated with CLBC progression. Thus, premenopausal weight loss may be an 
important interventional strategy with regard to prevention of overweight- and obesity-
associated CLBC progression. 
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Methods 
Animals and Diets  
All animal studies were approved by the Institutional Animal Care and Use Committee of 
the University of North Carolina at Chapel Hill and were performed in accordance with the 
recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. 
Animal facilities at UNC are accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC), and veterinary care meets National Institutes of Health 
standards set forth in the Guide for the Care and Use of Laboratory Animals (DHHS Publication 
No. (NIH) 85-23 Revised 1985). UNC also accepts as mandatory the Public Health Service 
Policy on Humane Care and Use of Laboratory Animals by Awardee Institutions, as well as NIH 
Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and 
Training. Animal studies comply with the ARRIVE guidelines. In accordance with humane 
euthanasia regulations, mice were anesthetized by intraperitoneal injection of avertin 
(tribromoethanol/amylene hydrate, 1.25%) (Sigma Aldrich) and cervical dislocation was 
performed before tissue collection. Mice were housed in a climate-controlled Department of 
Laboratory Animal Medicine facility with a 12-hour light:dark cycle, with ad libitum access to 
water and diets as described below. Female wild-type FVB/NJ mice (strain 001800) were 
obtained from Jackson Laboratories (Bar Harbor, ME) at 3 weeks of age and allowed to 
acclimate for 5 weeks before randomization to diets at 8 weeks of age. Diets obtained from 
Research Diets Inc. (New Brunswick, NJ, USA) were matched for sucrose, protein, vitamins, 
and minerals, and provided 10% kcal (“LFD”, D12450J) or 60% kcal (“HFD”, D12492) derived 
from fat.  Nulliparous female C3(1)-TAg mice were bred and maintained on chow diet (Harlan 
2918) until random assignment to diet groups at 10 weeks of age. Diets obtained from Research 
Diets Inc. (New Brunswick, NJ, USA) were matched for protein, vitamins, and minerals, and 
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provided 10% kcal (“LFD”; # D11012202); and 60% kcal (“HFD”; # D11012204) derived from fat 
(additional information on dietary composition can be found in [43]).  
 
Body Weight and Composition  
Body weight was measured at diet start and once weekly until sacrifice. Body 
composition of non-anesthetized mice, including lean mass, fat mass, free water content, and 
total water content, was measured at diet start, diet switch, orthotopic injection, and sacrifice 
using an EchoMRI-100 quantitative magnetic resonance whole body composition analyzer 
(Echo Medical Systems, Houston, TX). 
 
C3-Tag-luc Cell Line Characterization  
C3-Tag-luc cells were established by dissociation of mammary tumors from C3(1)-TAg 
mice as described [517]. Expression profiling of the C3-Tag-luc cell line was conducted as 
follows: RNA was isolated from the cell line using the Qiagen RNeasy mini kit (QIAGEN, 
Valencia, CA) and RNA quality was determined using an Agilent Bioanalyzer. Total RNA was 
labeled with Cy5 dye using the Agilent Low RNA Input Fluorescent Linear Amplification Kit. 
Likewise, whole mouse reference [149] RNA was labeled with Cy3 dye. For mouse reference 
and tumor cell line RNA, labeled RNA (2ug) was co-hybridized overnight to Agilent microarrays 
(GEO Platform GPL11383 / Agilent Design 25503 144K mouse Agilent Array). Intensity values 
were then uploaded to the UNC Microarray Database (UMD). In order to examine the features 
of this cell line, we combined the C3-Tag cell line data with array data associated with the 
published dataset [518].  For all arrays, expression values were calculated as the log2 Cy5/Cy3 
ratios with Lowess normalization applied. Genes with intensity values greater than 10 in both 
Cy5 and Cy3 channels were determined as present in each sample. To examine genes in the 
entire dataset we applied a filtering criteria requiring expression in at least 70% of all samples. 
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Next, duplicate genes (corresponding to multiple probes) were collapsed to their median 
expression, and missing values were imputed by K-means nearest neighbor imputation. Prior to 
clustering, genes were median-centered and arrays were standardized. For intrinsic analysis, 
the normalized dataset was filtered to the published intrinsic gene list [518]. Genes and arrays 
were clustered using Cluster 3.0 with selection of the correlation similarity metric and centroid 
linkage. Finally, results were visualized in Java Tree View[519]. Sample subtype annotations 
from Pfefferle et al. [518] were used for all previously published array data.  
The original C3(1)-TAg model has been characterized as basal-like breast cancer [149]. 
However, while C3-Tag-luc cells clustered in proximity to tumors from the original C3(1)-
TAg  basal-like tumors, they were more closely related to the Claudin-low molecular subtype 
(Figure 30A). For example, while both had high expression of proliferation-associated 
genes, relative to the original C3(1)-TAg model C3-Tag-luc cells exhibited much lower 
expression of claudins 3 and 7, a defining feature of claudin-low breast cancers [520] (Figure 
30B&C). On the other hand, keratins 14 and 17, associated with the basal-like gene 
cluster, showed high expression in C3(1)-TAg  tumors and low expression in the C3-Tag-luc cell 
line (Figure 30B&C). 
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Figure 30. Phenotyping of C3-Tag-luc cell line. A) Hierarchical clustering of our previously published 
microarray dataset [518] and the C3-Tag-luc cell line. The dataset was filtered to include only intrinsic genes 
and the dendrogram assembled by centroid linkage, illustrating the relationship of individual samples in the 
dataset. The red bar beneath the dendrogram indicates the position of the C3-Tag-luc cell line while the 
blue/turqouise bars depict the position of other tumor subtypes according to row annotations. Note, the C3-
Tag-luc cell line clusters with other claudin-low tumor samples. The heatmap below shows the relative 
expression profile of genes across samples and corresponding to the color bar along the bottom. (B). Using 
the assembly from panel A, we identified clusters highlighting important features of tumors segregating 
closely, including (i) the basal-like cluster, (ii) the claudin-cluster, and (iii) the proliferation cluster. (C) 
Selecting these clusters for just the C3-Tag-luc cell line shows low expression of the basal-like genes, a 
claudin-low gene expression profile, and high expression of the proliferation cluster. 
 
Orthotopic Injections and Tissue Harvest  
C3-Tag-luc cells were generously donated by William Y. Kim, MD, of the UNC 
Lineberger Comprehensive Cancer Center. Cells were passaged once before orthotopic 
injection and were grown in DMEM (Cellgro) with 10% FBS and 1% penicillin/streptomycin at 
37°C and 5% CO2. Eighteen-week-old female FVB/NJ mice (N=19-20/group) were orthotopically 
injected in the left fourth (abdominal) mammary fat pad with 2×105 viable C3-Tag-luc cells in a 
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1:1 mixture of high concentration Matrigel® (Cat # 354262, BD Biosciences, Bedford, MA) and 
Hank’s Saline Solution (Sigma Aldrich, St. Louis, MO). Tumor progression was monitored with 
electronic calipers three times weekly until sacrifice, and volumes were calculated using the 
modified ellipsoid formula (length × width2 × 0.5) as in previous studies [43]. Tissues collected 
included tumor, un-injected abdominal mammary fat pad, tumor-adjacent adipose, and liver. A 
portion of each tissue sample was frozen in liquid nitrogen and stored at -80˚C for gene 
expression analysis. The remaining tissue was formalin-fixed and paraffin embedded (FFPE) for 
histological analysis.  
At an average age of 18.20 weeks, mammary fat pads of C3(1)-TAg mice without palpable 
or visible tumors were collected as “normal” unaffected gland, although atypia of ductal epithelium 
could be present in C3(1)-TAg mice after 8 weeks of age [150]. 
 
Flow Cytometric Analysis  
Female mice were euthanized via CO2 asphyxiation and cervical dislocation at 21 weeks 
of age (n = 5 per diet). The left and right abdominal (4th and 7th) mammary adipose pads were 
removed and the intramammary lymph nodes excised. Fat pads were transferred to ice cold 
Dulbecco’s Modified Eagle’s Medium, high glucose (4.5 g/L) (DMEM, Corning, Corning, NY) 
containing 20 mM HEPES buffer (Cellgro, Manassas, VA), and supplemented with 10% bovine 
calf serum (HycloneTM, GE Healthcare Life Sciences, South Logan, Utah), 5mM glutamine, and 
10mM penicillin-streptomycin. Fat pads were minced with surgical scissors before enzymatic 
digestion in 2 mg/mL Type I collagenase (Worthington, Lakewood, NJ). A single-cell suspension 
was generated via mechanical dissociation with a Stomacher® 80 Biomaster small tissue lab 
paddle blender (Seward, Worthing, West Sussex, United Kingdom). Suspensions were diluted 
with an equal volume of HEPES-buffered DMEM and filtered through a 100-µm cell strainer, 
followed by centrifugation at 200 x g for 10 min at 4°C and removal of the mature adipocyte 
layer and red blood cell lysis (ACK lysis buffer; Gibco, Gaithersburg, MD) to generate an 
107 
 
immune cell-enriched stromal-vascular fraction (SVF). The resulting SVF from each mouse was 
blocked with Fc Block (CD16/32) (Biolegend, San Diego, CA), and stained with pre-titrated 
antibodies (see Table 1 for antibody information and dilutions). SVF cells were analyzed on a 
BD™ LSR II flow cytometer. Data were analyzed with FlowJo (FlowJo, LLC, Ashland, OR). 
Tumors were collected and immediately dissociated through enzymatic (collagenase 
type I; Worthington Biochemical Corporation, Lakewood, NJ) and mechanical dissociation with a 
Stomacher® 80 Biomaster small tissue lab paddle blender (Seward, Worthing, West Sussex, 
United Kingdom). Dissociation media was supplement DMEM, high glucose (4.5 g/L) (Sigma 
Aldrich, St. Louis, MO) containing 20 mM HEPES buffer (Corning, Manassus, VA) as described 
above. The resulting solution was filtered through a 100 µm filter and subjected to DNA 
digestion using DNAse I (Sigma Aldrich, St. Louis, MO) at 0.1 mg/mL in HEPES-buffered 
supplemented DMEM as described above. Cells were pelleted and underwent red blood cell 
lysis via ACK lysing buffer (Gibco, Grand Island, NY), after which cells were washed in a FACS 
Wash solution (1x Dulbecco's phosphate-buffered saline [DPBS, Corning, Manassus, VA] 
containing 1% fetal calf serum, 0.5% endotoxin-tested bovine serum albumin BSA, and 2 mM 
EDTA). Single cell suspensions were counted using a Scepter™ 2.0 Handheld Automated Cell 
Counter and blocked with Fc block (CD16/32; Biolegend, San Diego, CA) before staining. 
Antibody cocktails for staining were prepared in Brilliant Stain Buffer (BD Biosciences, Billerica, 
MA). Compensation was set using single-stained cellular controls and gating was determined 
based on fluorescence-minus-one (FMO) controls. Sample analysis was conducted using a 
FACSAriaII flow cytometer (BD Biosciences, Billerica, MA). 
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Table 1. Antibodies and dilutions used in analysis. 
Antibody Conjugate Dilutions Company Catalog # Lot # 
CD45 BV605 1:200 BioLegend   103140 B211813 
F4/80 PE-Cy7 1:200 eBioscience     25-4801-82 4281123 
CD11b BUV395 1:100 BD Biosciences  563553 7033600 
Ly6C BV421 1:100 BD Biosciences  562727 5357529 
MHCII (IA/IE) BV711 1:200 eBioscience   17-5321-81 6167935 
CD206 APC 1:100 
R&D Systems FAB25351A ADYJ0115081 
Tie2 PE 1:50 eBioscience   12-5987-83 E01993-1636 
Fc Block 
(CD16/CD32) 
 
N/A 1:50 BioLegend 101320 B200134 
Zombie Green 
Viability Dye 
 
N/A 1:400 BioLegend 423111 N/A 
 
 
 
Histological Analysis 
Formalin-fixed, paraffin-embedded (FFPE) tumor and corresponding uninjected 
mammary fat pad were sectioned at 5 μm in a serial interrupted fashion and mounted onto glass 
slides.  
Immunohistochemistry: Briefly, 5 μm FFPE tumor and normal mammary fat pad 
sections were baked, deparaffinized, and rehydrated. Following heat-induced epitope retrieval 
(Rodent Decloaker BM#RD913L), slides were treated with 3% hydrogen peroxide in de-ionized 
water. Tissues were treated with Avidin/Biotin Block (Vector #SP-2001) and exposed to primary 
antibodies (anti-CD31, anti-F4/80) diluted in Renoir Red Diluent at 4 °C overnight. Following 
incubation with biotin-conjugated secondary antibodies [Goat anti-rabbit IgG; Goat anti-rat IgG]  
tissue sections were treated with ABC Elite and DAB. Digital immunohistochemistry 
quantification was performed following the protocol previously described in Sundaram et al.[43]. 
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Stained slides were scanned into the Aperio Scanscope CS system (Aperio Technologies, 
Vista, CA, USA) at a magnification of 20× (F4/80) or 40× (CD31) and were quantified using the 
Aperio Imagescope software (Leica Biosystem, Buffalo Grove, IL). For CD31 percent positivity, 
scanned slides were analyzed using algorithms as described previously [42]. Microvessel 
density was quantified as total number of CD31/PECAM1+ vessels per tissue area (in mm2) in 
n=7-8 tumor histological sections per diet group.  Crown-like structure density was determined 
in n = 3 sections per mouse in n = 6-9 mice per diet group by counting the number of visible 
CLS and normalizing to tissue area analyzed (number/mm2). Images shown are representative.  
Adipocyte diameter: in hematoxylin-eosin (H&E) stained sections of uninjected 
mammary fat pad, a 20x field of view was randomly selected and the diameter of 100 white 
(unilocular) adipocytes was determined using the ruler function in ImageScope. (N = 7-8 
mice/group; 7-800 adipocytes total).  
Mast cell analysis: Slides were dewaxed and rehydrated with 60% ethyl alcohol, then 
exposed to Toluidine Blue O (C.I. 52040) for 1-2 minutes. Slides were then rinsed under water 
and dehydrated twice through acetone exposure for 1-2 minutes. Stained slides were scanned 
at a magnification of 40x into the Aperio Scanscope CS System. Total mast cell number in each 
section was manually counted and total tissue area analyzed was quantified in mm2 using 
Aperio Imagescope software. Mast cell density was reported as number of mast cells counted 
per section normalized to tissue section area.   
 
Quantitative PCR 
 Snap-frozen un-injected mammary fat pads were pulverized under liquid nitrogen. Total 
RNA was extracted (RNeasy Mini Plus kit, QIAGEN) and reverse-transcribed (1000 ng per 
sample; iScript Reverse Transcription Supermix, Bio-Rad) according to the manufacturers’ 
instructions. Gene expression was quantitated via quantitative reverse transcriptase PCR (qRT-
PCR) with the eukaryotic ribosomal 18S RNA as an endogenous control. TaqMan Assay-on-
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Demand (AOD) Gene Expression Assays (Applied Biosystems, Foster City, CA) were used for 
all probes, with the exception of Il10, Ccl2, and Nos2, which were measured using Roche 
Universal Probe Library Assays (Roche Diagnostics US, Indianapolis, IN) with the following 
oligonucleotide pairs: Il10: F: 5’-CAGAGCCACATGCTCCTAGA-3’; R: 5’-
GTCCAGCTGGTCCTTTGTTT-3’; Ccl2: F: 5’-AGCACCAGCCAACTCTCACT-3’; R: 5’-
GTGGGGCGTTAACTGCAT-3’; and Nos2: F: 5’-TGACACACAGCGCTACAACA-3’; R: 5’-
GCCAGTGTGTGGGTCTCC-3’. Data were analyzed using QuantStudio Real-Time PCR 
System software (Thermo Fisher Scientific, Waltham, MA) and the comparative ΔΔCT method.  
 
Microarray sample preparation 
FVB/NJ tumors: Total RNA was extracted (RNeasy Mini Plus kit, QIAGEN) and RNA 
purity and concentrations were determined using a NanoDropTM spectrophotometer (Thermo 
Fisher Scientific). All samples were diluted to a final concentration of 200 ng/uL for library 
preparation. RNA quality was determined using an Agilent TapeStation. One-color (Cy3) cDNA 
library preparation and microarray hybridization were conducted by the Lineberger 
Comprehensive Cancer Center Genomics Core using SurePrint G3 Mouse Gene Expression v2 
8x60K Microarray Kits (Agilent, Santa Clara, CA) and the Agilent Low RNA Input Fluorescent 
Linear Amplification Kit. Arrays were scanned using an Agilent Technologies G2505C Scanner 
with Feature Extraction software.  
 C3(1)-TAg mammary fat pads: Unaffected mammary fat pads were flash frozen in 
liquid nitrogen and prepared for microarray analysis as described above. Samples and universal 
mouse reference RNA were Cy5- and Cy3-labelled, respectively, using Agilent Low RNA Input 
Fluorescent Linear Amplification Kit, and hybridized to Mouse Gene Expression v2 4x44K 
microarrays (Agilent) according to the manufacturer’s protocol. 
Cancer-adjacent normal human breast: The Normal Breast Study (NBS) is an 
epidemiologic study of normal breast and breast cancer microenvironments conducted at UNC 
Hospitals in Chapel Hill, NC [521]. Women were eligible for inclusion if they were English-
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speaking, at least 18 years of age, undergoing breast surgery (mastectomy, lumpectomy, 
excisional biopsy, or cosmetic procedure) at UNC Hospitals between October 2009 and April 
2013, and consented to donate breast tissue. For microarray analysis, total RNA was extracted 
from snap-frozen tissue (Qiagen RNeasy) and quality was measured using an Agilent 
Bioanalyzer. Samples and universal human reference were Cy5- and Cy3-labelled, respectively, 
using Agilent Low RNA Input Fluorescent Linear Amplification Kit, and hybridized to Human 
Gene Expression v1 or v2 4x44K microarrays (Agilent). Only genes common to both array 
platforms were used in further analyses (see below).  
 
Microarray and gene signature analyses  
 FVB/NJ tumors: Gene expression estimates were calculating using the Agilent Feature 
Extractor software which performs background adjustment and total signal normalization. The 
normalized log2 Cy3 intensity was utilized for analysis, and histograms of t-test p-values 
between groups were used to assess global effects. Tests of gene level differential expression 
used the ‘Two class unpaired’ procedure in the Significance Analysis for Microarrays (SAM) 
algorithm [522]. Significantly up- or down-regulated pathways were identified using the 
Molecular Signatures Database (MSigDB) for Gene Set Enrichment Analysis. Genes and 
pathways were visualized using hierarchical cluster analysis ordering of heatmaps.  Clustering 
utilized average linkage with Pearson’s correlation as the distance metric.  
 
 C3(1)-TAg mammary fat pads, Normal Breast Study cancer-adjacent, and TCGA 
breast tumor samples: Expression values were calculated as the log2 Cy5/Cy3 ratios with 
Lowess normalization applied. Genes with intensity values greater than 10 in both Cy5 and Cy3 
channels were determined as present in each sample. Duplicate genes (corresponding to 
multiple probes) were collapsed by averaging. For C3(1)-TAg samples: Cy3-labeled reference 
was produced from Stratagene Universal Mouse Reference RNA following amplification with 
Agilent low RNA input amplification kit. Mouse mammary samples were labeled with Cy5. Data 
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were Lowess normalized, and probes with a signal <10 dpi in either channel were excluded as 
missing. In data preprocessing, we (1) eliminated probes without corresponding ENTREZ ID, (2) 
collapsed duplicate probes by averaging, (3) imputed missing data using k-nearest neighbors 
(KNN) method with k=10, and (4) median-centered genes. For NBS samples, women for whom 
microarray and BMI data (BMI >18.5 kg/m2) were available were included in this analysis. 
Patients undergoing cosmetic or prophylactic surgery were excluded, as were those for whom 
biopsy results indicated "no evidence of active disease” or “normal” tissue status. Specimens 
obtained from a second breast procedure were also excluded to avoid capturing gene 
expression patterns related to inflammation induced by a previous surgery (i.e., pre-existing 
granulation tissue). The final study population consisted of 131 unique patients and 193 tissue 
specimens. The clinicopathologic characteristics of these patients are included in Table 2. NBS 
microarray data were analyzed as previously described [523]. For TCGA samples, only data 
from invasive tumors were included (n = 1094). TCGA data and methods are available at the 
TCGA Data Portal (https://cga-data.nci.nih.gov). To calculate mast cell scores, the median 
centered gene expression profile for each sample was evaluated using published gene 
signatures. Mouse mammary tissue was analyzed using a previously validated, murine-specific 
128-gene signature for connective tissue mast cells [524], the type most commonly found in 
mammary tissue [514]. Human normal breast tissue was analyzed using a mast cell signature 
identified by Motakis et al. [525] through a comprehensive study of the mast cell transcriptome 
of ex vivo skin mast cells integrated with data from the FANTOM (Functional Annotation of the 
Mammalian Genome) consortium. Intratumoral mast cell gene expression was analyzed using 
the tumor mast cell gene signature described by Bindea et al. [526].  Since all genes in the 
original signatures were up-regulated in mast cells compared to the other cell types studied, the 
mast cell scores were derived from the average expression of mast cell signature genes in each 
sample.  
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Statistical Analysis  
All statistical analyses were conducted using GraphPad Prism 7 software (GraphPad 
Software, Inc. La Jolla, CA). Data are expressed as mean ± standard error of the mean (SEM) 
unless stated otherwise. Means were compared as indicated via one- or two-way Analysis of 
Variance (ANOVA) followed by Tukey’s Post Hoc Multiple Comparisons. Statistical outliers were 
identified using the robust non-linear regression with outlier removal (ROUT) method with 
Q=1%. P-values ≤0.05 are considered statistically significant.  
 
Results 
High-fat feeding and diet switch-induced weight loss modulated mammary adiposity and 
CLBC tumor growth  
Eight-week-old female FVB/NJ mice were randomized to one of three diet groups: 
“Lean” mice were fed LFD until sacrifice, “Overweight” mice were fed HFD until sacrifice, and 
“Weight Loss (WeLo)” mice received 5 weeks of HFD to increase adiposity, followed by a 5-
week diet switch to LFD to induce weight loss prior to tumor cell injection (N=19-20 mice/diet 
group, see study design diagram in Figure 31). Following 10 weeks on assigned diets, C3-Tag-
luc CLBC cells were orthotopically transplanted into the left fourth (abdominal) mammary fad 
pad of each mouse. Tumors were allowed to develop for 21 days, at which point all mice were 
sacrificed. Body composition and 6-hour fasted glucose were monitored at the indicated time 
points. Overweight mice displayed significantly greater body weights than Lean beginning two 
weeks after diet start and continuing until sacrifice (Figure 32A; P<0.01-P<0.0001 vs. Lean). 
Body weights of WeLo mice paralleled Overweight until diet switch (Figure 32A; P<0.01-
P<0.0001 vs. Lean). Diet switch restored body weights to Lean levels until sacrifice (Figure 
32A; P<0.01-P<0.0001 vs. Overweight). Similarly, body composition analysis demonstrated an 
approximately 2-fold increase in overall adiposity in Overweight and WeLo mice after 5 weeks 
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on HFD (P<0.0001 Overweight vs. Lean; P<0.0001 WeLo vs. Lean) (Figure 32B). Following 
diet switch, adiposity in WeLo mice was restored to Lean levels (P<0.0001 Overweight vs. Lean 
and vs. WeLo, Figure 32B).   
 
 
Figure 31. Study design with orthotopic transplant model and tissue collection diagram. N=19/diet. 
 
Following normalization to body weight, liver weight was significantly greater in 
Overweight compared to Lean and WeLo mice (Figure 32C; P<0.0001). A modest but 
significant elevation in fasting glucose was also observed in Overweight compared to Lean and 
WeLo mice at the time of orthotopic injection; however, at sacrifice this difference only remained 
significant between Overweight and Lean (Figure 32D). Gonadal (~2.5-fold) (Figure 32E) and 
mammary (~2-fold) (Figure 33A) adipose fat pad masses were significantly increased in 
Overweight mice (P<0.0001 Overweight vs. Lean, WeLo), with no differences observed 
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between WeLo and Lean mice. Importantly, increased adiposity in Overweight mice 
corresponded with significantly greater final tumor volume compared to Lean and WeLo (Figure 
33B; P<0.05 Overweight vs. Lean, P<0.05 Overweight vs. WeLo).  
 
 
Figure 32. High fat diet induced adiposity in female FVB/NJ mice was normalized by weight loss. A) 
Body weight was measured at baseline and weekly until sacrifice at 21 weeks of age. ^^P<0.01 Lean vs 
WeLo, **P<0.01 vs Overweight (OW), ##P<0.01  OW vs WeLo, by two-way ANOVA with post-hoc Tukey’s 
analysis). B) Body composition, including fat mass, was measured at diet start and specified time points 
until sacrifice using an EchoMRI-100 (****P<0.0001 Lean vs OW, ^^^^Lean vs WeLo, ####OW vs WeLo 
by two-way ANOVA with post-hoc Tukey’s analysis). C) Average liver weight at sacrifice, normalized to 
body weight (****P <0.0001 by one-way ANOVA with post-hoc Tukey’s multiple comparisons). D) Fasting 
glucose was measured in 6h fasted mice at indicated time points (*P<0.05, ***P<0.001 Lean vs OW, 
###P<0.001 OW vs WeLo by two-way ANOVA with post-hoc Tukey’s analysis). E) Gonadal fat pad masses 
at sacrifice (****P < 0.0001 OW vs Lean, WeLo mice by one-way ANOVA with post-hoc Tukey’s analysis). 
All values reported as mean ± SEM. N=19/diet group. 
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Figure 33. Increased mammary fat pad mass in Overweight mice was associated with increased 
tumor growth rate. A) mammary fat pad masses at sacrifice (****P < 0.0001 OW vs Lean, WeLo mice by 
one-way ANOVA with post-hoc Tukey’s analysis). B) Tumor growth was measured thrice weekly by 
electronic calipers (*P<0.05 OW vs Lean; #P<0.05 OW vs WeLo by two-way ANOVA with post-hoc Tukey’s 
multiple comparisons). Mean ± SEM. N=19/diet group. 
 
Accelerated tumor growth rate in Overweight mice was associated with macrophage and 
neutrophil influx into mammary adipose 
Given the known role of mammary inflammation in breast cancer progression [505], we 
next determined whether the observed increases in mammary adiposity and tumor volume 
occurred in conjunction with features of adipose inflammation typically observed in visceral 
adipose pads in obesity. We first compared mammary fat pad adipocyte diameter of Lean, 
Overweight, and WeLo mice. Average mammary adipocyte diameter was approximately 35% 
greater in Overweight mice relative to Lean (Figure 34A&B; P<0.01) and was not significantly 
different between WeLo and Lean animals.  
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As adipocyte hypertrophy in obesity is associated with increased myeloid cell content in 
visceral adipose depots, flow cytometric analysis was performed on lean and overweight mice to 
determine if myeloid content in mammary adipose tissue was also increased by overweight. 
CD11b-positive myeloid cell content was increased within the stromal-vascular fraction of 
Overweight mammary adipose by 52% relative to Lean animals (Figure 35A; P=0.0035) 
(complete gating scheme in Appendix, Supp. Figure 43). We next quantified markers of 
neutrophil and macrophage influx in whole mammary fat pad to identify which myeloid populations 
were regulated by adiposity. Expression of the neutrophil-specific enzyme neutrophil elastase 
(Elane) was significantly >2-fold greater (Figure 35B; P<0.01) in Overweight relative to Lean 
mammary fat pad and was reduced to Lean levels in WeLo mice.  
Figure 34. Overweight and weight loss regulated 
mammary adipocyte diameter. A) Average 
adipocyte diameter of 100 adipocytes/tissue section 
in n=7-8 normal mammary sections was calculated 
per diet group. **P <0.01 OW vs Lean, OW vs WeLo 
by one-way ANOVA with post-hoc Tukey’s multiple 
comparisons. Mean ± SEM. Representative images 
shown. B) Histogram of adipocyte diameter from 100 
adipocytes/tissue section in n=7-8 normal mammary 
sections per diet group. 
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Figure 35. Accelerated tumor growth in Overweight mice occurred in association with increased 
mammary adipose myeloid cell content. A) CD11b+ myeloid cell composition shown as a percentage of 
total stromal-vascular cells in abdominal mammary fat pads. n=5-6 per diet group. **P= 0.0043 by Mann-
Whitney. Representative dot plots shown along with representative images of mammary fat pads used for 
flow cytometric analysis. B) mRNA expression of the enzyme neutrophil elastase (Elane) was elevated in 
mammary fat pad of OW mice.  
 
With respect to macrophages, mammary adipose CLS density was 2.20-fold (P=0.040) 
and 3.76-fold (P=0.0021) greater in Overweight compared to Lean and WeLo animals, 
respectively (Figure 36A). Notably, CLS were present in 90.3% of histologic mammary sections 
from Overweight mice yet were observed in only 50% of Lean and 31.8% of WeLo tissue sections. 
Accordingly, Overweight mammary glands exhibited a >4-fold increase in expression of F4/80 
(Emr1) relative to both Lean and WeLo (Figure 36B, P<0.05).  
Adipose tissue macrophages express a mixture of canonical pro- and anti-inflammatory 
markers (e.g., both CD11c [Itgax] and Arginase 1 [Arg1]) [370, 372, 527]. Consistent with this 
“mixed” macrophage phenotype, significant increases were observed in both Itgax and Arg1 
expression in Overweight mammary adipose (Figure 36C, *P<0.05, Overweight vs. Lean, 
WeLo; Figure 36D, **P<0.01 vs. Lean, ***P<0.001 vs. WeLo), while expression of monocyte-
chemoattractant protein (MCP1; Ccl2) (Figure 36E) and tumor necrosis factor alpha (TNF-, 
not shown) were increased but not significantly. Collectively, these findings suggest that 
adiposity-induced changes within the mammary microenvironment regulate myeloid cell content 
and/or activation, with potential to influence tumor growth in Overweight mice. 
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Figure 36. Overweight increased mammary adipose CLS density and expression of macrophage 
markers. A). Crown-like structure (CLS) density in the mammary fat pad was calculated in n=3 non-
sequential sections per mouse from n = 6-9 mice/diet group. Scale bar = 100 µm. *P<0.05 OW vs Lean, 
**P <0.0001 OW vs WeLo by one-way ANOVA with post-hoc Tukey’s multiple comparisons. Representative 
images shown, CLS indicated with arrows. B-E) mRNA expression of Emr1, the enzyme Arg1, the integrin 
Itgax, and Ccl2 (also known as Mcp1) were measured in the mammary fat pad by RT-qPCR analysis. All 
gene expression analyses were normalized by the delta delta Ct method to 18S and the same randomly 
selected Lean sample.  *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA with post-hoc Tukey’s analysis 
(n=5-7/diet). Mean ± SEM. 
 
Weight loss reversed overweight-associated increases in growth factor and inflammatory 
cytokine production 
To further probe the effect of adiposity and weight loss on mammary inflammation, we 
next examined expression of select interleukins (ILs) implicated in adipose tissue inflammation 
and breast tumor growth promotion. Compared to Lean mice, overweight increased expression 
of IL-6 (Il6), while weight loss significantly reduced Il6 expression by >8-fold relative to 
Overweight mice (Figure 37A; P=0.025 Overweight vs. Lean, P=0.014 Overweight vs. WeLo). 
Similarly, IL-1β (Il1b) expression was upregulated in Overweight mice relative to WeLo animals 
(P = 0.03) (Figure 37B). On the other hand, expression of immunosuppressive IL-10 (Il10) [441] 
was elevated by >4-fold in Overweight compared to Lean mammary fat pad (Figure 37C, P = 
0.041). Il10 expression in mammary pad of WeLo mice resembled that of Lean mice but did not 
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reach significance relative to Overweight (P = 0.054). Consistent with our flow cytometry data, 
these results support the existence of a mixed pro- and anti-inflammatory milieu within 
Overweight mammary adipose, with restoration of a lean-like microenvironment upon weight 
loss.  
Weight gain can also increase expression of growth factors that are relevant to breast 
cancer progression, including hepatocyte growth factor (HGF, Hgf) [42, 43, 264, 528] and 
vascular endothelial growth factor (VEGF; Vegfa) [147, 225]. Notably, Hgf expression in the 
mammary fat pad was increased by approximately 2.7-fold in Overweight relative to Lean 
animals; this upregulation was abrogated in WeLo mice (Figure 37D; P=0.038 and P=0.030, 
respectively). WeLo mice also exhibited a significant reduction in Vegfa expression relative to 
Overweight mice (Figure 37E; P=0.025). 
 
 
Figure 37. Weight loss restored mammary fat pad expression of mixed inflammatory cytokines, 
growth factors, and markers of neutrophil infiltration to lean levels. A-E) mRNA expression of the 
interleukins Il1β, Il6, and Il10, and the growth factors hepatocyte growth factor (Hgf) and vascular 
endothelial growth factor (Vegfa) were measured in the mammary fat pad by RT-qPCR analysis. All gene 
expression analyses were normalized by the delta delta Ct method to 18S and the same randomly selected 
Lean sample.  *P<0.05, **P<0.01, by one-way ANOVA with post-hoc Tukey’s analysis (n=5-7/diet). All 
graphs shown as mean ± SEM. 
 
Local, obesity-induced changes in the mammary adipose microenvironment may 
augment angiogenesis and infiltration of immune cells, such as macrophages, into developing 
mammary tumors [45, 529]. Based on our findings that overweight increased mammary CLS 
density and expression of the pro-angiogenic growth factors Hgf and Vegfa, we determined 
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whether these changes translated into greater tumor microvessel density or tumor-associated 
macrophage content. However, no significant differences were observed in either CD31+ tumor 
area or microvessel density (Figure 38A-B). Similarly, flow cytometric analyses revealed no 
diet-induced differences in total leukocytes (CD45+) (Figure 38C), tumor-associated 
macrophages (TAMs, defined as CD45+F4/80hiFSCmidSSCmid; Figure 38D), or other myeloid 
cells (defined as CD45+F4/80lo/midFSChiSSChi; Figure 38E) (gating scheme in Suppl Figure 2). 
 
 
Figure 38. Accelerated early tumor growth in Overweight was not explained by differences in 
vascular density or leukocyte infiltration. A) Vascular density was measured using 
immunohistochemistry against the endothelial marker CD31/PECAM1 (n=7-8/diet group) Mean ± SD. B) 
Microvessel density was quantified as total number of CD31+ vessels per tissue area (mm2). C-G) 
Intratumoral leukocyte analysis was conducted via flow cytometry on n=3 tumors/diet group. *P = 0.04, 
WeLo vs Lean. All values reported as mean ± SEM. 
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Weight loss reduced expression of mitogenic and metastasis-associated gene pathways 
To further probe potential mechanisms whereby changes in weight status influenced tumor 
progression, we next conducted microarray analysis on total tumor lysates. Tumors were 
selected based on proximity to the median tumor volume within each respective diet group. 
Initial analysis comparing all three diet groups revealed minimal differences in gene expression 
in tumors from Lean and Overweight mice (data not shown), suggesting that increased tumor 
volume in Overweight mice was not driven by differences within the intratumoral 
microenvironment. However, WeLo mice exhibited a distinct transcriptional profile, prompting 
additional analyses using a two class Significance Analysis for Microarray (FDR <5%) to 
emphasize unique intratumoral changes in response to weight loss (Figure 39A). Relative to 
Lean and Overweight, WeLo mice exhibited downregulation of CXCR4/CXCL12 (Figure 39B) 
and erythropoietin (EPO) signaling (Figure 39C), as well as reduced expression of multiple 
genes within the IGF-1, ERK5, IL-4, and extracellular matrix (ECM) pathways (Figures 39D-G).  
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Figure 39. Weight loss altered intratumoral expression of pathways associated with growth, ECM 
remodeling, immune response, and metastasis. A) Heat map of genes with FDR <5% from a 2-class 
ANOVA using SAM. B-G) Tumor gene expression pathways significantly altered by diet exposure. Pathway 
analysis conducted using the Molecular Signatures Database (MSigDB). Y-axis of boxplots shows 
normalized log gene expression. Indicated P-values correspond to Weight loss vs Other.  
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Adiposity status regulated mast cell density and activation in mouse mammary fat pad 
Similar to other myeloid-lineage immune cells, mast cell-derived factors are also 
implicated in breast cancer progression. To determine the effect of diet-induced weight gain and 
weight loss on mammary tissue mast cell content we next quantified mast cell density in un-
injected mammary gland. Toluidine blue-positive mast cells were observed most frequently 
within the collagenous stroma of mammary ducts, in close proximity to ductal epithelial cells 
(Figure 40A), and in the adventitia of mammary blood vessels (not shown). While no significant 
difference in mast cell density was observed between Lean and Overweight mice, weight loss 
resulted in an approximately 51% increase in average mast cell density compared to 
Overweight animals (Figure 40A; P<0.05 vs. WeLo). On the other hand, the mast cell-specific 
marker tryptase beta-2 (Tpsb2) was non-significantly increased in Overweight mice (P=0.063 
Overweight vs. Lean), and significantly (>3-fold) reduced by weight loss (Figure 40B; P=0.017 
WeLo vs. Overweight).  
To further investigate mast cell activation in response to mammary adiposity, we 
analyzed pre-existing, unpublished microarray data from lean and overweight nulliparous 
transgenic C3(1)-TAg mice mammary fat pads. These mice were randomly assigned to LFD and 
HFD at 10 weeks of age, and mammary fat pads without palpable or visible tumors were 
collected as unaffected mammary glands at an average of 18.2 weeks of age. We calculated a 
mast cell score for each sample using a previously validated, murine-specific 128-gene 
signature for connective tissue mast cells [524], the type most commonly found in mammary 
tissue [514]. Similar to our histologic findings in FVB/NJ mice, mast cell score was significantly 
greater in overweight as compared to lean C3(1)-TAg mammary fat pad (Fig. 40C).  
To determine whether the presence of CLBC influenced mammary mast cell content we 
next compared mast cell density within un-injected mammary pad to mast cell density within the 
corresponding tumor-adjacent tissue of the same animal. Interestingly, a significant increase in 
mast cell density in tumor-adjacent mammary gland relative to the corresponding un-injected 
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mammary tissue was observed in Overweight mice (Figure 40E; P=0.016 vs. un-injected 
mammary) but not in Lean or WeLo mice (Figure 40D&F). However, neither overweight nor 
weight loss affected intratumoral mast cell density in CLBC tumors (not shown). Likewise, 
microarray analyses revealed no significant difference in expression of mast cell-associated 
genes across diet groups in our murine model of CLBC. Restated, mammary adipose conditions 
in the context of overweight prompted an increase in tumor-adjacent mast cell content in 
response to CLBC tumor development without affecting intratumoral mast cells.  
 
 
Figure 40. Overweight and weight loss regulated mast cell density and activation in normal and 
tumor-adjacent mammary adipose.  A) Mammary mast cell density was calculated as number of toluidine 
blue-positive mast cells in a given mammary fat pad tissue section normalized to total tissue area analyzed 
(cells/mm2) n = 7-8 mammary sections/diet group. *P<0.05 WeLo vs OW. Representative image of toluidine 
blue staining shown with mast cells indicated by black arrows. B) mRNA expression of tryptase beta-2 
(Tpsb2), a mast cell-specific enzyme, was quantified in mammary fat pad from n=5-7 mice/diet group by 
RT-qPCR analysis. All gene expression analyses were normalized by the delta delta Ct method to 18S and 
the same randomly selected Lean sample. Reported as mean ± SEM. C) Mast cell score was determined 
use microarray gene expression analyses of n=4-6 unaffected mammary fat pads from Lean and 
Overweight female C3(1)-TAg mice. P= 0.0095 by Mann-Whitney analysis. D-F) Mast cell density in un-
injected mammary fat pad and corresponding tumor-adjacent adipose (cells/mm2) n =7-8 sections. 
Overweight *P=0.016 by paired t-test. 
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Mast cell score is increased in breast tissue of overweight and obese women 
Our findings in murine mammary gland indicated the potential for increased mast cell 
activation in overweight and obese human breast tissue. Thus, we next investigated expression 
of mast cell-associated genes in existing microarray data from cancer-adjacent normal human 
breast tissue samples obtained through the UNC Normal Breast Study, a hospital-based study 
of normal breast tissue and breast cancer microenvironments [521] (see Table 2 for patient 
characteristics).  
Table 2. Demographic and clinicopathologic features of Normal Breast Study participants. 
  
Mean + SD n % 
Demographic factors       
    Age  54.2 + 11.8     
        <50    44 33.6 
        >50    87 66.4 
    Race       
        Caucasian   82 62.6 
        African American   43 32.8 
        Other/Not reported 
 
  6 4.6 
Anthropometric data 
    1BMI (kg/m2) 29.8 + 7.1     
        Normal-weight   38 29.0 
        Overweight   37 28.2 
        Obese 
 
  56 42.7 
IHC-based subtype of 
corresponding tumor 
      
    Luminal A (ER+PR+HER2-)   52 39.7 
    Luminal B 
(ER+PR+HER2+) 
  14 10.7 
    HER2-enriched (ER-PR-
HER2+) 
  15 11.5 
    Triple-negative (ER-PR-
HER2-) 
  24 18.3 
    2Other/Not reported   26 19.8 
1May not equal 100% due to rounding. 
2Includes borderline, benign, and in situ cases. 
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A mast cell score for each patient was calculated using a previously validated panel of 
human mast cell-specific genes [525]. Consistent with our murine model data, mast cell score in 
human breast tissue was elevated with increased adiposity (Fig. 41A-B; P<0.05 Normal weight 
vs. Overweight, P<0.01 Normal weight vs. Obese). Thus, collectively our results demonstrated 
adiposity-mediated modulation of mast cell dynamics within both the mammary fat pad of mice 
and human breast tissue. 
Figure 41. Overweight and obesity 
increased expression of mast-cell 
associated genes within human 
breast tissue samples. A) Mast cell 
score was determined using gene 
expression data from N= 255 cancer-
adjacent human breast tissue samples 
obtained through the Normal Breast 
Study, a hospital-based study 
investigating potentially predictive 
markers within normal breast tissue 
surrounding a tumor. B) Distribution of 
mast cell scores in NBS human breast 
tissue analyses. See Methods for 
species-specific mast cell score 
derivation.  
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Lower intratumoral mast cell score is associated with triple-negative breast cancer and 
elevated risk of recurrence 
Linked anthropometric data such as BMI are often not available for large, publicly-
available human breast cancer gene expression datasets. However, as intratumoral mast cell 
density is correlated with more favorable outcomes in breast cancer [452], and because breast 
cancer outcomes vary across subtypes [530], we next utilized TCGA breast cancer datasets to 
inquire whether mast cell score varied in accordance with tumor subtype. Indeed, mast cell 
scores calculated in basal-like tumors were dramatically lower than those in luminal A cancers, 
a subtype with relatively high long-term survival rates [530] (Figure 42A, BBC vs. Luminal A; 
P<0.0001). A modest, yet significant, difference in mast cell scores was also seen between 
luminal B and HER2+ breast cancers (Figure 42A, P<0.05). These data indicate that breast 
cancer subtype is a strong determinant of intratumoral mast cell content. 
 The striking underrepresentation of mast cell-associated genes in BBCs, which display 
elevated 5-year distant recurrence rates relative to other breast cancer subtypes [509], led us to 
investigate whether mast cell score was also associated with predicted risk of tumor recurrence. 
For these analyses we used the previously assigned ROR-P score, which is a risk-of-recurrence 
score weighted to the PAM50 11-gene proliferation index available through TCGA [531]. 
Consistent with subtype findings, mast cell score was inversely associated with ROR-P score, 
with the greatest expression of mast cell-associated genes measured in tumors assigned a low 
ROR-P range, intermediate expression in the medium ROR-P group, and lowest expression in 
tumors assigned a high ROR-P score (Figure 42B, P<0.0001 for all comparisons).   
129 
 
 
Figure 42. Intratumoral mast cell score was subtype-specific and associated with risk-of-recurrence 
score. A) Mast cell score by tumor subtype using gene expression data from N=1010 human tumors, 
generated by The Cancer Genome Atlas (TCGA) Research Network. *P<0.05, ****P<0.0001 B) Mast cell 
score differed significantly across ROR-P risk groups. Reported as mean ± SEM. See Methods for mast 
cell score derivation. ****P<0.0001 vs Low risk, ^^^^ VS Medium risk. 
 
Discussion 
Obesity at the time of breast cancer diagnosis is associated with an estimated 34% 
increase in breast cancer-specific mortality in postmenopausal women and a 75% increase in 
premenopausal women [55]. Importantly, the inflammatory changes seen in obese breast 
adipose and implicated in promotion of breast cancer progression are also present in 
overweight women [366, 513]. As overweight and obesity in women are now more than three 
times as prevalent as normal weight [504], an understanding of the mechanisms whereby 
excess adiposity and weight loss influence breast cancer aggression is critical to inform public 
health recommendations and therapeutic approaches. 
Our previous findings in the transgenic C3(1)-TAg model of BBC demonstrated 
accelerated tumor progression in response to weight gain that was reversed in animals wherein 
weight loss occurred before tumor onset [264].  An unknown was how the mammary gland 
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microenvironment contributed to tumor growth as opposed to effects of weight gain or loss that 
were tumor-intrinsic. Herein, we show that overweight mice exhibited significantly greater tumor 
volume at sacrifice, whereas tumor growth in mice induced to lose weight paralleled that of lean 
animals. As inflammation is a well-established risk factor for breast cancer onset and 
progression, our studies herein employed mouse models of overweight and weight loss to 
identify the influences of changes in adiposity status on inflammation within mammary adipose 
tissue and the CLBC tumor microenvironment. Prolonged high-fat feeding in Overweight mice 
resulted in a doubling of overall adiposity, hepatomegaly, elevated fasting glucose, and a nearly 
2-fold increase in mammary fat pad weight relative to Lean and WeLo mice, consistent with 
reports of both regional and systemic effects of high-fat feeding in FVB/NJ mice despite a lower 
degree of overall adipose gain relative to the C57BL/6 strain [516]. Increased CLBC growth rate 
in Overweight mice occurred in the context of inflammatory changes within the surrounding 
mammary fat pad that are characteristic of visceral adipose depots in obesity, including 
increased adipocyte diameter and greater CLS density [275, 364, 532]. We also observed 
increased expression of markers (Itgax and Arg1) supporting infiltration of the overweight 
mammary fat pad by a population of mixed-phenotype macrophages, as has been reported in 
obese abdominal adipose depots of both mice and humans [372, 375-377]. Also in accord with 
previous studies [532], decreased mammary adipocyte diameter in WeLo mice corresponded 
with a decline in expression of macrophage-associated markers. 
In addition to increased macrophage content, our results indicated enhanced neutrophil 
content in mammary adipose tissue of Overweight mice. Notably, studies to date regarding 
adipose neutrophil infiltration in response to weight gain have investigated this question 
exclusively in male mice [361, 420], leaving unclear as to what extent, or when, neutrophils 
infiltrate the overweight or obese mammary fat pad. Our findings support both the increased 
presence of neutrophils in mammary fat of overweight mice and a reduction in neutrophil 
content with weight loss. Weight loss also reversed elevated expression of cytokines (Il6, Il10, 
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Il1b) and growth factors (Hgf and Vegfa) implicated in both inflammation and breast cancer 
progression [505]. Among these factors, Hgf is particularly noteworthy, as HGF/MET signaling 
appears to be a defining feature of CLBCs [533]. Together with the macrophage findings above, 
these results describe establishment of an inflammatory microenvironment in overweight 
mammary fat pad, with restoration of a lean-like cytokine milieu following weight loss.   
Despite these changes in the surrounding mammary fat pad, our analyses revealed no 
diet-mediated differences in either tumor microvessel density or total tumor leukocyte content. 
However, leukocytes comprised 40-50% of total CLBC tumor cellularity, a dramatic immune 
infiltrate which is consistent with previous reports of a strong immune signature in CLBCs [507, 
508]. Similarly, tumor microarray analysis demonstrated minimal differences in tumors resected 
from Lean and Overweight mice, results which were paralleled in additional microarray analyses 
of tumors from lean and overweight transgenic C3(1)-TAg mice (data not shown). However, 
weight loss before tumor development reduced expression of signaling pathways implicated in 
ECM remodeling, cancer cell survival and proliferation (IGF-1, ERK5, IL-4) [534-536], and 
metastasis (CXCR4/CXCL12 and EPO) [536-538]. Of particular interest are the reductions 
observed in CXCR4 and EPO pathways. CXCR4 is a G-protein coupled receptor with 
demonstrated roles in promotion of breast cancer metastasis. In mice, overexpression of 
CXCR4 alone significantly increased bone metastases of a CLBC cell line [537], while blockade 
of CXCR4 signaling in the same cell line reduced lung metastases [539]. In humans, CXCR4 
expression in breast cancer is associated with both lymph node status and distant metastases, 
as well as reduced 5-year disease-free survival and overall survival [540]. Weight loss also 
reduced expression of the EPO signaling pathway, which is implicated in tumor-initiating cell 
self-renewal [517], reduced response to chemotherapy [541], and lymph node metastasis [538]. 
Additional analyses are ongoing to identify the prognostic potential of these weight loss-
associated transcriptional changes with regard to breast cancer outcomes in other molecular 
subtypes.  
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In addition to increased macrophage and neutrophil content in mammary adipose, our 
findings herein also support a novel role for weight gain and loss in regulation of breast tissue 
mast cell dynamics. Accumulation and proinflammatory activation of mast cells in obese visceral 
adipose has been reported in both mice [437] and humans [435, 436]. However, to our 
knowledge ours is the first study to investigate mast cell content and activation with regard to 
mammary adiposity in both mice and humans and to incorporate a weight loss intervention. 
Interestingly, our results demonstrated increased mast cell content in un-injected mammary not 
in overweight mice, but instead in a subset of the mice assigned to undergo weight loss. On the 
other hand – and more relevant to breast cancer progression – mast cell content in tumor-
adjacent adipose was increased relative to un-injected mammary exclusively in overweight 
animals. Indicators of mast cell activation were also elevated in overweight mammary gland 
across two different mouse models, an increase which was significantly attenuated by weight 
loss.  
Importantly, increased expression of mast cell-associated genes was also observed in 
overweight and obese human breast tissue collected through the UNC Normal Breast Study 
[521]. Others have reported that mast cells isolated from omental (visceral) and subcutaneous 
adipose depots of obese subjects secreted increased levels of pro-inflammatory cytokines, 
chemokines, and growth factors relative to those isolated from lean subjects, indicating a more 
activated state [436]. An increase in mast cell content and/or activation within the obese breast 
may influence breast cancer progression in obese individuals. For example, tryptase-containing 
mast cells are typically found in greater number within peritumoral tissue, and are associated 
with myofibroblast differentiation, higher lymphangiogenic and angiogenic microvessel density, 
and lymph node metastasis [505]. Notably, our data indicated lower expression of tryptase in 
mammary mast cells of mice following weight loss. Taken together, our findings of increased 
mast cell markers in overweight and obese normal breast warrants additional investigation into 
mast cell-mediated mechanism of obesity-associated tumor progression. The close proximity of 
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mast cells in normal breast tissue to the ductal epithelium also suggests potential roles for mast 
cells in progression of pre-neoplastic lesions such as ductal carcinoma in situ or neoplastic 
transformation of mammary ductal epithelium. 
Finally, using TCGA data we reported that mast cell gene expression varied based on 
breast cancer subtype, with low mast cell-associated gene expression observed in BBCs and 
higher expression in luminal subtypes. Our studies herein also revealed an inverse relationship 
between intratumoral mast cell markers and risk-of-recurrence category (ROR-P), which 
provided the most significant prognostic information, compared with other prognostic gene 
signatures, regarding post‑relapse survival when added to a clinical model [531]. Our finding of 
low mast cell-associated gene expression in BBCs is consistent with reports of a high density of 
tryptase-positive mast cells in luminal A breast cancers yet low mast cell content in TNBCs 
[542]. Tryptase-positive mast cell density was also associated with expression of the 
proliferation marker Ki67 as well as tumor size and Nottingham Histologic Grade [542]. 
Collectively, these analyses suggest a potential role for mast cells in regulation of tumor 
characteristics associated with breast cancer recurrence, and complement previous reports of 
intratumoral mast cells as exerting a protective effect in breast cancer [452]. Additionally, the 
paradoxical relationship between mast cell localization and tumor prognosis suggests that 
peritumoral and intratumoral mast cells may in fact exhibit distinct phenotypes. Future analyses 
should address intratumoral mast cell score in CLBCs, which are not currently well represented 
in TCGA, and by anthropometric data such as BMI, which is not at this time linked TCGA to 
breast cancer data sets.   
Collectively, our results indicate that local inflammatory changes within the surrounding 
mammary fat pad, including increased myeloid cell content and growth factor expression, 
accelerated tumor progression in overweight mice, and suggest the potential for cross-talk 
between mammary adipose immune populations and developing CLBCs. Moreover, these 
findings elucidate the impact of overweight and subsequent weight loss on the mammary 
134 
 
microenvironment and progression of CLBC. The distinct patterns of gene expression observed 
in tumors from mice who experienced weight loss before tumor growth are encouraging for 
public health and emphasize the importance of clarifying physiological changes within the breast 
adipose or intratumoral microenvironment in response to body weight fluctuations. Furthermore, 
our findings of a relationship between weight status and mast cell dynamics in mammary 
adipose of both mice and humans argues for further investigation into peritumoral mast cells as 
key players in obesity-associated BBC and CLBC progression.  
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CHAPTER 4: SYNTHESIS, SIGNIFICANCE, AND FUTURE DIRECTIONS 
Triple-negative breast cancers: a heterogeneous disease 
The classification of breast cancers and subsequent clinical decisions for treatment 
remain reliant upon IHC4, a histopathologic scoring system which combines expression of 
known “molecular drivers” of breast cancer progression – estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2), and the proliferation marker 
Ki67 – with clinicopathological parameters such as Nottingham Histologic Grade. IHC4 provides 
an estimation of the risk of distant disease recurrence in breast cancer patients and guides 
treatment selection from within the currently limited arsenal of targeted adjuvant and 
neoadjuvant therapies. The focus of this dissertation, TNBCs, are called as such because they 
lack expression of ER, PR, and HER2 when assessed using IHC4. For this reason, TNBCs 
currently lack FDA-approved targeted therapies, leaving systemic chemotherapy as the 
standard-of-care treatment for patients with both early- and advanced-stage disease. 
Importantly, the category of TNBC applies to all tumors that lack ER, PR, and HER2 expression, 
resulting in profound heterogeneity within this subgroup [543] and complicating identification of 
actionable molecular targets. While TNBCs, particularly BBCs, are often more sensitive to 
chemotherapy than other phenotypes (e.g., ER and/or HER2 positive) [544], they paradoxically 
also exhibit elevated recurrence and metastasis rates relative to other breast cancer subtypes 
[509]. Critically, fewer than 30% of women with metastatic breast cancer survive five years 
[545], and virtually all women with metastatic TNBC will ultimately die of their disease. 
However, the additional complexity in breast cancer classification exposed by ongoing 
analyses under The Cancer Genome Atlas (TCGA), in conjunction with high-throughput gene 
sequencing and transcriptomic profiling, has allowed for molecular subtyping of breast cancers 
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and increased emphasis on personalized approaches to treatment. The studies presented 
herein have investigated the effects of weight status on tumor progression using multiple 
molecular subtypes of TNBC (BBC and CLBC) and employing both orthotopic transplant models 
and models of spontaneous tumor development. Consideration of molecular subtypes when 
investigating the impact of overweight and obesity on breast cancer outcomes is paramount. 
Elucidation of unique mechanisms of overweight- and obesity-related cancer pathogenesis in a 
subtype-specific manner may reveal therapeutic targets to improve outcomes and further inform 
personalized treatment options for these patient populations. 
In the studies conducted in Chapter 2 of this dissertation we sought to reverse the 
acceleration of basal-like TNBC latency previously observed in HFD-fed mice and inhibit tumor 
progression in LFD- and HFD-fed C3(1)-TAg mice using the small molecule cMET inhibitor 
crizotinib. A strength of our study is that we tested this question in models of both prevention 
and treatment, providing a better understanding of cMET dependence in both preneoplastic 
lesions and invasive basal-like mammary carcinoma. In the prevention arm we investigated 
whether administering crizotinib in a window prior to frank tumor development would inhibit or 
delay tumorigenesis. Thus, mice were started on diet at 8 weeks of age to ensure crizotinib 
administration occurred within the primary window of AH/CIS precursor lesions (9-12 weeks of 
age), based on previous findings of increased precursor lesion formation in C3(1)-TAg mice 
following HFD-induced weight gain [546]. Although preventive crizotinib administration 
significantly accelerated tumor progression in the primary (first detected) tumor in both diet 
groups, no differences were measured when total tumor progression (all tumors considered 
collectively) was assessed. Similarly, no effect was seen on total tumor multiplicity with 
prophylactic administration of crizotinib. Interestingly, we also did not observe accelerated tumor 
latency in HFD-fed mice, as has been seen in our previous studies of adult weight gain [43, 
263]. Instead these results paralleled those of female C3(1)-TAg mice weaned onto LFD or HFD 
– generating a model of lifelong obesity – wherein no difference in latency was observed but 
tumors progressed an at an accelerated rate [264]. The differences in adiposity-associated 
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phenotype observed across these studies (shortened tumor latency vs increased rate of tumor 
progression) emphasize the importance of clarifying “windows of susceptibility” [470, 480] during 
which overweight and obesity play disproportionately greater, and varied, roles in breast cancer.  
In the treatment arm of our study crizotinib administration was initiated upon detection of 
the first palpable tumor; i.e., in mice with established invasive mammary carcinoma. In mice with 
established basal-like mammary cancer, crizotinib treatment inhibited subsequent tumor 
formation in our study such that total tumor multiplicity was significantly reduced at sacrifice, 
irrespective of diet or weight status. The degree of tumor inhibition was paralleled by a similar 
degree of suppression of tumor vascularity, which is consistent with HGF/cMET signaling as a 
potent driver of tumor angiogenesis [265, 497]. 
 
Diet, overweight, obesity, and weight loss in breast cancer outcomes 
Herein we have also reported that overweight and weight loss reciprocally regulated 
CLBC tumor volume, along with numerous pro-inflammatory changes in surrounding mammary 
adipose. Increased CLS density and mammary inflammation in Overweight mice were 
associated with increased rate of CLBC tumor growth, as well as an increase in mast cell 
density in tumor-adjacent adipose. Increased expression of a mast cell gene signature was also 
observed in cancer-adjacent normal breast tissue from both overweight and obese human 
subjects compared to normal weight. Interestingly, while weight status did not influence 
intratumoral mast cells, weight loss resulted in reduced expression of mast cell activation 
markers within the mouse mammary adipose pad and a unique transcriptional signature in 
tumors of WeLo mice, including reduced expression of mitogenic and metastasis-associated 
gene pathways.  
While the studies in Chapter 3 are primarily descriptive in nature, our selection of a 
model of overweight, rather than outright obesity, allows insight into potential risk factors for 
CLBC progression in this understudied population. Additionally, we emphasized tissue- and 
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species-specificity in selection of the mast cell signatures for microarray analysis, based on 
reports of nontrivial differences in mast cells across species and in a given tissue context [547]. 
Importantly, our results indicate that weight loss following overweight significantly attenuated 
inflammation-induced CLBC progression. As overweight and obesity in women are now more 
than three times as prevalent as normal weight  [504], an understanding of the mechanisms 
whereby excess adiposity facilitates TNBC aggression is critical, while information regarding 
efficacy of preventive measures such as weight loss could have tremendous potential for public 
health.  
However, a limitation of diet-induced obesity studies in rodents that must be 
acknowledged is the high fat content of the diet used to induce adiposity, which raises questions 
regarding whether dietary composition or adiposity per se is the primary driver of the observed 
acceleration in tumor progression in overweight or obese animals. Our observation of extensive 
differences in expression of tumor growth-promoting pathways between lean mice and mice 
induced to lose weight – groups which consumed the same diet both before and during the 
tumor growth period – supports that adiposity as well as associated local and systemic changes 
that occur in response to weight loss are nontrivial in tumor biology. Moreover, recent studies 
evaluating the impact of low-fat diets in breast cancer patient populations argue against the 
reduction of dietary fat as an effective strategy for mitigating breast cancer risk or improving 
outcomes. For example, a randomized controlled trial in Canada reported that a low-fat dietary 
intervention in 4,690 women with high breast density did not significantly influence breast 
cancer incidence across 10 years of follow-up [548]. Similarly, the Women’s Healthy Eating and 
Living (WHEL) trial randomly assigned 3,088 breast cancer patients to a low-fat diet high in 
vegetables, fruit, and fiber and observed no differences in disease-free survival or overall 
survival between intervention and control groups [549]. Moreover, the Women’s Health Initiative 
Dietary Modification trial, a randomized controlled trial in post-menopausal patients within the 
larger Women's Intervention Nutrition Study (WINS), reported no significant effects on either 
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breast cancer incidence rate or breast cancer-specific mortality relative to the control group 
following prolonged consumption of a low-fat diet (16.1 years average follow-up) [550]. 
However, deaths after breast cancer (all-cause mortality) were significantly reduced in the 
dietary intervention group [550]. Thus, currently available data does not support an influence of 
dietary fat composition on breast cancer risk. Additionally, the difference in overall survival 
findings between the WHEL and WINS studies may be less directly linked to dietary 
composition and instead due to a modest decrease in weight (average loss of approximately 6 
lbs maintained over 5 years) in WINS participants but not those in WHEL.  
Nonetheless, the relationship between weight loss and breast cancer incidence and 
outcomes in overweight and/or obese individuals also remains ambiguous. Despite reports of 
improvement in levels of metabolic markers associated with cancer progression following weight 
loss [551], a secondary analysis of the Women’s Health Initiative randomized clinical trials found 
no association between breast cancer risk and weight loss (prior to cancer) among already 
overweight or obese postmenopausal women over a median of 13 years of follow-up [47]. On 
the other hand, Chlebowski et al. also evaluated associations between weight change and 
invasive breast cancer risk in postmenopausal women within the Women's Health Initiative over 
11.4 years (mean) of follow-up, and reported a significant 12% reduction in breast cancer risk in 
women with weight loss ≥ 5%, intentional or otherwise, compared with women of stable weight 
[552]. Importantly, weight gain ≥ 5% significantly increased risk of TNBC by 54%, without 
affecting overall breast cancer risk [552]. 
With regard to weight loss and breast cancer outcomes, a meta-analysis of 
observational studies did not support an association between weight loss and improved survival; 
in fact, several studies have reported dramatically increased mortality associated with weight 
loss in overweight and obese breast cancer survivors [553]. Critically, several of the included 
studies did not differentiate between purposeful weight loss and disease-specific weight loss 
after breast cancer diagnosis. Intentional weight loss through diet and/or exercise is inarguably 
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different from weight loss due to, for example, cancer-associated cachexia, a fatal energy-
wasting syndrome that is estimated to be the immediate cause of death in approximately 20-
40% of end-stage cancer patients [195].  
Collectively, the limited evidence supporting improved prognosis in response to weight 
loss after diagnosis, and the lack of studies separating intentional weight loss from disease-
associated weight loss, complicates recommendations regarding weight loss for breast cancer 
survivors. However, the studies reviewed above regarding breast cancer risk, as well as our 
results herein, argue for further investigation into the potential impact of weight loss before 
cancer diagnosis on breast cancer risk and outcomes. Finally, our use of murine pre-clinical 
models, human tissue samples collected through the Normal Breast Study, and secondary 
analysis of existing, publicly available data sets (TCGA) informs future translational studies with 
potential for clinical impact.  
 
Directions for future research 
Our crizotinib treatment arm results presented in Chapter 2 are consistent with initial 
mechanism-of-action studies for crizotinib, which showed a dose-dependent reduction of 
microvessel density (CD31+ area) in response to cMET inhibition in gastric carcinoma, 
glioblastoma, and prostate carcinoma [478]. cMET inhibition has also shown promising results 
in xenograft models of aggressive cancers such as lung [496] and pancreatic cancers [497] as 
well as pre-clinical models of TNBC models such as ours [498]. However, clinical trials 
investigating cMET inhibitors in metastatic TNBCs have so far not been in accord with 
preclinical findings, and at the time of submission of this dissertation no receptor tyrosine kinase 
inhibitors primarily targeting cMET have been approved for the treatment of breast cancer. 
Bearing this caveat in mind, inhibition of the cMET signaling pathway through chemical or 
antibody-mediated inhibition in a patient population may not be as effective as preclinical 
studies, including ours, have suggested. Of note, a potential contributor to the high rate of 
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attrition when translating preclinical to clinical contexts may be that essentially all preclinical 
drug studies are conducted in lean mice fed chow diets. In America, and increasingly worldwide, 
individuals of normal body weight are the minority. Perhaps inclusion of overweight and obese 
animal models in preclinical drug studies would more adequately predict therapeutic success in 
human trials. 
Nonetheless, clinical pursuit of the HGF/cMET pathway as a potential TNBC target 
continues, though the plan of attack has changed. Two currently active clinical trials are 
exploring efficacy of chimeric antigen receptor T cells (CAR-T cells) programmed to target 
cMET. One employs autologous cMET-redirected T cells administered intravenously in patients 
with melanoma or TNBC (ClinicalTrials.gov Identifier: NCT03060356), while the other 
administers autologous cMET-redirected T cells intratumorally in patients with metastatic breast 
cancer or newly diagnosed TNBC (ClinicalTrials.gov Identifier: NCT01837602). CAR-T cells 
have shown incredible promise in hematologic malignancies such as lymphoma [554]; 
unfortunately, they have been largely ineffective in patients with metastatic solid cancers, in part 
due to tumor heterogeneity and the paucity of suitable cell-surface targetable molecules 
expressed by solid cancers. In both of the highlighted trials, inclusion criteria specify ≥30% 
cMET positivity by IHC, and I eagerly await the results of these two trials. 
Data presented in Chapter 3 suggested that weight status influences breast mast cell 
dynamics in both mice and humans. However, the analyses conducted did not allow for 
differentiation between an increase in mast cell content as opposed to an increase in activation 
status of existing mast cells. Flow cytometric analyses of mammary mast cells from normal and 
tumor-adjacent mammary tissue of lean and overweight or obese mice would address this 
question, allowing for both quantification of mast cell content in mammary tissue as well as 
quantification of mediators of interest, such as select serine proteases or histamine. In vitro 
culture of isolated mast cells with media conditioned by lean and obese mammary adipose 
tissue would further clarify whether the obese mammary microenvironment alters activation 
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status of mast cells. The close proximity of mast cells in normal breast tissue to the ductal 
epithelium also suggests potential roles for mast cells in progression of pre-neoplastic lesions 
such as ductal carcinoma in situ or neoplastic transformation of mammary ductal epithelium. In 
vitro cell culture studies utilizing bone marrow-derived mast cells or mast cell-derived mediators 
could be used to determine the impact of an increased concentration of mast-cell derived 
factors, such as tryptase-β2, on various stages within the progression of breast cancer available 
through the MCF10 breast cancer cell series - MCF10A, MCF10AT1, MCF10DCIS.com and 
MCF10CA1a [555].  
The biological significance of the difference in mast cell content by breast cancer 
subtype seen in our study and that of Glajcar et al. [542] is intriguing, particularly in light of our 
finding that higher mast cell gene expression was significantly associated with a lower risk of 
recurrence score. To investigate whether mast cells directly influence tumor characteristics 
associated with breast cancer recurrence, co-culture studies with breast cancer cell lines could 
be conducted to determine whether mast cells increase migration, invasion of the basement 
membrane, or colony formation. Incorporation of cell lines of various molecular subtypes would 
also probe whether they do so in a subtype-specific manner and could be further used to 
determine the directionality of any observed effects. For example, perhaps production of mast 
cell-eliciting chemokines differs by breast cancer molecular subtype. Orthotopic transplant 
studies in mast-cell deficient and wild-type mice would also confirm molecular subtype-specific 
mast cell interactions in vivo. Studies reporting a differential association between peritumoral 
and intratumoral mast cell density and breast cancer prognosis suggest that analysis at a 
single-cell level of phenotypic differences between peritumoral and intratumoral mast cell 
phenotypes may also yield interesting findings. 
Finally, our analysis of tumor gene expression revealed a unique gene expression profile 
in tumors resected from mice that lost weight before orthotopic transplant. However, additional 
questions are raised by these findings, including: can the weight loss gene expression signature 
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– particularly the reduced signaling observed through the CXCR4 and EPO signaling pathways - 
be recapitulated by interventions such as caloric restriction or exercise? Does weight loss result 
in consistent transcriptional changes in other breast cancer subtypes? To the latter point, 
additional analyses are ongoing to identify an intratumoral weight loss “signature” and establish 
its prognostic potential with regard to breast cancer outcomes in human breast cancers and 
across molecular subtypes.  
Cancer research has traditionally focused on identifying altered gene expression and cell 
signaling within tumor cells. However, the tumor microenvironment, including immune cells and 
the signaling extracellular milieu, also strongly influences tumor onset and progression. This is 
the “seed and soil” hypothesis originally posed by Dr. Stephen Paget [556], and furthered 
developed by pioneers such as Mina Bissell, Ph.D. [557], wherein the seed (cancer cell) must 
be nurtured by the metabolites, growth factors, or angiogenic factors provided by the 
surrounding soil (stroma). The body of work presented herein speaks to the importance in 
overweight- and obesity-associated breast cancers of considering not only tumor-intrinsic 
factors, but also changes to the normal mammary and tumor-adjacent microenvironments.  
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APPENDIX: SUPPLEMENTAL FIGURES  
 
 
Supplemental Figure 43. Complete gating scheme for analysis of total leukocyte and CD11b+ 
myeloid cell content of Lean and Overweight mammary fat pads. 
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Supplemental Figure 44. Complete gating scheme for analysis of leukocyte infiltration into 
claudin-low tumors of Lean, Overweight, and WeLo mice
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